Circovirus sequences associated with piglet weight loss disease (PWD)

ABSTRACT

The genome sequences and the nucleotide sequences coding for the PWD circovirus polypeptides, such as the circovirus structural and non-strucutral polypeptides, vectors including the sequences, and cells and animals transformed by the vectors are provided. Methods for detecting the nucleic acids or polypeptides, and kits for diagnosing infection by a PWD circovirus, also are provided. Method for selecting compounds capable of modulating the viral infection are further provided. Pharmaceutical, including vaccines, compositions for preventing and/or treating viral infections caused by PWD circovirus and the use of vectors for preventing and/or treating diseases also are provided.

INFORMATION ON RELATED APPLICATIONS

[0001] The present application claims the priority benefit, under 35 U.S.C. § 119, of International Application No. PCT/FR98/02634, filed Dec. 4, 1998.

BACKGROUND OF THE INVENTION

[0002] The invention relates to the genomic sequence and nucleotide sequences coding for polypeptides of PWD circovirus, such as the structural and nonstructural polypeptides of said circovirus, as well as vectors including said sequences and cells or animals transformed by these vectors. The invention likewise relates to methods for detecting these nucleic acids or polypeptides and kits for diagnosing infection by the PWD circovirus. The invention is also directed to a method for selecting compounds capable of modulating the viral infection. The invention further comprises pharmaceutical compositions, including vaccines, for the prevention and/or the treatment of viral infections by PWD circovirus as well as the use of a vector according to the invention for the prevention and/or the treatment of diseases by gene therapy.

[0003] Piglet weight loss disease (PWD), alternatively called fatal piglet wasting (FPW) has been widely described in North America (Harding, J. C., 1997), and authors have reported the existence of a relationship between this pathology and the presence of porcine circovirus (Daft, B. et al., 1996; Clark, E. G., 1997; Harding, J. C., 1997; Harding, J. C. and Clark, E. G., 1997; Nayar, G. P. et al., 1997). A porcine circovirus has already been demonstrated in established lines of cell cultures derived from pigs and chronically infected (Tischer, I., 1986, 1988, 1995; Dulac, G. C., 1989; Edwards, S., 1994; Allan, G. M., 1995 and McNeilly, F., 1996). This virus, during experimental infection of piglets, does not prove pathogenic for pigs (Tischer, I., 1986, Horner, G. W., 1991) and its nucleotide sequence has been determined and characterized (Tischer, I., 1982; Meehan, B. M. et al., 1997; Mankertz., A., 1997). The porcine circovirus, called PCV virus, is part of the circovirus genus of the circoviridae family (Murphy, F. A. et al., 1995) whose virion has a circular DNA of size between 1.7 and 2.3 kb, which DNA comprises three open reading frames (ORF1 to ORF3), coding for a replication protein REP involved in the initiation and termination phase of rolling circular replication (RCR) (Heyraud-Nitschke, F., et al., 1995; Harding, M. R. et al., 1993; Hanson, S. F. et al., 1995; Fontes, E. P. B. et al., 1994), coding for a capsid protein (Boulton, L. H. et al., 1997; Hackland, A. F. et al., 1994; Chu, P. W. G. et al., 1993) and coding for a nonstructural protein called a dissemination protein (Lazarowitz., S. G. et al., 1989).

[0004] The authors of the present invention have noticed that the clinical signs perceptible in pigs and linked to infection by the PWD circovirus are very distinctive. These manifestations in general appear in pigs of 8 to 12 weeks of age, weaned for 4 to 8 weeks. The first signs are hypotonia without it being possible to speak of prostration. Rapidly (48 hours), the flanks hollow, the line of the spine becomes apparent, and the pigs “blanch.” These signs are in general accompanied by hyperthermia, anorexia and most often by respiratory signs (coughing, dyspnea, polypnea). Transitory diarrhea can likewise appear. The disease state phase lasts approximately one month at the end of which the rate of mortality varies from 5 to 20%. To these mortalities, it is expedient to add a variable proportion (5-10%) of cadaveric animals which are no longer able to present an economic future. It is to be noted that outside of this critical stage of the end of post-weaning, no anomaly appears on the farms. In particular, the reproductive function is totally maintained.

[0005] On the epidemiological level, the first signs of this pathology appeared at the start of 1995 in the east of the Côtes d'Armor region in France, and the farms affected are especially confined to this area of the region. In December 1996, the number of farms concerned could not be evaluated with precision because of the absence of a specific laboratory diagnostic method or of an epidemioligical surveillance system of the livestock. Based on the clinical facts as well as on results of postmortem examinations supplied by veterinarians, it is possible to estimate this number as several dozen (80-100). The contagiousness of the disease is weak to moderate. Cases are being reported outside the initial area and for the majority are following the transfer of animals coming from farms familiar with the problem. On the other hand, a characteristic of the condition is its strong remanence. Thus, farms which have been affected for a year are still affected in spite of the massive administration of therapeutics. Farms with clinical expression are drawn from various categories of specialization (breeders/fatteners, post-weaners/fatteners) and different economic structures are concerned. In addition, the disorders appear even in farms where the rules of animal husbandry are respected.

[0006] Numerous postmortem examinations have been carried out either on farms or in the laboratory. The elements of the lesional table are disparate. The most constant macroscopic lesions are pneumonia which sometimes appears in patchy form as well as hypertrophy of the lymphatic ganglia. The other lesions above all affect the thoracic viscera including, especially, pericarditis and pleurisy. However, arthritis and gastric ulcers are also observed. The lesions revealed in the histological examination are essentially situated at the pulmonary level (interstitial pneumonia), ganglionic level (lymphoid depletion of the lymph nodes, giant cells) and renal level (glomerulonephritis, vasculitis). The infectious agents have been the subject of wide research. It has been possible to exclude the intervention of pestiviruses and Aujeszky's disease. The disorders appear in the seropositive PDRS (Porcine Dysgenic and Respiratory Syndrome, an infection linked to an arteriovirus) herds, but it has not been possible to establish the role of the latter in the genesis of the disorders (the majority of the farms in Brittany are PDRS seropositive).

[0007] The authors of the present invention, with the aim of identifying the etiological agent responsible for PWD, have carried out “contact” tests between piglets which are obviously “ill” and SPF pigs (specific pathogen-free) from CNEVA (Centre National d'Etudes Vétérinaires et Alimentaires, France). These tests allow the development of signs comparable to those observed on the farm to be observed in protected animal houses. The discrete signs such as moderate hyperthermia, anorexia and intermittent diarrhea appeared after one week of contact. It must be noted that the PDRS virus only diffused subsequent to the clinical signs. In addition, inocculations of organ homogenates of sick animals to healthy pigs allowed signs related to those observed on the farms to be reproduced, although with a lower incidence, linked to the favorable conditions of upkeep of the animals in the experimental installations.

[0008] Thus, the authors of the present invention have been able to demonstrate that the pathological signs appear as a well-defined entity affecting the pig at a particular stage of its growth.

[0009] This pathology has never been described in France. However, sparse information, especially Canadian, relates to similar facts.

[0010] The disorders cannot be mastered with the existing therapeutics.

[0011] The data collected both on the farm and by experimentation have allowed the following points to be higlighted:

[0012] PWD is transmissible but its contagiousness is not very high,

[0013] its etiological origin is of infectious and probably viral nature,

[0014] PWD has a persistent character in the affected farms.

[0015] Considerable economic consequences ensue for the farms.

[0016] Thus, there is currently a significant need for a specific and sensitive diagnostic, whose production is practical and rapid, allowing the early detection of the infection.

[0017] A reliable, sensitive and practical test which allows the distinction between strains of porcine circovirus (PCV) is thus strongly desirable.

[0018] On the other hand, a need for efficient and well-tolerated treatment of infections with PWD circovirus likewise remains desirable, no vaccine currently being available against PWD circovirus.

[0019] Concerning PWD circovirus, it will probably be necessary to understand the role of the immune defense in the physiology and the pathology of the disease to develop satisfactory vaccines.

[0020] Fuller information concerning the biology of these strains, their interactions with their hosts, the associated infectivity phenomena and those of escape from the immune defenses of the host especially, and finally their implication in the development of associated pathologies, will allow a better understanding of these mechanisms. Taking into account the facts which have been mentioned above and which show in particular the limitations of combatting infection by the PWD circovirus, it is thus essential today on the one hand to develop molecular tools, especially starting from a better genetic knowledge of the PWD circovirus, and likewise to perfect novel preventive and therapeutic treatments, novel methods of diagnosis and specific, efficacious and tolerated novel vaccine strategies. This is precisely the subject of the present invention.

SUMMARY OF THE INVENTION

[0021] The present invention relates to vaccines comprising a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof, and an acceptable pharmaceutical or veterinary vehicle. In one embodiment of the invention, the nucleotide sequence is selected from SEQ ID No. 15, SEQ ID No. 19 SEQ ID No. 23, or SEQ ID No. 25, or a homologue or fragment thereof. In another embodiment of the invention, the homologue has at least 80% sequence identity to SEQ ID No. 15, SEQ ID No. 19, SEQ ID No. 23 or SEQ ID No. 25. In yet another embodiment, the vaccines further comprising an adjuvant

[0022] The present invention also relates to vaccines comprising a polypeptide encoded by a nucleotide sequence of the genome of PCVB, or a homologue or fragment thereof, and an acceptable pharmaceutical or veterinary vehicle. In one embodiment, the homologue has at least 80% sequence identity to SEQ ID No. 15, SEQ ID No. 19, SEQ ID No. 23 or SEQ ID No. 25. In another embodiment of the invention, the nucleotide sequence is selected from SEQ ID No. 23 or SEQ ID No. 25, or a homologue or fragment thereof. In still another embodiment, the polypeptide has the amino acid sequence of SEQ ID No. 24 or SEQ ID No. 26. In yet another embodiment, the homologue has at least 80% sequence identity to SEQ ID No. 24 or SEQ ID No. 26. In another embodiment, the polypeptide has the amino acid sequence of SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31, or SEQ ID No. 32.

[0023] A further aspect of the invention relates to vaccines comprising a vector and an acceptable pharmaceutical or veterinary vehicle, the vector comprising a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof. In one embodiment, the vaccine further comprises a gene coding for an expression product capable of inhibiting or retarding the establishment or development of a genetic or acquired disease.

[0024] The present invention also relates to vaccines comprising a cell and an acceptable pharmaceutical or veterinary vehicle, wherein the cell is transformed with a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof.

[0025] Still further, the present invention relates to vaccines comprising a pharmaceutically acceptable vehicle and a single polypetide, wherein the single polypeptide consists of SEQ ID No. 26.

[0026] Additionally, the present invention relates to methods of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of the vaccines desribed above.

[0027] These and other aspects of the invention will become apparent to the skilled artisan in view of the teachings contained herein.

BRIEF DESCRIPTION OF THE DRAWINGS

[0028]FIG. 1: Experimental scheme which has made it possible to bring about the isolation and the identification of the circovirus associated with PWD of type A and B.

[0029] Test 1: experimental reproduction of the PWD by inoculation of pig organ homogenates from farms affected by PWD.

[0030] Test 2: experimental reproduction of PWD.

[0031] Test 3: experimental reproduction of PWD.

[0032] Test 4: no experimental reproduction of PWD.

[0033]FIG. 2: Organization of the genome of the circovirus associated with PWD of type A (PCVA)

[0034] strand of (+) polarity (SEQ ID No. 1);

[0035] strand of (−) polarity (SEQ ID No. 5, represented according to the orientation 3′→5′);

[0036] sequences of amino acids of proteins encoded by the two DNA strands in the three possible reading frames SEQ ID NOS: 2-4 and 6-8 respectively.

[0037]FIG. 3: Alignment of the nucleotide sequence SEQ ID No. 1 of the PWD circovirus of type A (PCVA) and of the MEEHAN SEQ ID No. 163 strain and MANKERTZ SEQ ID No. 164 strain circoviruses of the porcine cell lines.

[0038]FIG. 4: Alignment of the sequence of amino acids SEQ ID No. 10 of a polypeptide encoded by the nucleotide sequence SEQ ID No. 9 (ORF1) of the PWD circovirus of type A (PCVA) and of corresponding nucleotide sequences of the MEEHAN SEQ ID No. 165 strain and MANKERTZ SEQ ID No. 166 strain circoviruses of the porcine cell lines.

[0039]FIG. 5: Alignment of the sequence of amino acids SEQ ID No. 12 of a polypeptide encoded by the nucleotide sequence SEQ ID No. 11 (ORF2) of the PWD circovirus of type A (PCVA) and of corresponding nucleotide sequences of the MEEHAN SEQ ID No. 167 strain and MANKERTZ SEQ ID No. 168 strain circoviruses of the porcine cell lines.

[0040]FIG. 6: Alignment of the sequence of amino acids SEQ ID No. 14 of a polypeptide encoded by the nucleotide sequence SEQ ID No. 13 (ORF3) of the PWD circovirus of type A (PCVA) and of corresponding nucleotide sequences of the MEEHAN SEQ ID No. 169 strain and MANKERTZ SEQ ID No. 170 strain circoviruses of the porcine cell lines.

[0041]FIG. 7: Western blot analysis of recombinant proteins of the PWD circovirus of type A (PCVA).

[0042] The analyses were carried out on cell extracts of Sf9 cells obtained after infection with recombinant baculovirus PCF ORF 1.

[0043]FIG. 8: Organization of the genome of the circovirus associated with the PWD of type B (PCVB)

[0044] strand of (+) polarity (SEQ ID No. 15);

[0045] strand of (−) polarity (SEQ ID No. 19, represented according to the orientation 3′→5′);

[0046] sequence of amino acids of proteins encoded by the two DNA strands in the three possible reading frames SEQ ID NOS: 16-18 and 20-22 respectively.

[0047]FIG. 9: Evolution of the daily mean gain (DMG) of pig farms affected by piglet weight loss disease (PWD), placed under experimental conditions.

[0048]FIG. 10: DMG compared for the 3 batches of pigs (F1, F3 and F4) calculated over a period of 28 days, after vaccination test.

[0049]FIG. 11: Hyperthermia greater than 41° C., expressed as a percentage compared for the 3 batches of pigs (F1, F3 and F4) calculated per week over a period of 28 days, after vaccination test.

[0050]FIG. 12: Membranes of peptide spots corresponding to the ORF2s revealed with the aid of an infected pig serum, originating from a conventional farm.

[0051] The numbers of specific peptides of the circovirus of type B as well as their nonreactive homologs (type A) are indicated in bold.

[0052] The nonspecific immunogenic peptides are indicated in italics.

[0053]FIG. 13: Alignment of amino acid sequences of proteins encoded by the ORF2 of the PWD circovirus of type A SEQ ID No. 12 and by the ORF′2 of the PWD circovirus of type B SEQ ID No. 26. The position of 4 peptides corresponding to specific epitopes of the PWD circovirus of type B is indicated on the corresponding sequence by a bold line, their homolog on the sequence of the PWD circovirus of type A is likewise indicated by an ordinary line.

[0054]FIG. 14: Charts the results of experiments that demonstrate, in terms of percent hyperthermia, that vaccination with ORF′1 and ORF′2 of PCV-B enhances the level of protection in swine challeneged with PCV-B.

[0055]FIG. 15: Charts the results of experiments that demonstrate, in terms of animal growth, that vaccination with ORF′1 and ORF′2 of PCV-B enhances the level of protection in swine challeneged with PCV-B.

[0056]FIG. 16: Immunoperoxidase staining of PK15 cells at 24 h post-transfection with the pcDNA3/ORF′2 plasmid. Expression of PCVB ORF′2 was confirmed by IPMA following incubation in the presence of the swine anti-PCVB monospecific serum

DETAILED DESCRIPTION OF THE INVENTION

[0057] The present invention relates to nucleotide sequences of the genome of PWD circovirus selected from the sequences SEQ ID No. 1, SEQ ID No. 5, SEQ ID No. 15, SEQ ID No. 19 or one of their fragments.

[0058] The nucleotide sequences of sequences SEQ ID No. 1 and SEQ ID No. 5 correspond respectively to the genome sequence of the strand of (+) polarity and of the strand of (−) polarity of the PWD circovirus of type A (or PCVA), the sequence SEQ ID No. 5 being represented according to the orientation 5′→3′.

[0059] The nucleotide sequences of sequences SEQ ID No. 15 and SEQ ID No. 19 correspond respectively to the genome sequence of the strand of (+) polarity and of the strand of (−) polarity of the PWD circovirus of type B (or PCVB), the sequence SEQ ID No. 19 being represented according to the orientation 5′→3′.

[0060] The present invention likewise relates to nucleotide sequences, characterized in that they are selected from:

[0061] a) a nucleotide sequence of a specific fragment of the sequence SEQ ID No. 1, SEQ ID No. 5, SEQ ID No. 15, SEQ ID No. 19 or one of their fragments;

[0062] b) a nucleotide sequence homologous to a nucleotide sequence such as defined in a);

[0063] c) a nucleotide sequence complementary to a nucleotide sequence such as defined in a) or b), and a nucleotide sequence of their corresponding RNA;

[0064] d) a nucleotide sequence capable of hybridizing under stringent conditions with a sequence such as defined in a), b) or c);

[0065] e) a nucleotide sequence comprising a sequence such as defined in a), b), c) or d); and

[0066] f) a nucleotide sequence modified by a nucleotide sequence such as defined in a), b), c), d) or e).

[0067] Nucleotide, polynucleotide or nucleic acid sequence will be understood according to the present invention as meaning both a double-stranded or single-stranded DNA in the monomeric and dimeric (so-called in tandem) forms and the transcription products of said DNAs.

[0068] It must be understood that the present invention does not relate to the genomic nucleotide sequences taken in their natural environment, that is to say in the natural state. It concerns sequences which it has been possible to isolate, purify or partially purify, starting from separation methods such as, for example, ion-exchange chromatography, by exclusion based on molecular size, or by affinity, or alternatively fractionation techniques based on solubility in different solvents, or starting from methods of genetic engineering such as amplification, cloning and subcloning, it being possible for the sequences of the invention to be carried by vectors.

[0069] The nucleotide sequences SEQ ID No. 1 and SEQ ID No. 15 were obtained by sequencing of the genome by the Sanger method.

[0070] Nucleotide sequence fragment according to the invention will be understood as designating any nucleotide fragment of the PWD circovirus, type A or B, of length of at least 8 nucleotides, preferably at least 12 nucleotides, and even more preferentially at least 20 consecutive nucleotides of the sequence from which it originates.

[0071] Specific fragment of a nucleotide sequence according to the invention will be understood as designating any nucleotide fragment of the PWD circovirus, type A or B, having, after alignment and comparison with the corresponding fragments of known porcine circoviruses, at least one nucleotide or base of different nature. For example, the specific nucleotide fragments of the PWD circovirus of type A can easily be determined by referring to FIG. 3 of the present invention in which the nucleotides or bases of the sequence SEQ ID No. 1 (circopordfp) are shown which are of different nature, after alignment of said sequence SEQ ID No. 1 with the other two sequences of known porcine circovirus (circopormeeh and circopormank).

[0072] Homologous nucleotide sequence in the sense of the present invention is understood as meaning a nucleotide sequence having at least a percentage identity with the bases of a nucleotide sequence according to the invention of at least 80%, preferably 90% or 95%, this percentage being purely statistical and it being possible to distribute the differences between the two nucleotide sequences at random and over the whole of their length.

[0073] Specific homologous nucleotide sequence in the sense of the present invention is understood as meaning a homologous nucleotide sequence having at least one nucleotide sequence of a specific fragment, such as defined above. Said “specific” homologous sequences can comprise, for example, the sequences corresponding to the genomic sequence or to the sequences of its fragments representative of variants of PWD circovirus of type A or B. These specific homologous sequences can thus correspond to variations linked to mutations within strains of PWD circovirus of type A and B, and especially correspond to truncations, substitutions, deletions and/or additions of at least one nucleotide. Said homologous sequences can likewise correspond to variations linked to the degeneracy of the genetic code.

[0074] The term “degree or percentage of sequence homology” refers to “degree or percentage of sequence identity between two sequences after optimal alignment” as defined in the present application.

[0075] Two amino-acids or nucleotidic sequences are said to be “identical” if the sequence of amino-acids or nucleotidic residues, in the two sequences is the same when aligned for maximum correspondence as described below. Sequence comparisons between two (or more) peptides or polynucleotides are typically performed by comparing sequences of two optimally aligned sequences over a segment or “comparison window” to identify and compare local regions of sequence similarity. Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman, Ad. App. Math 2: 482 (1981), by the homology alignment algorithm of Neddleman and Wunsch, J. Mol. Biol. 48: 443 (1970), by the search for similarity method of Pearson and Lipman, Proc. Natl. Acad. Sci. (U.S.A.) 85: 2444 (1988), by computerized implementation of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis.), or by visual inspection.

[0076] “Percentage of sequence identity” (or degree or identity) is determined by comparing two optimally aligned sequences over a comparison window, where the portion of the peptide or polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical amino-acid residue or nucleic acid base occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

[0077] The definition of sequence identity given above is the definition that would use one of skill in the art. The definition by itself does not need the help of any algorithm, said algorithms being helpful only to achieve the optimal alignments of sequences, rather than the calculation of sequence identity.

[0078] From the definition given above, it follows that there is a well defined and only one value for the sequence identity between two compared sequences which value corresponds to the value obtained for the best or optimal alignment.

[0079] In the BLAST N or BLAST P “BLAST 2 sequence”, software which is available in the web site http://www.ncbi.nlm.nih.gov/gorf/b12.html, and habitually used by the inventors and in general by the skilled man for comparing and determining the identity between two sequences, gap cost which depends on the sequence length to be compared is directly selected by the software (i.e. 11.2 for substitution matrix BLOSUM-62 for length >85).

[0080] In the present description, PWD circovirus will be understood as designating the circoviruses associated with piglet weight loss disease (PWD) of type A (PCVA) or type B (PCVB), defined below by their genomic sequence, as well as the circoviruses whose nucleic sequences are homologous to the sequences of PWD circoviruses of type A or B, such as in particular the circoviruses corresponding to variants of the type A or of the type B.

[0081] Complementary nucleotide sequence of a sequence of the invention is understood as meaning any DNA whose nucleotides are complementary to those of the sequence of the invention, and whose orientation is reversed (antiparallel sequence).

[0082] Hybridization under conditions of stringency with a nucleotide sequence according to the invention is understood as meaning a hybridization under conditions of temperature and ionic strength chosen in such a way that they allow the maintenance of the hybridization between two fragments of complementary DNA.

[0083] By way of illustration, conditions of great stringency of the hybridization step with the aim of defining the nucleotide fragments described above are advantageously the following.

[0084] The hybridization is carried out at a preferential temperature of 65° C. in the presence of SSC buffer, 1×SSC corresponding to 0.15 M NaCl and 0.05 M Na citrate. The washing steps, for example, can be the following:

[0085] 2×SSC, at ambient temperature followed by two washes with 2×SSC, 0.5% SDS at 65° C.; 2×0.5×SSC, 0.5% SDS; at 65° C. for 10 minutes each.

[0086] The conditions of intermediate stringency, using, for example, a temperature of 42° C. in the presence of a 2×SSC buffer, or of less stringency, for example a temperature of 37° C. in the presence of a 2×SSC buffer, respectively require a globally less significant complementarity for the hybridization between the two sequences.

[0087] The stringent hybridization conditions described above for a polynucleotide with a size of approximately 350 bases will be adapted by the person skilled in the art for oligonucleotides of greater or smaller size, according to the teaching of Sambrook et al., 1989.

[0088] Among the nucleotide sequences according to the invention, those are likewise preferred which can be used as a primer or probe in methods allowing the homologous sequences according to the invention to be obtained, these methods, such as the polymerase chain reaction (PCR), nucleic acid cloning and sequencing, being well known to the person skilled in the art.

[0089] Among said nucleotide sequences according to the invention, those are again preferred which can be used as a primer or probe in methods allowing the presence of PWD circovirus or one of its variants such as defined below to be diagnosed.

[0090] The nucleotide sequences according to the invention capable of modulating, of inhibiting or of inducing the expression of PWD circovirus gene, and/or capable of modulating the replication cycle of PWD circovirus in the host cell and/or organism are likewise preferred. Replication cycle will be understood as designating the invasion and the multiplication of PWD circovirus, and its propagation from host cell to host cell in the host organism.

[0091] Among said nucleotide sequences according to the invention, those corresponding to open reading frames, called ORF sequences, and coding for polypeptides, such as, for example, the sequences SEQ ID No. 9 (ORF1), SEQ ID No. 11 (ORF2) and SEQ ID No. 13 (ORF3) respectively corresponding to the nucleotide sequences between the positions 47 and 985 determined with respect to the position of the nucleotides on the sequence SEQ ID No. 1, the positions 1723 and 1022 and the positions 658 and 38 with respect to the position of the nucleotides on the sequence SEQ ID No. 5 (represented according to the orientation 3′→5′), the ends being included, or alternatively the sequences SEQ ID No. 23 (ORF′1), SEQ ID No. 25 (ORF′2) and SEQ ID No. 27 (ORF′3), respectively corresponding to the sequences between the positions 51 and 995 determined with respect to the position of the nucleotides on the sequence SEQ ID No. 15, the positions 1734 and 1033 and the positions 670 and 357, the positions being determined with respect to the position of the nucleotides on the sequence SEQ ID No. 19 (represented according to the orientation 3′→5′), the ends being included, are finally preferred.

[0092] The nucleotide sequence fragments according to the invention can be obtained, for example, by specific amplification, such as PCR, or after digestion with appropriate restriction enzymes of nucleotide sequences according to the invention, these methods in particular being described in the work of Sambrook et al., 1989. Said representative fragments can likewise be obtained by chemical synthesis when their size is not very large and according to methods well known to persons skilled in the art.

[0093] Modified nucleotide sequence will be understood as meaning any nucleotide sequence obtained by mutagenesis according to techniques well known to the person skilled in the art, and containing modifications with respect to the normal sequences according to the invention, for example mutations in the regulatory and/or promoter sequences of polypeptide expression, especially leading to a modification of the rate of expression of said polypeptide or to a modulation of the replicative cycle.

[0094] Modified nucleotide sequence will likewise be understood as meaning any nucleotide sequence coding for a modified polypeptide such as defined below.

[0095] The present invention relates to nucleotide sequences of PWD circovirus according to the invention, characterized in that they are selected from the sequences SEQ ID No. 9, SEQ ID No. 11, SEQ ID No. 13, SEQ ID No. 23, SEQ ID No. 25, SEQ ID No. 27 or one of their fragments.

[0096] The invention likewise relates to nucleotide sequences characterized in that they comprise a nucleotide sequence selected from:

[0097] a) a nucleotide sequence SEQ ID No. 9, SEQ ID No. 11, SEQ ID No. 13, SEQ ID No. 23, SEQ ID No. 25, SEQ ID No. 27 or one of their fragments;

[0098] b) a nucleotide sequence of a specific fragment of a sequence such as defined in a);

[0099] c) a homologous nucleotide sequence having at least 80% identity with a sequence such as defined in a) or b);

[0100] d) a complementary nucleotide sequence or sequence of RNA corresponding to a sequence such as defined in a), b) or c); and

[0101] e) a nucleotide sequence modified by a sequence such as defined in a), b), c) or d).

[0102] As far as homology with the nucleotide sequences SEQ ID No. 9, SEQ ID No. 11, SEQ ID No. 13, SEQ ID No. 23, SEQ ID No. 25, SEQ ID No. 27 or one of their fragments is concerned, the homologous, especially specific, sequences having a percentage identity with one of the sequences SEQ ID No. 9, SEQ ID No. 11, SEQ ID No. 13, SEQ ID No. 23, SEQ ID No. 25, SEQ ID No. 27 or one of their fragments of at least 80%, preferably 90% or 95%, are preferred. Said specific homologous sequences can comprise, for example, the sequences corresponding to the sequences ORF1, ORF2, ORF3, ORF′1, ORF′2 and ORF′3 of PWD circovirus variants of type A or of type B. In the same manner, these specific homologous sequences can correspond to variations linked to mutations within strains of PWD circovirus of type A or of type B and especially correspond to truncations, substitutions, deletions and/or additions of at least one nucleotide.

[0103] Among nucleotide sequences according to the invention, the sequence SEQ ID No. 23 which has a homology having more than 80% identity with the sequence SEQ ID No. 9, as well as the sequence SEQ ID No. 25, are especially preferred.

[0104] Preferably, the invention relates to the nucleotide sequences according to the invention, characterized in that they comprise a nucleotide sequence selected from the following sequences: a) 170 5′ TGTGGCGA 3′; SEQ ID No. 33 b) 450 5′ AGTTTCCT 3′; SEQ ID No. 34 c) 1026 5′ TCATTTAGAGGGTCTTTCAG 3′, SEQ ID No. 35 d) 1074 5′ GTCAACCT 3′; SEQ ID No. 36 e) 1101 5′ GTGGTTGC 3′; SEQ ID No. 37 f) 1123 5′ AGCCCAGG 3′; SEQ ID No. 38 g) 1192 5′ TTGGCTGG 3′; SEQ ID No. 39 h) 1218 5′ TCTAGCTCTGGT 3′; SEQ ID No. 40 i) 1501 5′ ATCTCAGCTCGT 3′ SEQ ID No. 41 j) 1536 5′ TGTCCTCCTCTT 3′; SEQ ID No. 42 k) 1563 5′ TCTCTAGA 3′; SEQ ID No. 43 l) 1623 5′ TGTACCAA 3′; SEQ ID No. 44 m) 1686 5′ TCCGTCTT 3′; SEQ ID No. 45

[0105] and their complementary sequences.

[0106] In the list of nucleotide sequences a)-m) above, the underlined nucleotides are mutated with respect to the two known sequences of circovirus which are nonpathogenic to pigs. The number preceding the nucleotide sequence represents the position of the first nucleotide of said sequence in the sequence SEQ ID No. 1.

[0107] The invention comprises the polypeptides encoded by a nucleotide sequence according to the invention, preferably a polypeptide whose sequence is represented by a fragment, especially a specific fragment, of one of the six sequences of amino acids represented in FIG. 2, these six amino acid sequences corresponding to the polypeptides which can be encoded according to one of the three possible reading frames of the sequence SEQ ID No. 1 or of the sequence SEQ ID No. 5, or a polypeptide whose sequence is represented by a fragment, especially a specific fragment, of one of the six sequences of amino acids shown in FIG. 8, these six sequences of amino acids corresponding to the polypeptides which can be encoded according to one of the three possible reading frames of the sequence SEQ ID No. 15 or of the sequence SEQ ID No. 19.

[0108] The invention likewise relates to the polypeptides, characterized in that they comprise a polypeptide selected from the amino acid sequences SEQ ID No. 10, SEQ ID No. 12, SEQ ID No. 14, SEQ ID No. 24, SEQ ID No. 26, SEQ ID No. 28 or one of their fragments.

[0109] Among the polypeptides according to the invention, the polypeptide of amino acid sequence SEQ ID No. 24 which has a homology having more than 80% identity with the sequence SEQ ID No. 10, as well as the polypeptide of sequence SEQ ID No. 26, are especially preferred.

[0110] The invention also relates to the polypeptides, characterized in that they comprise a polypeptide selected from:

[0111] a) a specific fragment of at least 5 amino acids of a polypeptide of an amino acid sequence according to the invention;

[0112] b) a polypeptide homologous to a polypeptide such as defined in a);

[0113] c) a specific biologically active fragment of a polypeptide such as defined in a) or b); and

[0114] d) a polypeptide modified by a polypeptide such as defined in a), b) or c).

[0115] Among the polypeptides according to the invention, the polypeptides of amino acid sequences SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31 and SEQ ID No. 32 are also preferred, these polypeptides being especially capable of specifically recognizing the antibodies produced during infection by the PWD circovirus of type B. These polypeptides thus have epitopes specific for the PWD circovirus of type B and can thus be used in particular in the diagnostic field or as immunogenic agent to confer protection in pigs against infection by PWD circovirus, especially of type B.

[0116] In the present description, the terms polypeptide, peptide and protein are interchangeable.

[0117] It must be understood that the invention does not relate to the polypeptides in natural form, that is to say that they are not taken in their natural environment but that they can be isolated or obtained by purification from natural sources, or else obtained by genetic recombination, or alternatively by chemical synthesis and that they can thus contain unnatural amino acids, as will be described below.

[0118] Polypeptide fragment according to the invention is understood as designating a polypeptide containing at least 5 consecutive amino acids, preferably 10 consecutive amino acids or 15 consecutive amino acids.

[0119] In the present invention, specific polypeptide fragment is understood as designating the consecutive polypeptide fragment encoded by a specific fragment nucleotide sequence according to the invention.

[0120] Homologous polypeptide will be understood as designating the polypeptides having, with respect to the natural polypeptide, certain modifications such as, in particular, a deletion, addition or substitution of at least one amino acid, a truncation, a prolongation, a chimeric fusion, and/or a mutation. Among the homologous polypeptides, those are preferred whose amino acid sequence has at least 80%, preferably 90%, homology with the sequences of amino acids of polypeptides according to the invention.

[0121] Specific homologous polypeptide will be understood as designating the homologous polypeptides such as defined above and having a specific fragment of polypeptide according to the invention.

[0122] In the case of a substitution, one or more consecutive or nonconsecutive amino acids are replaced by “equivalent” amino acids. The expression “equivalent” amino acid is directed here at designating any amino acid capable of being substituted by one of the amino acids of the base structure without, however, essentially modifying the biological activities of the corresponding peptides and such that they will be defined by the following.

[0123] These equivalent amino acids can be determined either by depending on their structural homology with the amino acids which they substitute, or on results of comparative tests of biological activity between the different polypeptides, which are capable of being carried out.

[0124] By way of example, the possibilities of substitutions capable of being carried out without resulting in an extensive modification of the biological activity of the corresponding modified polypeptides will be mentioned, the replacement, for example, of leucine by valine or isoleucine, of aspartic acid by glutamic acid, of glutamine by asparagine, of arginine by lysine etc., the reverse substitutions naturally being envisageable under the same conditions.

[0125] The specific homologous polypeptides likewise correspond to polypeptides encoded by the specific homologous nucleotide sequences such as defined above and thus comprise in the present definition the polypeptides which are mutated or correspond to variants which can exist in PWD circovirus, and which especially correspond to truncations, substitutions, deletions and/or additions of at least one amino acid residue.

[0126] Specific biologically active fragment of a polypeptide according to the invention will be understood in particular as designating a specific polypeptide fragment, such as defined above, having at least one of the characteristics of polypeptides according to the invention, especially in that it is:

[0127] capable of inducing an immunogenic reaction directed against a PWD circovirus; and/or

[0128] capable of being recognized by a specific antibody of a polypeptide according to the invention; and/or

[0129] capable of linking to a polypeptide or to a nucleotide sequence of PWD circovirus; and/or

[0130] capable of exerting a physiological activity, even partial, such as, for example, a dissemination or structural (capsid) activity; and/or

[0131] capable of modulating, of inducing or of inhibiting the expression of PWD circovirus gene or one of its variants, and/or capable of modulating the replication cycle of PWD circovirus in the cell and/or the host organism.

[0132] The polypeptide fragments according to the invention can correspond to isolated or purified fragments naturally present in a PWD circovirus or correspond to fragments which can be obtained by cleavage of said polypeptide by a proteolytic enzyme, such as trypsin or chymotrypsin or collagenase, or by a chemical reagent, such as cyanogen bromide (CNBr) or alternatively by placing said polypeptide in a very acidic environment, for example at pH 2.5. Such polypeptide fragments can likewise just as easily be prepared by chemical synthesis, from hosts transformed by an expression vector according to the invention containing a nucleic acid allowing the expression of said fragments, placed under the control of appropriate regulation and/or expression elements.

[0133] “Modified polypeptide” of a polypeptide according to the invention is understood as designating a polypeptide obtained by genetic recombination or by chemical synthesis as will be described below, having at least one modification with respect to the normal sequence. These modifications will especially be able to bear on amino acids at the origin of a specificity, of pathogenicity and/or of virulence, or at the origin of the structural conformation, and of the capacity of membrane insertion of the polypeptide according to the invention. It will thus be possible to create polypeptides of equivalent, increased or decreased activity, and of equivalent, narrower, or wider specificity. Among the modified polypeptides, it is necessary to mention the polypeptides in which up to 5 amino acids can be modified, truncated at the N- or C-terminal end, or even deleted or added.

[0134] As is indicated, the modifications of the polypeptide will especially have as objective:

[0135] to render it capable of modulating, of inhibiting or of inducing the expression of PWD circovirus gene and/or capable of modulating the replication cycle of PWD circovirus in the cell and/or the host organism,

[0136] of allowing its incorporation into vaccine compositions,

[0137] of modifying its bioavailability as a compound for therapeutic use.

[0138] The methods allowing said modulations on eukaryotic or prokaryotic cells to be demonstrated are well known to the person skilled in the art. It is likewise well understood that it will be possible to use the nucleotide sequences coding for said modified polypeptides for said modulations, for example through vectors according to the invention and described below, in order, for example, to prevent or to treat the pathologies linked to the infection.

[0139] The preceding modified polypeptides can be obtained by using combinatorial chemistry, in which it is possible to systematically vary parts of the polypeptide before testing them on models, cell cultures or microorganisms for example, to select the compounds which are most active or have the properties sought.

[0140] Chemical synthesis likewise has the advantage of being able to use:

[0141] unnatural amino acids, or

[0142] nonpeptide bonds.

[0143] Thus, in order to improve the duration of life of the polypeptides according to the invention, it may be of interest to use unnatural amino acids, for example in D form, or else amino acid analogs, especially sulfur-containing forms, for example.

[0144] Finally, it will be possible to integrate the structure of the polypeptides according to the invention, its specific or modified homologous forms, into chemical structures of polypeptide type or others. Thus, it may be of interest to provide at the N- and C-terminal ends compounds not recognized by the proteases.

[0145] The nucleotide sequences coding for a polypeptide according to the invention are likewise part of the invention.

[0146] The invention likewise relates to nucleotide sequences utilizable as a primer or probe, characterized in that said sequences are selected from the nucleotide sequences according to the invention.

[0147] Among the pairs of nucleotide sequences utilizable as a pair of primers according to the invention, the pairs of primers selected from the following pairs are preferred: SEQ ID No. 46 a) 5′ GTG TGC TCG ACA TTG GTG TG 3′, and SEQ ID No. 47 5′ TGG AAT GTT AAC GAG CTG AG 3′; SEQ ID No. 46 b) 5′ GTG TGC TCG ACA TTG GTG TG 3′, and SEQ ID No. 48 5′ CTC GCA GCC ATC TTG GAA TG 3′; SEQ ID No. 49 c) 5′ CGC GCG TAA TAC GAC TCA CT 3′, and SEQ ID No. 46 5′ GTG TGC TCG ACA TTG GTG TG 3′; SEQ ID No. 49 d) 5′ CGC GCG TAA TAC GAC TCA CT 3′, and SEQ ID No. 48 5′ CTC GCA GCC ATC TTG GAA TG 3′; and SEQ ID No. 50 e) 5′ CCT GTC TAC TGC TGT GAG TAC CTT GT 3′, and SEQ ID No. 51 5′ GCA GTA GAC AGG TCA CTC CGT TGT CC 3′.

[0148] The cloning and the sequencing of the PWD circovirus, type A and B, has allowed it to be identified, after comparative analysis with the nucleotide sequences of other porcine circoviruses, that, among the sequences of fragments of these nucleic acids, were those which are strictly specific to the PWD circovirus of type A, of type B or of type A and B, and those which correspond to a consensus sequence of porcine circoviruses other than the PWD circoviruses of type A and/or B.

[0149] There is likewise a great need for nucleotide sequences utilizable as a primer or probe specific to the whole of the other known and nonpathogenic porcine circoviruses.

[0150] Said consensus nucleotide sequences specific to all circoviruses, other than PWD circovirus of type A and B, are easily identifiable from FIG. 3 and the sequence SEQ ID No. 15, and are part of the invention.

[0151] Among said consensus nucleotide sequences, that which is characterized in that it is part of the following pair of primers is preferred: a) 5′ GTG TGC TCG ACA TTG GTG TG 3′, and SEQ ID No. 46 5′ TGG AAT GTT AAC TAC CTC AA 3′. SEQ ID No. 52

[0152] The invention likewise comprises a nucleotide sequence according to the invention, characterized in that said sequence is a specific consensus sequence of porcine circovirus other than PWD circovirus of type B and in that it is one of the primers of the following pairs of primers: SEQ ID No. 53 a) 5′ GGC GGC GCC ATC TGT AAC GGT TT 3′, and SEQ ID No.54 5′ GAT GGC GCC GAA AGA CGG GTA TC 3′.

[0153] It is well understood that the present invention likewise relates to specific polypeptides of known porcine circoviruses other than PWD circovirus, encoded by said consensus nucleotide sequences, capable of being obtained by purification from natural polypeptides, by genetic recombination or by chemical synthesis by procedures well known to the person skilled in the art and such as described in particular below. In the same manner, the labeled or unlabeled mono- or polyclonal antibodies directed against said specific polypeptides encoded by said consensus nucleotide sequences are also part of the invention.

[0154] It will be possible to use said consensus nucleotide sequences, said corresponding polypeptides as well as said antibodies directed against said polypeptides in procedures or sets for detection and/or identification such as described below, in place of or in addition to nucleotide sequences, polypeptides or antibodies according to the invention, specific to PWD circovirus type A and/or B.

[0155] These protocols have been improved for the differential detection of the circular monomeric forms of specific replicative forms of the virion or of the DNA in replication and the dimeric forms found in so-called in-tandem molecular constructs.

[0156] The invention additionally relates to the use of a nucleotide sequence according to the invention as a primer or probe for the detection and/or the amplification of nucleic acid sequences.

[0157] The nucleotide sequences according to the invention can thus be used to amplify nucleotide sequences, especially by the PCR technique (polymerase chain reaction) (Erlich, 1989; Innis et al., 1990; Rolfs et al., 1991; and White et al., 1997).

[0158] These oligodeoxyribonucleotide or oligoribonucleotide primers advantageously have a length of at least 8 nucleotides, preferably of at least 12 nucleotides, and even more preferentially at least 20 nucleotides.

[0159] Other amplification techniques of the target nucleic acid can be advantageously employed as alternatives to PCR.

[0160] The nucleotide sequences of the invention, in particular the primers according to the invention, can likewise be employed in other procedures of amplification of a target nucleic acid, such as:

[0161] the TAS technique (Transcription-based Amplification System), described by Kwoh et al. in 1989;

[0162] the 3SR technique (Self-Sustained Sequence Replication), described by Guatelli et al. in 1990;

[0163] the NASBA technique (Nucleic Acid Sequence Based Amplification), described by Kievitis et al. in 1991;

[0164] the SDA technique (Strand Displacement Amplification) (Walker et al., 1992);

[0165] the TMA technique (Transcription Mediated Amplification).

[0166] The polynucleotides of the invention can also be employed in techniques of amplification or of modification of the nucleic acid serving as a probe, such as:

[0167] the LCR technique (Ligase Chain Reaction), described by Landegren et al. in 1988 and improved by Barany et al. in 1991, which employs a thermostable ligase;

[0168] the RCR technique (Repair Chain Reaction), described by Segev in 1992;

[0169] the CPR technique (Cycling Probe Reaction), described by Duck et al. in 1990;

[0170] the amplification technique with Q-beta replicase, described by Miele et al. in 1983 and especially improved by Chu et al. in 1986, Lizardi et al. in 1988, then by Burg et al. as well as by Stone et al. in 1996.

[0171] In the case where the target polynucleotide to be detected is possibly an RNA, for example an mRNA, it will be possible to use, prior to the employment of an amplification reaction with the aid of at least one primer according to the invention or to the employment of a detection procedure with the aid of at least one probe of the invention, an enzyme of reverse transcriptase type in order to obtain a cDNA from the RNA contained in the biological sample. The cDNA obtained will thus serve as a target for the primer(s) or the probe(s) employed in the amplification or detection procedure according to the invention.

[0172] The detection probe will be chosen in such a manner that it hybridizes with the target sequence or the amplicon generated from the target sequence. By way of sequence, such a probe will advantageously have a sequence of at least 12 nucleotides, in particular of at least 20 nucleotides, and preferably of at least 100 nucleotides.

[0173] The invention also comprises the nucleotide sequences utilizable as a probe or primer according to the invention, characterized in that they are labeled with a radioactive compound or with a nonradioactive compound.

[0174] The unlabeled nucleotide sequences can be used directly as probes or primers, although the sequences are generally labeled with a radioactive element (³²P, ³⁵S, ³H, ¹²⁵I) or with a nonradioactive molecule (biotin, acetylaminofluorene, digoxigenin, 5-bromodeoxyuridine, fluorescein) to obtain probes which are utilizable for numerous applications.

[0175] Examples of nonradioactive labeling of nucleotide sequences are described, for example, in French Patent No. 78.10975 or by Urdea et al. or by Sanchez-Pescador et al. in 1988.

[0176] In the latter case, it will also be possible to use one of the labeling methods described in patents FR-2 422 956 and FR-2 518 755.

[0177] The hybridization technique can be carried out in various manners (Matthews et al., 1988). The most general method consists in immobilizing the nucleic acid extract of cells on a support (such as nitrocellulose, nylon, polystyrene) and in incubating, under well-defined conditions, the immobilized target nucleic acid with the probe. After hybridization, the excess of probe is eliminated and the hybrid molecules formed are detected by the appropriate method (measurement of the radioactivity, of the fluorescence or of the enzymatic activity linked to the probe).

[0178] The invention likewise comprises the nucleotide sequences according to the invention, characterized in that they are immobilized on a support, covalently or noncovalently.

[0179] According to another advantageous mode of employing nucleotide sequences according to the invention, the latter can be used immobilized on a support and can thus serve to capture, by specific hybridization, the target nucleic acid obtained from the biological sample to be tested. If necessary, the solid support is separated from the sample and the hybridization complex formed between said capture probe and the target nucleic acid is then detected with the aid of a second probe, a so-called detection probe, labeled with an easily detectable element.

[0180] Another subject of the present invention is a vector for the cloning and/or expression of a sequence, characterized in that it contains a nucleotide sequence according to the invention.

[0181] The vectors according to the invention, characterized in that they contain the elements allowing the expression and/or the secretion of said nucleotide sequences in a determined host cell, are likewise part of the invention.

[0182] The vector must then contain a promoter, signals of initiation and termination of translation, as well as appropriate regions of regulation of transcription. It must be able to be maintained stably in the host cell and can optionally have particular signals specifying the secretion of the translated protein. These different elements are chosen as a function of the host cell used. To this end, the nucleotide sequences according to the invention can be inserted into autonomous replication vectors within the chosen host, or integrated vectors of the chosen host.

[0183] Such vectors will be prepared according to the methods currently used by the person skilled in the art, and it will be possible to introduce the clones resulting therefrom into an appropriate host by standard methods, such as, for example, lipofection, electroporation and thermal shock.

[0184] The vectors according to the invention are, for example, vectors of plasmid or viral origin.

[0185] A preferred vector for the expression of polypeptides of the invention is baculovirus.

[0186] The vector pBS KS in which is inserted the in-tandem DNA sequence of the PWD circovirus type A (or DFP) as deposited at the CNCM on Jul. 3, 1997, under the number 1-1891, is likewise preferred.

[0187] These vectors are useful for transforming host cells in order to clone or to express the nucleotide sequences of the invention.

[0188] The invention likewise comprises the host cells transformed by a vector according to the invention.

[0189] These cells can be obtained by the introduction into host cells of a nucleotide sequence inserted into a vector such as defined above, then the culturing of said cells under conditions allowing the replication and/or expression of the transfected nucleotide sequence.

[0190] The host cell can be selected from prokaryotic or eukaryotic systems, such as, for example, bacterial cells (Olins and Lee, 1993), but likewise yeast cells (Buckholz, 1993), as well as animal cells, in particular the cultures of mammalian cells (Edwards and Aruffo, 1993), and especially Chinese hamster ovary (CHO) cells, but likewise the cells of insects in which it is possible to use procedures employing baculoviruses, for example (Luckow, 1993).

[0191] A preferred host cell for the expression of the proteins of the invention is constituted by sf9 insect cells.

[0192] A more preferred host cell according to the invention is E. coli, such as deposited at the CNCM on Jul. 3, 1997, under the number 1-1891.

[0193] The invention likewise relates to animals comprising one of said transformed cells according to the invention.

[0194] The obtainment of transgenic animals according to the invention overexpressing one or more of the genes of PWD circovirus or part of the genes will be preferably carried out in rats, mice or rabbits according to methods well known to the person skilled in the art, such as by viral or nonviral transfections. It will be possible to obtain the transgenic animals overexpressing one or more of said genes by transfection of multiple copies of said genes under the control of a strong promoter of ubiquitous nature, or selective for one type of tissue. It will likewise be possible to obtain the transgenic animals by homologous recombination in embryonic cell strains, transfer of these cell strains to embryos, selection of the affected chimeras at the level of the reproductive lines, and growth of said chimeras.

[0195] The transformed cells as well as the transgenic animals according to the invention are utilizable in procedures for preparation of recombinant polypeptides.

[0196] It is today possible to produce recombinant polypeptides in relatively large quantity by genetic engineering using the cells transformed by expression vectors according to the invention or using transgenic animals according to the invention.

[0197] The procedures for preparation of a polypeptide of the invention in recombinant form, characterized in that they employ a vector and/or a cell transformed by a vector according to the invention and/or a transgenic animal comprising one of said transformed cells according to the invention, are themselves comprised in the present invention.

[0198] Among said procedures for preparation of a polypeptide of the invention in recombinant form, the preparation procedures employing a vector, and/or a cell transformed by said vector and/or a transgenic animal comprising one of said transformed cells, containing a nucleotide sequence according to the invention coding for a polypeptide of PWD circovirus, are preferred.

[0199] The recombinant polypeptides obtained as indicated above can just as well be present in glycosylated form as in nonglycosylated form and can or cannot have the natural tertiary structure.

[0200] A preferred variant consists in producing a recombinant polypeptide used to a “carrier” protein (chimeric protein). The advantage of this system is that it allows a stabilization of and a decrease in the proteolysis of the recombinant product, an increase in the solubility in the course of renaturation in vitro and/or a simplification of the purification when the fusion partner has an affinity for a specific ligand.

[0201] More particularly, the invention relates to a procedure for preparation of a polypeptide of the invention comprising the following steps:

[0202] a) culture of transformed cells under conditions allowing the expression of a recombinant polypeptide of nucleotide sequence according to the invention;

[0203] b) if need be, recovery of said recombinant polypeptide.

[0204] When the procedure for preparation of a polypeptide of the invention employs a transgenic animal according to the invention, the recombinant polypeptide is then extracted from said animal.

[0205] The invention also relates to a polypeptide which is capable of being obtained by a procedure of the invention such as described previously.

[0206] The invention also comprises a procedure for preparation of a synthetic polypeptide, characterized in that it uses a sequence of amino acids of polypeptides according to the invention.

[0207] The invention likewise relates to a synthetic polypeptide obtained by a procedure according to the invention.

[0208] The polypeptides according to the invention can likewise be prepared by techniques which are conventional in the field of the synthesis of peptides. This synthesis can be carried out in homogeneous solution or in solid phase.

[0209] For example, recourse can be made to the technique of synthesis in homogeneous solution described by Houben-Weyl in 1974.

[0210] This method of synthesis consists in successively condensing, two by two, the successive amino acids in the order required, or in condensing amino acids and fragments formed previously and already containing several amino acids in the appropriate order, or alternatively several fragments previously prepared in this way, it being understood that it will be necessary to protect beforehand all the reactive functions carried by these amino acids or fragments, with the exception of amine functions of one and carboxyls of the other or vice-versa, which must normally be involved in the formation of peptide bonds, especially after activation of the carboxyl function, according to the methods well known in the synthesis of peptides.

[0211] According to another preferred technique of the invention, recourse will be made to the technique described by Merrifield.

[0212] To make a peptide chain according to the Merrifield procedure, recourse is made to a very porous polymeric resin, on which is immobilized the first C-terminal amino acid of the chain. This amino acid is immobilized on a resin through its carboxyl group and its amine function is protected. The amino acids which are going to form the peptide chain are thus immobilized, one after the other, on the amino group, which is deprotected beforehand each time, of the portion of the peptide chain already formed, and which is attached to the resin. When the whole of the desired peptide chain has been formed, the protective groups of the different amino acids forming the peptide chain are eliminated and the peptide is detached from the resin with the aid of an acid.

[0213] The invention additionally relates to hybrid polypeptides having at least one polypeptide according to the invention, and a sequence of a polypeptide capable of inducing an immune response in man or animals.

[0214] Advantageously, the antigenic determinant is such that it is capable of inducing a humoral and/or cellular response.

[0215] It will be possible for such a determinant to comprise a polypeptide according to the invention in glycosylated form used with a view to obtaining immunogenic compositions capable of inducing the synthesis of antibodies directed against multiple epitopes. Said polypeptides or their glycosylated fragments are likewise part of the invention.

[0216] These hybrid molecules can be formed, in part, of a polypeptide carrier molecule or of fragments thereof according to the invention, associated with a possibly immunogenic part, in particular an epitope of the diphtheria toxin, the tetanus toxin, a surface antigen of the hepatitis B virus (patent FR 79 21811), the VP1 antigen of the poliomyelitis virus or any other viral or bacterial toxin or antigen.

[0217] The procedures for synthesis of hybrid molecules encompass the methods used in genetic engineering for constructing hybrid nucleotide sequences coding for the polypeptide sequences sought. It will be possible, for example, to refer advantageously to the technique for obtainment of genes coding for fusion proteins described by Minton in 1984.

[0218] Said hybrid nucleotide sequences coding for a hybrid polypeptide as well as the hybrid polypeptides according to the invention characterized in that they are recombinant polypeptides obtained by the expression of said hybrid nucleotide sequences are likewise part of the invention.

[0219] The invention likewise comprises the vectors characterized in that they contain one of said hybrid nucleotide sequences. The host cells transformed by said vectors, the transgenic animals comprising one of said transformed cells as well as the procedures for preparation of recombinant polypeptides using said vectors, said transformed cells and/or said transgenic animals are, of course, likewise part of the invention.

[0220] The polypeptides according to the invention, the antibodies according to the invention described below and the nucleotide sequences according to the invention can advantageously be employed in procedures for the detection and/or identification of PWD circovirus, or of porcine circovirus other than a PWD circovirus, in a biological sample (biological tissue or fluid) capable of containing them. These procedures, according to the specificity of the polypeptides, the antibodies and the nucleotide sequences according to the invention which will be used, will in particular be able to detect and/or to identify a PWD circovirus or a porcine circovirus other than a PWD circovirus or other than the PWD circovirus of type B.

[0221] The polypeptides according to the invention can advantageously be employed in a procedure for the detection and/or the identification of PWD circovirus of type A, of type B, of type A or B, or porcine circovirus other than the PWD circovirus of type B, or of porcine circovirus other than the PWD circovirus of type A or B, in a biological sample (biological tissue or fluid) capable of containing them, characterized in that it comprises the following steps:

[0222] a) contacting of this biological sample with a polypeptide or one of its fragments according to the invention (under conditions allowing an immunological reaction between said polypeptide and the antibodies possibly present in the biological sample);

[0223] b) demonstration of the antigen-antibody complexes possibly formed.

[0224] In the present description, PWD circovirus, except if a particular mention is indicated, will be understood as designating a PWD circovirus of type A or of type B, and porcine circovirus other than PWD, except if a particular mention is indicated, will be understood as designating a porcine circovirus other than a PWD circovirus of type A and B.

[0225] Preferably, the biological sample is formed by a fluid, for example a pig serum, whole blood or biopsies.

[0226] Any conventional procedure can be employed for carrying out such a detection of the antigen-antibody complexes possibly formed.

[0227] By way of example, a preferred method brings into play immunoenzymatic processes according to the ELISA technique, by immunofluorescence, or radioimmunological processes (RIA) or their equivalent.

[0228] Thus, the invention likewise relates to the polypeptides according to the invention, labeled with the aid of an adequate label such as of the enzymatic, fluorescent or radioactive type.

[0229] Such methods comprise, for example, the following steps:

[0230] deposition of determined quantities of a polypeptide composition according to the invention in the wells of a microtiter plate,

[0231] introduction into said wells of increasing dilutions of serum, or of a biological sample other than that defined previously, having to be analyzed,

[0232] incubation of the microplate,

[0233] introduction into the wells of the microtiter plate of labeled antibodies directed against pig immunoglobulins, the labeling of these antibodies having been carried out with the aid of an enzyme selected from those which are capable of hydrolyzing a substrate by modifying the absorption of the radiation of the latter, at least at a determined wavelength, for example at 550 nm,

[0234] detection, by comparison with a control test, of the quantity of hydrolyzed substrate.

[0235] The invention likewise relates to a kit or set for the detection and/or identification of PWD circovirus, of porcine circovirus other than a PWD circovirus or of porcine circovirus other than the PWD circovirus of type B, characterized in that it comprises the following elements:

[0236] a polypeptide according to the invention,

[0237] if need be, the reagents for the formation of the medium favorable to the immunological or specific reaction,

[0238] if need be, the reagents allowing the detection of the antigen-antibody complexes produced by the immunological reaction between the polypeptide(s) of the invention and the antibodies possibly present in the biological sample, these reagents likewise being able to carry a label, or to be recognized in their turn by a labeled reagent, more particularly in the case where the polypeptide according to the invention is not labeled,

[0239] if need be, a biological reference sample (negative control) devoid of antibodies recognized by a polypeptide according to the invention,

[0240] if need be, a biological reference sample (positive control) containing a predetermined quantity of antibodies recognized by a polypeptide according to the invention.

[0241] The polypeptides according to the invention allow monoclonal or polyclonal antibodies to be prepared which are characterized in that they specifically recognize the polypeptides according to the invention. It will advantageously be possible to prepare the monoclonal antibodies from hybridomas according to the technique described by Kohler and Milstein in 1975. It will be possible to prepare the polyclonal antibodies, for example, by immunization of an animal, in particular a mouse, with a polypeptide or a DNA, according to the invention, associated with an adjuvant of the immune response, and then purification of the specific antibodies contained in the serum of the immunized animals on an affinity column on which the polypeptide which has served as an antigen has previously been immobilized. The polyclonal antibodies according to the invention can also be prepared by purification, on an affinity column on which a polypeptide according to the invention has previously been immobilized, of the antibodies contained in the serum of pigs infected by a PWD circovirus.

[0242] The invention likewise relates to mono- or polyclonal antibodies or their fragments, or chimeric antibodies, characterized in that they are capable of specifically recognizing a polypeptide according to the invention.

[0243] It will likewise be possible for the antibodies of the invention to be labeled in the same manner as described previously for the nucleic probes of the invention, such as a labeling of enzymatic, fluorescent or radioactive type.

[0244] The invention is additionally directed at a procedure for the detection and/or identification of PWD circovirus, of porcine circovirus other than a PWD circovirus, or other than the PWD circovirus of type B, in a biological sample, characterized in that it comprises the following steps:

[0245] a) contacting of the biological sample (biological tissue or fluid) with a mono- or polyclonal antibody according to the invention (under conditions allowing an immunological reaction between said antibodies and the polypeptides of PWD circovirus, of porcine circovirus other than a PWD circovirus, of porcine circovirus other than the PWD circovirus of type B, possibly present in the biological sample);

[0246] b) demonstration of the antigen-antibody complex possibly formed.

[0247] Likewise within the scope of the invention is a kit or set for the detection and/or the identification of PWD circovirus, of porcine circovirus other than a PWD circovirus or of porcine circovirus other than the PWD circovirus of type B, characterized in that it comprises the following components:

[0248] a polyclonal or monoclonal antibody according to the invention, if need be labeled;

[0249] if need be, a reagent for the formation of the medium favorable to the carrying out of the immunological reaction;

[0250] if need be, a reagent allowing the detection of the antigen-antibody complexes produced by the immunological reaction, this reagent likewise being able to carry a label, or being capable of being recognized in its turn by a labeled reagent, more particularly in the case where said monoclonal or polyclonal antibody is not labeled;

[0251] if need be, reagents for carrying out the lysis of cells of the sample tested.

[0252] The present invention likewise relates to a procedure for the detection and/or the identification of PWD, of porcine circovirus other than a PWD circovirus or of porcine circovirus other than the PWD circovirus of type B, in a biological sample, characterized in that it employs a nucleotide sequence according to the invention.

[0253] More particularly, the invention relates to a procedure for the detection and/or the identification of PWD circovirus, of porcine circovirus other than a PWD circovirus or of porcine circovirus other than the PWD circovirus of type B, in a biological sample, characterized in that it contains the following steps:

[0254] a) if need be, isolation of the DNA from the biological sample to be analyzed;

[0255] b) specific amplification of the DNA of the sample with the aid of at least one primer, or a pair of primers, according to the invention;

[0256] c) demonstration of the amplification products.

[0257] These can be detected, for example, by the technique of molecular hybridization utilizing a nucleic probe according to the invention. This probe will advantageously be labeled with a nonradioactive (cold probe) or radioactive element.

[0258] For the purposes of the present invention, “DNA of the biological sample” or “DNA contained in the biological sample” will be understood as meaning either the DNA present in the biological sample considered, or possibly the cDNA obtained after the action of an enzyme of reverse transcriptase type on the RNA present in said biological sample.

[0259] Another aim of the present invention consists in a procedure according to the invention, characterized in that it comprises the following steps:

[0260] a) contacting of a nucleotide probe according to the invention with a biological sample, the DNA contained in the biological sample having, if need be, previously been made accessible to hybridization under conditions allowing the hybridization of the probe with the DNA of the sample;

[0261] b) demonstration of the hybrid formed between the nucleotide probe and the DNA of the biological sample.

[0262] The present invention also relates to a procedure according to the invention, characterized in that it comprises the following steps:

[0263] a) contacting of a nucleotide probe immobilized on a support according to the invention with a biological sample, the DNA of the sample having, if need be, previously been made accessible to hybridization, under conditions allowing the hybridization of the probe with the DNA of the sample;

[0264] b) contacting of the hybrid formed between the nucleotide probe immobilized on a support and the DNA contained in the biological sample, if need be after elimination of the DNA of the biological sample which has not hybridized with the probe, with a nucleotide probe labeled according to the invention;

[0265] c) demonstration of the novel hybrid formed in step b).

[0266] According to an advantageous embodiment of the procedure for detection and/or identification defined previously, this is characterized in that, prior to step a), the DNA of the biological sample is first amplified with the aid of at least one primer according to the invention.

[0267] The invention is additionally directed at a kit or set for the detection and/or the identification of PWD circovirus, of porcine circovirus other than the PWD circovirus or of porcine circovirus other than the PWD circovirus of type B, characterized in that it comprises the following elements:

[0268] a) a nucleotide probe according to the invention;

[0269] b) if need be, the reagents necessary for the carrying out of a hybridization reaction;

[0270] c) if need be, at least one primer according to the invention as well as the reagents necessary for an amplification reaction of the DNA.

[0271] The invention likewise relates to a kit or set for the detection and/or the identification of PWD circovirus, of porcine circovirus other than a PWD circovirus or of porcine circovirus other than the PWD circovirus of type B, characterized in that it comprises the following components:

[0272] a) a nucleotide probe, called a capture probe, according to the invention;

[0273] b) an oligonucleotide probe, called a revealing probe, according to the invention,

[0274] c) if need be, at least one primer according to the invention, as well as the reagents necessary for an amplification reaction of the DNA.

[0275] The invention also relates to a kit or set for the detection and/or identification of PWD circovirus, of porcine circovirus other than a PWD circovirus or of porcine circovirus other than the PWD circovirus of type B, characterized in that it comprises the following elements:

[0276] a) at least one primer according to the invention;

[0277] b) if need be, the reagents necessary for carrying out a DNA amplification reaction;

[0278] c) if need be, a component allowing the sequence of the amplified fragment to be verified, more particularly an oligonucleotide probe according to the invention.

[0279] The invention additionally relates to the use of a nucleotide sequence according to the invention, of a polypeptide according to the invention, of an antibody according to the invention, of a cell according to the invention, and/or of an animal transformed according to the invention, for the selection of an organic or inorganic compound capable of modulating, inducing or inhibiting the expression of genes, and/or of modifying the cellular replication of PWD circovirus or capable of inducing or of inhibiting the pathologies linked to an infection by a PWD circovirus.

[0280] The invention likewise comprises a method of selection of compounds capable of binding to a polypeptide or one of its fragments according to the invention, capable of binding to a nucleotide sequence according to the invention, or capable of recognizing an antibody according to the invention, and/or capable of modulating, inducing or inhibiting the expression of genes, and/or of modifying the cellular replication of PWD circovirus or capable of inducing or inhibiting the pathologies linked to an infection by a PWD circovirus, characterized in that it comprises the following steps:

[0281] a) contacting of said compound with said polypeptide, said nucleotide sequence, or with a cell transformed according to the invention and/or administration of said compound to an animal transformed according to the invention;

[0282] b) determination of the capacity of said compound to bind to said polypeptide or said nucleotide sequence, or to modulate, induce or inhibit the expression of genes, or to modulate the growth or the replication of PWD circovirus, or to induce or inhibit in said transformed animal the pathologies linked to an infection by PWD circovirus (designated activity of said compound).

[0283] The compounds capable of being selected can be organic compounds such as polypeptides or carbohydrates or any other organic or inorganic compounds already known, or novel organic compounds elaborated by molecular modelling techniques and obtained by chemical or biochemical synthesis, these techniques being known to the person skilled in the art.

[0284] It will be possible to use said selected compounds to modulate the cellular replication of PWD circovirus and thus to control infection by this virus, the methods allowing said modulations to be determined being well known to the person skilled in the art.

[0285] This modulation can be carried out, for example, by an agent capable of binding to a protein and thus of inhibiting or of potentiating its biological activity, or capable of binding to an envelope protein of the external surface of said virus and of blocking the penetration of said virus into the host cell or of favoring the action of the immune system of the infected organism directed against said virus. This modulation can likewise be carried out by an agent capable of binding to a nucleotide sequence of a DNA of said virus and of blocking, for example, the expression of a polypeptide whose biological or structural activity is necessary for the replication or for the proliferation of said virus host cells to host cells in the host animal.

[0286] The invention relates to the compounds capable of being selected by a selection method according to the invention.

[0287] The invention likewise relates to a pharmaceutical composition comprising a compound selected from the following compounds:

[0288] a) a nucleotide sequence according to the invention;

[0289] b) a polypeptide according to the invention;

[0290] c) a vector, a viral particle or a cell transformed according to the invention;

[0291] d) an antibody according to the invention;

[0292] e) a compound capable of being selected by a selection method according to the invention;

[0293] possibly in combination with a pharmaceutically acceptable vehicle and, if need be, with one or more adjuvants of the appropriate immunity.

[0294] The invention also relates to an immunogenic and/or vaccine composition, characterized in that it comprises a compound selected from the following compounds:

[0295] a) a nucleotide sequence according to the invention;

[0296] b) a polypeptide according to the invention;

[0297] c) a vector or a viral particle according to the invention; and

[0298] d) a cell according to the invention.

[0299] In one embodiment, the vaccine composition according to the invention is characterized in that it comprises a mixture of at least two of said compounds a), b), c) and d) above and in that one of the two said compounds is related to the PWD circovirus of type A and the other is related to the PWD circovirus of type B.

[0300] In another embodiment of the invention, the vaccine composition is characterized in that it comprises at least one compound a), b), c), or d) above which is related to PWD circovirus of type B. In still another embodiment, the the vaccine composition is characterized in that it comprises at least one compound a), b), c), or d) above which is related to PWD circovirus of type B ORF′2.

[0301] A compound related to the PWD circovirus of type A or of type B is understood here as respectively designating a compound obtained from the genomic sequence of the PWD circovirus of type A or of type B.

[0302] The invention is additionally aimed at an immunogenic and/or vaccine composition, characterized in that it comprises at least one of the following compounds:

[0303] a nucleotide sequence SEQ ID No. 23, SEQ ID No. 25, or one of their fragments or homologues;

[0304] a polypeptide of sequence SEQ ID No. 24, SEQ ID No. 26, or one of their fragments, or a modification thereof;

[0305] a vector or a viral particle comprising a nucleotide sequence SEQ ID No. 23, SEQ ID No. 25, or one of their fragments or homologues;

[0306] a transformed cell capable of expressing a polypeptide of sequence SEQ ID No. 24, SEQ ID No. 26, or one of their fragments, or a modification thereof; or

[0307] a mixture of at least two of said compounds.

[0308] The invention also comprises an immunogenic and/or vaccine composition according to the invention, characterized in that it comprises said mixture of at least two of said compounds as a combination product for simultaneous, separate or protracted use for the prevention or the treatment of infection by a PWD circovirus, especially of type B.

[0309] In a preferred embodiment, the vaccine composition according to the invention comprises the mixture of the following compounds: a pcDNA3 plasmid containing a nucleic acid of sequence SEQ ID No. 23;

[0310] a pcDNA3 plasmid containing a nucleic acid of sequence SEQ ID No. 25;

[0311] a pcDNA3 plasmid containing a nucleic acid coding for the GM-CSF protein;

[0312] a recombinant baculovirus containing a nucleic acid of sequence SEQ ID No. 23;

[0313] a recombinant baculovirus containing a nucleic acid of sequence SEQ ID No. 25; and

[0314] if need be, an adjuvant of the appropriate immunity, especially the adjuvant AIF™.

[0315] The invention is likewise directed at a pharmaceutical composition according to the invention, for the prevention or the treatment of an infection by a PWD circovirus.

[0316] The invention is also directed at a pharmaceutical composition according to the invention for the prevention or the treatment of an infection by the PWD circovirus of type B.

[0317] The invention likewise concerns the use of a composition according to the invention, for the preparation of a medicament intended for the prevention or the treatment of infection by a PWD circovirus, preferably by the PWD circovirus of type B.

[0318] Under another aspect, the invention relates to a vector, a viral particle or a cell according to the invention, for the treatment and/or the prevention of a disease by gene therapy.

[0319] Finally, the invention comprises the use of a vector, of a viral particle or of a cell according to the invention for the preparation of a medicament intended for the treatment and/or the prevention of a disease by gene therapy.

[0320] The polypeptides of the invention entering into the immunogenic or vaccine compositions according to the invention can be selected by techniques known to the person skilled in the art such as, for example, depending on the capacity of said polypeptides to stimulate the T cells, which is translated, for example, by their proliferation or the secretion of interleukins, and which leads to the production of antibodies directed against said polypeptides.

[0321] In pigs, as in mice, in which a weight dose of the vaccine composition comparable to the dose used in man is administered, the antibody reaction is tested by taking of the serum followed by a study of the formation of a complex between the antibodies present in the serum and the antigen of the vaccine composition, according to the usual techniques.

[0322] The pharmaceutical compositions according to the invention will contain an effective quantity of the compounds of the invention, that is to say in sufficient quantity of said compound(s) allowing the desired effect to be obtained, such as, for example, the modulation of the cellular replication of PWD circovirus. The person skilled in the art will know how to determine this quantity, as a function, for example, of the age and of the weight of the individual to be treated, of the state of advancement of the pathology, of the possible secondary effects and by means of a test of evaluation of the effects obtained on a population range, these tests being known in these fields of application.

[0323] According to the invention, said vaccine combinations will preferably be combined with a pharmaceutically acceptable vehicle and, if need be, with one or more adjuvants of the appropriate immunity.

[0324] Today, various types of vaccines are available for protecting animals or man against infectious diseases: attenuated living microorganisms (M. bovis—BCG for tuberculosis), inactivated microorganisms (influenza virus), acellular extracts (Bordetella pertussis for whooping cough), recombined proteins (surface antigen of the hepatitis B virus), polysaccharides (pneumococcal). Vaccines prepared from synthetic peptides or genetically modified microorganisms expressing heterologous antigens are in the course of experimentation. More recently still, recombined plasmid DNAs carrying genes coding for protective antigens have been proposed as an alternative vaccine strategy. This type of vaccination is carried out with a particular plasmid originating from a plasmid of E. coli which does not replicate in vivo and which codes uniquely for the vaccinating protein. Animals have been immunized by simply injecting the naked plasmid DNA into the muscle. This technique leads to the expression of the vaccine protein in situ and to an immune response of cellular type (CTL) and of humoral type (antibody). This double induction of the immune response is one of the principal advantages of the vaccination technique with naked DNA.

[0325] The vaccine compositions comprising nucleotide sequences or vectors into which are inserted said sequences are especially described in the international application No. WO 90/11092 and likewise in the international application No. WO 95/11307.

[0326] The constitutive nucleotide sequence of the vaccine composition according to the invention can be injected into the host after having been coupled to compounds which favor the penetration of this polynucleotide into the interior of the cell or its transport to the cell nucleus. The resultant conjugates can be encapsulated in polymeric microparticles, as described in the international application No. WO 94/27238 (Medisorb Technologies International).

[0327] According to another embodiment of the vaccine composition according to the invention, the nucleotide sequence, preferably a DNA, is complexed with DEAE-dextran (Pagano et al., 1967) or with nuclear proteins (Kaneda et al., 1989), with lipids (Felgner et al., 1987) or encapsulated in liposomes (Fraley et al., 1980) or else introduced in the form of a gel facilitating its transfection into the cells (Midoux et al., 1993, Pastore et al., 1994). The polynucleotide or the vector according to the invention can also be in suspension in a buffer solution or be combined with liposomes.

[0328] Advantageously, such a vaccine will be prepared according to the technique described by Tacson et al. or Huygen et al. in 1996 or alternatively according to the technique described by Davis et al. in the international application No. WO 95/11307.

[0329] Such a vaccine can likewise be prepared in the form of a composition containing a vector according to the invention, placed under the control of regulation elements allowing its expression in man or animal. It will be possible, for example, to use, by way of in vivo expression vector of the polypeptide antigen of interest, the plasmid pcDNA3 or the plasmid pcDNA1/neo, both marketed by Invitrogen (R&D Systems, Abingdon, United Kingdom). It is also possible to use the plasmid V1Jns.tPA, described by Shiver et al. in 1995. Such a vaccine will advantageously comprise, apart from the recombinant vector, a saline solution, for example a sodium chloride solution.

[0330] Pharmaceutically acceptable vehicle is understood as designating a compound or a combination of compounds entering into a pharmaceutical composition or vaccine which does not provoke secondary reactions and which allows, for example, the facilitation of the administration of the active compound, an increase in its duration of life and/or its efficacy in the body, an increase in its solubility in solution or alternatively an improvement in its conservation. These pharmaceutically acceptable vehicles are well known and will be adapted by the person skilled in the art as a function of the nature and of the mode of administration of the chosen active compound.

[0331] As far as the vaccine formulations are concerned, these can comprise adjuvants of the appropriate immunity which are known to the person skilled in the art, such as, for example, aluminum hydroxide, a representative of the family of muramyl peptides such as one of the peptide derivatives of N-acetyl muramyl, a bacterial lysate, or alternatively Freund's incomplete adjuvant.

[0332] These compounds can be administered by the systemic route, in particular by the intravenous route, by the intramuscular, intradermal or subcutaneous route, or by the oral route. In a more preferred manner, the vaccine composition comprising polypeptides according to the invention will be administered by the intramuscular route, through the food or by nebulization several times, staggered over time.

[0333] Their administration modes, dosages and optimum pharmaceutical forms can be determined according to the criteria generally taken into account in the establishment of a treatment adapted to an animal such as, for example, the age or the weight, the seriousness of its general condition, the tolerance to the treatment and the secondary effects noted. Preferably, the vaccine of the present invention is administered in an amount that is protective against piglet weight loss disease.

[0334] For example, in the case of a vaccine according to the present invention comprising a polypeptide encoded by a nucleotide sequence of the genome of PCV, or a homolgue or fragment thereof, the polypeptide will be administered one time or several times, spread out over time, directly or by means of a transformed cell capable of expressing the polypeptide, in an amount of about 0.1 to 10 μg per kilogram weight of the animal, prefereably about 0.2 to about 5 μg/kg, more preferably about 0.5 to about 2 μg/kg for a dose.

[0335] The present invention likewise relates to the use of nucleotide sequences of PWD circovirus according to the invention for the construction of autoreplicative retroviral vectors and the therapeutic applications of these, especially in the field of human gene therapy in vivo.

[0336] The feasibility of gene therapy applied to man no longer needs to be demonstrated and this relates to numerous therapeutic applications like genetic diseases, infectious diseases and cancers. Numerous documents of the prior art describe the means of employing gene therapy, especially through viral vectors. Generally speaking, the vectors are obtained by deletion of at least some of the viral genes which are replaced by the genes of therapeutic interest. Such vectors can be propagated in a complementation line which supplies in trans the deleted viral functions in order to generate a defective viral vector particle for replication but capable of infecting a host cell. To date, the retroviral vectors are amongst the most widely used and their mode of infection is widely described in the literature accessible to the person skilled in the art.

[0337] The principle of gene therapy is to deliver a functional gene, called a gene of interest, of which the RNA or the corresponding protein will produce the desired biochemical effect in the targeted cells or tissues. On the one hand, the insertion of genes allows the prolonged expression of complex and unstable molecules such as RNAs or proteins which can be extremely difficult or even impossible to obtain or to administer directly. On the other hand, the controlled insertion of the desired gene into the interior of targeted specific cells allows the expression product to be regulated in defined tissues. For this, it is necessary to be able to insert the desired therapeutic gene into the interior of chosen cells and thus to have available a method of insertion capable of specifically targeting the cells or the tissues chosen.

[0338] Among the methods of insertion of genes, such as, for example, microinjection, especially the injection of naked plasmid DNA (Derse, D. et al., 1995, and Zhao, T. M. et al., 1996), electroporation, homologous recombination, the use of viral particles, such as retroviruses, is widespread. However, applied in vivo, the gene transfer systems of recombinant retroviral type at the same time have a weak infectious power (insufficient concentration of viral particles) and a lack of specificity with regard to chosen target cells.

[0339] The production of cell-specific viral vectors, having a tissue-specific tropism, and whose gene of interest can be translated adequately by the target cells, is realizable, for example, by fusing a specific ligand of the target host cells to the N-terminal part of a surface protein of the envelope of PWD circovirus. It is possible to mention, for example, the construction of retroviral particles having the CD4 molecule on the surface of the envelope so as to target the human cells infected by the HIV virus (YOUNG, J. A. T. et al., Sciences 1990, 250, 1421-1423), viral particles having a peptide hormone fused to an envelope protein to specifically infect the cells expressing the corresponding receptor (KASAHARA, N. et al., Sciences 1994, 266, 1373-1376) or else alternatively viral particles having a fused polypeptide capable of immobilizing on the receptor of the epidermal growth factor (EGF) (COSSET, F. L. et al., J. of Virology 1995, 69, 10, 6314-6322). In another approach, single-chain fragments of antibodies directed against surface antigens of the target cells are inserted by fusion with the N-terminal part of the envelope protein (VALSESIA-WITTMAN, S. et al., J. of Virology 1996, 70, 3, 2059-2064; TEARINA CHU, T. H. et al., J. of Virology 1997, 71, 1, 720-725).

[0340] For the purposes of the present invention, a gene of interest in use in the invention can be obtained from a eukaryotic or prokaryotic organism or from a virus by any conventional technique. It is, preferably, capable of producing an expression product having a therapeutic effect and it can be a product homologous to the cell host or, alternatively, heterologous. In the scope of the present invention, a gene of interest can code for an (i) intracellular or (ii) membrane product present on the surface of the host cell or (iii) secreted outside the host cell. It can therefore comprise appropriate additional elements such as, for example, a sequence coding for a secretion signal. These signals are known to the person skilled in the art.

[0341] In accordance with the aims pursued by the present invention, a gene of interest can code for a protein corresponding to all or part of a native protein as found in nature. It can likewise be a chimeric protein, for example arising from the fusion of polypeptides of various origins or from a mutant having improved and/or modified biological properties. Such a mutant can be obtained, by conventional biological techniques, by substitution, deletion and/or addition of one or more amino acid residues.

[0342] It is very particularly preferred to employ a gene of therapeutic interest coding for an expression product capable of inhibiting or retarding the establishment and/or the development of a genetic or acquired disease. A vector according to the invention is in particular intended for the prevention or for the treatment of cystic fibrosis, of hemophilia A or B, of Duchenne's or Becker's myopathy, of cancer, of AIDS and of other bacteria or infectious diseases due to a pathogenic organism: virus, bacteria, parasite or prion. The genes of interest utilizable in the present invention are those which code, for example, for the following proteins:

[0343] a cytokine and especially an interleukin, an interferon, a tissue necrosis factor and a growth factor and especially a hematopoietic growth factor (G-CSF, GM-CSF),

[0344] a factor or cofactor involved in clotting and especially factor VIII, von Willebrand's factor, antithrombin III, protein C, thrombin and hirudin,

[0345] an enzyme or an enzyme inhibitor such as the inhibitors of viral proteases,

[0346] an expression product of a suicide gene such as thymidine kinase of the HSV virus (herpesvirus) of type 1,

[0347] an activator or an inhibitor of ion channels,

[0348] a protein of which the absence, the modification or the deregulation of expression is responsible for a genetic disease, such as the CFTR protein, dystrophin or minidystrophin, insulin, ADA (adenosine diaminose), glucocerebrosidase and phenylhydroxylase,

[0349] a protein capable of inhibiting the initiation or the progression of cancers, such as the expression products of tumor suppressor genes, for example the P53 and Rb genes,

[0350] a protein capable of stimulating an immune or an antibody response, and

[0351] a protein capable of inhibiting a viral infection or its development, for example the antigenic epitopes of the virus in question or altered variants of viral proteins capable of entering into competition with the native viral proteins.

[0352] The invention thus relates to the vectors characterized in that they comprise a nucleotide sequence of PWD circovirus according to the invention, and in that they additionally comprise a gene of interest.

[0353] The present invention likewise relates to viral particles generated from said vector according to the invention. It additionally relates to methods for the preparation of viral particles according to the invention, characterized in that they employ a vector according to the invention, including viral pseudoparticles (VLP, virus-like particles).

[0354] The invention likewise relates to animal cells transfected by a vector according to the invention.

[0355] Likewise comprised in the invention are animal cells, especially mammalian, infected by a viral particle according to the invention.

[0356] The present invention likewise relates to a vector, a viral particle or a cell according to the invention, for the treatment and/or the prevention of a genetic disease or of an acquired disease such as cancer or an infectious disease. The invention is likewise directed at a pharmaceutical composition comprising, by way of therapeutic or prophylactic agent, a vector or a cell according to the invention, in combination with a vehicle acceptable from a pharmaceutical point of view.

[0357] Other characteristics and advantages of the invention appear in the examples and the figures.

[0358] The invention is described in more detail in the following illustrative examples. Although the examples may represent only selected embodiments of the invention, it should be understood that the following examples are illustrative and not limiting.

EXAMPLES Example 1 Cloning, Sequencing and Characterization of the PWD Circovirus of type A (PCVA)

[0359] 1. Experimental Procedures

[0360] Experimental reproduction of the infection and its syndrome (cf. FIG. 1).

[0361] A first test was carried out with pigs from a very well-kept farm, but affected by piglet weight loss disease (PWD), likewise called fatal piglet wasting (FPW). Tests carried out with SPF (specific pathogen-free) pigs showed a transfer of contaminant(s) finding expression in a complex pathology combining hyperthermia, retardation of growth, diarrhea and conjunctivitis. The PDRS (porcine dysgenic and respiratory syndrome) virus, an infectious disease due to an arteriovirus) was rapidly isolated from breeding pigs and contact pigs. It should have been possible to attribute all the clinical signs to the presence of the PDRS virus. However, two farm pigs presented signs of FPW without the PDRS virus being isolated. The histological analyses and blood formulas, however, showed that these pigs were suffering from an infectious process of viral origin.

[0362] In a second test, 8-week SPF pigs were inoculated by the intratracheal route with organ homogenates of two farm pigs suffering from FPW. The inoculated pigs exhibited hyperthermia 8 to 9 days post-infection, then their growth was retarded. Other SPF pigs, placed in contact, had similar, attenuated signs 30 days after the initial experiment. No seroconversion with respect to a European or Canadian strain of PDRS virus was recorded in these animals.

[0363] A third test allowed the syndrome to be reproduced from samples taken from the pigs of the second test.

[0364] Conclusion

[0365] The syndrome is reproduced under the experimental conditions. It is determined by at least one infectious agent, which is transmittable by direct contact. The clinical constants are a sometimes high hyperthermia (greater than or equal to 41.5° C.) which develops 8 to 10 days after infection. Retardation of the growth can be observed. The other signs are a reversal of the blood formula (reversal of the lymphocyte/polynuclear ratio from 70/30 to 30/70) and frequent lesions on the ganglia, especially those draining the respiratory apparatus (ganglionic hypertrophy, loss of structure with necrosis and infiltration by mononucleated or plurinucleated giant cells).

[0366] 2. Laboratory Studies

[0367] Various cell supports including primary pig kidney cells or cell lines, pig testicle cells, monkey kidney cells, pig lymphocytes, pig alveolar macrophages and circulating blood monocytes were used to demonstrate the possible presence of a virus. No cytopathic effect was demonstrated in these cells. On the other hand, the use of a serum of a pig sick after experimental infection allowed an intracellular antigen to be revealed in the monocytes, the macrophages and approximately 10% of pig kidney (PK) cells infected with organ homogenates. This indirect revealing was carried out kinetically at different culture times. It is evident from this that the antigen initially appears in the nucleus of the infected cells before spreading into the cytoplasm. The successive passages in cell culture did not allow the signal to be amplified.

[0368] Under electron microscopy on organ homogenates, spherical particles labeled specifically by the serum of sick pigs, infected under the experimental conditions, were visualized. The size of these particles is estimated at 20 nm.

[0369] After two passages of these organ homogenates over pig lymphocytes and then three passages over pig kidney or testicle cells, a cytopathic effect developed and was amplified. An adenovirus was visualized in the electron microscope, which, under the experimental conditions, did not reproduce FPW (only a hyperthermia peak was noted 24 to 48 hours after infection, and then nothing more).

[0370] It has been possible to demonstrate DNA bands in certain samples of pigs infected under the experimental conditions and having exhibited signs of the disease (results not shown). A certain connection exists between the samples giving a positive result in cell culture and those having a DNA band.

[0371] Conclusion

[0372] At least two types of virus were demonstrated in the organ homogenates from pigs suffering from FPW. One is an adenovirus, but by itself alone it does not reproduce the disease. The other type of virus is a circovirus and is associated with FPW. This circovirus, of which two types have been isolated and sequenced, designated below PWD circovirus type A (or PCVA) and PWD circovirus of type B (or PCVB) have mutations with respect to the known sequences of circovirus which are nonpathogenic for the pig.

[0373] 3. Cloning and Sequencing of the DNA of the PWD Circovirus of Type A

[0374] Extraction of the replicative form (RF) DNA, cleavage by the Kpn 1 enzyme and amplification by a pair of primers flanking the Kpn 1 restriction site. Sequencing of the two strands at least twice by the Sanger method.

[0375] The nucleic sequence of the strand of (+) polarity of the genome of the PWD circovirus of type A (or PCVA), strain FPW, is represented by the sequence SEQ ID No. 1 in the list of sequences, the nucleic sequence of the strand of (−) polarity of the genome of the PWD circovirus of type A (or PCVA) being represented by the nucleic sequence 3′→5′ of FIG. 3 or by the sequence SEQ ID No. 5 (represented according to the orientation 5′→3′) in the list of sequences.

[0376] The amino acid sequences SEQ ID No. 10, SEQ ID No. 12 and SEQ ID No. 14 of the list of sequences respectively represent the sequences of proteins encoded by the nucleic sequences of the 3 open reading frames SEQ ID No. 9 (ORF1), corresponding to the REP protein, SEQ ID No. 11 (ORF2) and SEQ ID No. 13 (ORF3), determined from the sequence SEQ ID No. 1 of the strand of (+) polarity or of the nucleic sequence SEQ ID No. 5 of the strand of (−) polarity of the genome of the PWD circovirus of type A.

[0377] 4. Comparison of the Nucleotide sequences and Amino Acids of the PWD Circovirus of Type A (or Associated With PWD) Which are Obtained With the Corresponding Sequences of MEEHAN and MANKERTZ Circoviruses of Porcine Cell Lines

[0378] Use of the DNA sequence analysis software, DNASIS.

[0379] Sequences of Oligonucleotides Used as Primers or Probes in the Detection and/or Identification Procedures

[0380] 1. Specific detection of the PWD circovirus of type A: primer PCV 5: 5′ GTG TGC TCG ACA TTG GTG TG 3′; SEQ ID No. 46 primer PCV 10: 5′ TGG AAT GTT AAC GAG CTG AG 3′; SEQ ID No. 47

[0381] 2. Specific detection of the circovirus of the cell lines: primer PCF 5: 5′ GTG TGC TCG ACA TTG GTG TG 3′; SEQ ID No. 46 primer MEE 1: 5′ TGG AAT GTT AAC TAC CTC AA 3′; SEQ ID No. 52

[0382] 3. Differential detection:

[0383] the pairs of primers used are those described, for example, in the paragraphs 1 and 2 above;

[0384] 4. Detection of the monomeric circular replicative forms RF: primer PCV 5: 5′ GTG TGC TCG ACA TTG GTG TG 3′; SEQ ID No. 46 primer PCV 6: 5′ CTC GCA GCC ATC TTG GAA TG 3′; SEQ ID No. 48

[0385] 5. Detection of the vectors carrying the dimers in tandem:

[0386] Nar dimer: primer KS 620: 5′ CGC GCG TAA TAC GAC TCA CT 3′; SEQ ID No. 49 primer PCV 5: 5′ GTG TGC TCG ACA TTG GTG TG 3′; SEQ ID No. 46

[0387] Kpn dimer: primer KS 620: 5′ CGC GCG TAA TAC GAC TCA CT 3′; SEQ ID No. 49 primer PCV 6: 5′ CTC GCA GCC ATC TTG GAA TG 3′; SEQ ID No. 48

[0388] 6. Differential detection:

[0389] The pairs of primers used are those described, for example, in paragraphs 4 and 5 above.

[0390] The procedures using the pairs or primers described in paragraphs 4 and 5 are of particular interest for differentially detecting the circular monomeric forms of specific replicative forms of the virion or of the DNA in replication and the dimeric forms found in the so-called in-tandem molecular constructs.

[0391] The in-tandem constructs of the viral genome (dimers) such as the constructs used for the preparation of the pBS KS+tandem PCV Kpn I vector, deposited at the CNCM under the number I-1891, 3 July 1997 (E. coli transformed by said vector) are very interesting for their use in methods of production in sufficient quantity of an inoculum formed of DNA, intended for the virus production, this in the absence of a satisfactory virus production protocol in a cell system. These said methods of production using these in-tandem constructs of the viral genome will allow the virulence factors to be studied by mutation and by way of consequence will be able to be used for the production of a collection of viruses carrying the mutations indicated in the construction of vectors which will have the appropriate tropism and virulence. These vectors with autoreplicative structure have the sought gene transfer properties, especially for their applications in gene therapy, and in vaccinology.

[0392] Western-Blot Analysis of Recombinant Proteins of the PWD Circovirus of Type A

[0393] The results were obtained using a specific antiserum of the PWD circovirus produced during test 1 (cf. FIG. 1).

[0394] Type of products analyzed.

[0395] The analyses were carried out on cell extracts of Sf9 cells obtained after infection by the recombinant baculovirus PCV ORF 1.

[0396] The culture of Sf9 cells was carried out in a 25 cm² Petri dish according to the standard culture methods for these cells. After centrifugation, the cell pellets are taken up with 300 μl of PBS buffer (phosphate saline buffer).

[0397] Electrophoresis (PAGE-SDS)

[0398] The electrophoresis is carried out on the cell extracts of Sf9 cells obtained previously on 5 samples (cf. Table 1 below) under the following conditions:

[0399] % polyacrylamide gel: 8%; conditions: denaturing

[0400] Voltage: 80 V; duration: 135 nm. TABLE 1 Nature of the samples subjected to electrophoresis Well No. 1 2 3 4 5 Sample applied PM Raoul Raoul Raoul Raoul Rainbow 24 h 48 h 72 h 96 h μl of sample 10 15 15 15 15 μl of 0 5 5 5 5 Laemmli 4X

[0401] Legends to Table 1:

[0402] Laemmli 4×: loading buffer

[0403] PM Rainbow: molecular-weight markers (35, 52, 77, 107, 160 and 250 kD)

[0404] Raoul 24 h, 48 h, 72 h and 96 h: expression products of the ORF1 of the PWD circovirus of-type A.

[0405] Western Blot

[0406] After electrophoresis, the bands obtained in the different wells are transferred to nitrocellulose membrane for 1 h at 100 v in a TGM buffer (tris-glycine-methanol).

[0407] The Western blot is carried out under the following conditions:

[0408] 1) Saturation with a solution containing 5% of skimmed milk; 0.05% of Tween 20 in a TBS 1× buffer (tris buffer saline) for 30 min.

[0409] 2) 1st antibody:

[0410] 10 ml of PWD anticircovirus antibody of type A are added diluted to 1/100, then the reaction mixture is incubated for one night at 4° C. Three washes of 10 min in TBS 1× are carried out.

[0411] 3) 2nd antibody:

[0412] 10 ml of pig rabbit P164 antibody anti-immunoglobulins, coupled to peroxidase (Dakopath) are added diluted to 1/100, then the reaction medium is incubated for 3 hours at 37° C. Three washes of 10 min in TBS 1×are carried out.

[0413] 4) Visualization

[0414] The substrate 4-chloro-1-naphthol in the presence of oxygenated water is used for visualization.

[0415] Results

[0416] The results are shown in FIG. 7.

[0417] Kinetics of Appearance of Antibodies Specific for the REP Recombinant Protein of the PWD Circovirus of Type A Expressed in Baculovirus After Infection of Pigs by the PWD Circovirus of Type A (Test 4, cf. FIG. 1)

[0418] After infection of the pigs, a sample of serum of each of the infected pigs is taken at different periods expressed in the table by the date of taking (carried out here in the same year) and is then analyzed by Western blot.

[0419] The visualization of the specific antibodies is carried out in the manner described previously.

[0420] The results obtained are shown by Table 2 below. TABLE 2 Kinetics of appearance of specific antibodies Sample Pigs 10/6 16/06 23/06 01/07 08/07 15/07 21/07 A3 1 Neg. Control 2 Neg. B2 Infec. 1 Neg. Neg. Neg. + + + + + + + RP+ 2 Neg. Neg. Neg. Neg. Neg. Neg. Neg. 3 Neg. Neg. Neg. Neg. + + + 4 Neg. Neg. Neg. Neg. Neg. Neg. + +

Example 2 Cloning, Sequencing and Characterization of the Type B PWD Circovirus (PCVB)

[0421] The techniques used for cloning, sequencing and characterization of the type B PWD circovirus (PCVB) are those used in Example 1 above for the type A PWD circovirus (PCVA).

[0422] The nucleic sequence of the strand of (+) polarity of the genome of the PWD circovirus of type B (or PCVB) is represented by the sequence SEQ ID No. 15 in the sequence listing, the nucleic sequence of the strand of (−) polarity of the genome of the PWD circovirus of type B (or PCVB) being represented by the nucleic sequence 3′→5′ of FIG. 8 or by the sequence SEQ ID No. 19 (represented according to the orientation 5′→3′) in the sequence listing.

[0423] The amino acid sequences SEQ ID No. 24, SEQ ID No. 26 and SEQ ID No. 28 of the sequence listing respectively represent the sequences of the proteins encoded by the. nucleic sequences of the 3 open reading frames SEQ ID No. 23 (ORF′1), corresponding to the REP protein, SEQ ID No. 25 (ORF′2) and SEQ ID No. 27 (ORF′3), determined from the sequence SEQ ID No. 15 of the strand of (+) polarity or from the nucleic sequence SEQ ID No. 19 of the strand of (−) polarity of the genome of the PWD circovirus of type B.

Example 3 Comparative Analysis of Nucleotide Sequences (ORF 1, ORF2 and Genomic) and Amino Acid Sequences Encoded by the ORF1 and the ORF2 of the PWD Circoviruses of Type A (PCVA) and of Type B (PCVB)

[0424] The results expressed in % of homology are shown in Tables 3 and 4 below. TABLE 3 Compared analysis of the amino acid sequences % homology ORF1 ORF2 PCVA/PCVB 80.4 56.2

[0425] TABLE 4 Compared analysis of the nucleotide sequences % homology Genomic ORF1 ORF2 The remainder PCVA/PCVB 70.4 80.4 60.1 66.1

Example 4 Observation of the Disease and Reproduction of the Disease Under Experimental Conditions

[0426] a) Test No. 1: Observation of the disease

[0427] The objective is to take breeding animals at the start of disease and to place them under experimental conditions to follow the progression of the pathology and describe all the clinical signs thereof. This first test was carried out on 3 breeding pigs aged 10 weeks of which 2 were already ill (suffering from wasting), and on 3 other pigs aged 13 weeks, not having signs of disease. The clinical observation was spread over a period of 37 days. Two pigs of 10 weeks wasted rapidly (pigs 1 and 2, FIG. 9) and had to be painlessly killed 5 and 6 days after their arrival. A single pig exhibited hyperthermia over 5 days and diarrhea. Two other pigs exhibited dyspnea and cough, of which one additionally had hyperthermia, greater than 41° C., for the two first days of its stay. Another pig had retarded growth in the second week (pig 6, FIG. 9), without any other clinical sign being recorded. On the lesional level, 5 pigs out of 6 exhibited macroscopic lesions of gray pneumonia, the sixth exhibited cicatricial lesions on the lung.

[0428] b) Test No. 2: Reproduction of the disease from inocula prepared in farm pigs.

[0429] The two sick pigs in test 1 served to prepare inocula which were tested in test 2 on specific-pathogen-free (SPF) pigs. The SPF pigs were aged 9 weeks at the time of inoculation. The clinical and lesional results are shown in Table 5. TABLE 5 Summary of the measurements carried out during experimental reproduction of PWD. (The values of the control animals are reported in brackets, the underlined values indicate a difference between infected animals and control animals) Test Measurement 2 3 4 5 6 7 Status of the SPF SPF SPF SPF Conventional Conventional pigs CNEVA field CNEVA CNEVA Age 9 weeks 6 weeks 5 weeks 5 weeks 5 weeks 6-7 weeks Number 4 6 12 8 8 8 Inoculation Intratracheal route Intratracheal route Intratracheal + Intratracheal + Intratracheal + Intratracheal + route intramuscular route intramuscular route intramuscular route intramuscular route Inoculum titer ND* ND* 10^(4.53) TCID₅₀ per ml: 10^(4.53) TCID₅₀ per ml: 10^(4.53) TCID₅₀ per ml: 10^(4.53) TCID₅₀ per ml: per pig 1 ml IM + 5 ml IT 1 ml IM + 5 ml IT 1 ml IM + 5 ml IT 1 ml IM + 5 ml IT Start of 10 days 9-13 days 12-13 days 9-14 days 8-12 days 12 days hyperthermia post-infection post-infection post-infection post-infection post-infection post-infection % of pigs in 100% 83% 92% 100% 75% 88% hyperthermia** Number of 7 4.5 3.3 5.8 7.5 11.6 days of hyperthermia per pig** Maximum 40.4 to 41.7° C. 40.6 to 42.3° C. 40.2 to 41.6° C. 40.3 to 40.8° C. 40.6 to 42° C. 40.2 to 41.9° C. tempera- tures*** Hyper- thermia**** % per week W1 3.5 (3.5) 17 (36) 7 (5) 37 (17) 16 (17) 20 (28) W2 42 (3.5) 7 (13) 13 (1) 21 (3) 52 (10) 37 (28) W3 35 (3.5) 33 (10) 28 (7) 62 (2) 34 (12) 79 (17) W4 21 (3.5) 28 (7) 5 (0) 6 (3) 25 (22) 55 (3) DMG: W1 928 (1053) 417 (357) 564 (620) 650 (589) 401 (407) 509 (512) W2 678 (1028) 428 (617) 503 (718) 612 (584) 294 (514) 410 (310) W3 661 (1000) 771 (642) 381 (657) 520 (851) 375 (586) 435 (440) W4 786 (1100) 550 (657) 764 (778) 641 (696) 473 (610) 451 (681) Contact pigs Yes to 100% Yes to 75% Not tested Not tested Not tested Not tested transmission % of 25 75 0 25 25 12 pulmonary lesions % of 17 33 67 25 50 12 ganglionic lesions

[0430] In this test, there was no wasting, at the very most a retardation of the growth in the second, third or fourth week after infection. These data illustrate that certain breeding conditions probably favor the expression of the disease.

[0431] c) Tests No. 3 to No. 7: Reproduction of the experimental tests

[0432] The increase in the number of the experimental tests on pigs had the mastering and better characterization of the experimental model as an objective. All of the results are presented in Table 5.

[0433] Under the experimental conditions, PWD is thus characterized by a long incubation, of 8 to 14 days, true hyperthermia over 2 to 8 days, a decrease in food consumption and a retardation of the increase in weight on the second, third or fourth week post-infection. The lesional table associated with this clinical expression includes, in the main, ganglionic hypertrophy and lesions of pneumonia.

[0434] Conclusion

[0435] The perfection of this experimental model allows the direct etiological role of the PWD circovirus in the disease to be indisputably demonstrated. In addition, this model is an indispensable tool for the understanding of pathogenic mechanisms and the study of future vaccine candidates.

Example 5 Demonstration of the Vaccine Composition Protective Efficacy Produced From Nucleic Fragments of PWD Circovirus Sequence

[0436] 1) Animals used for the study

[0437] Piglets having the PWD disease, reproduced under experimental conditions described in paragraph c) of Example 4, were used in a protocol for evaluating the vaccine composition efficacy, comprising nucleic fragments of PWD circovirus sequence.

[0438] 2) Tested vaccine composition and vaccination protocol

[0439] a) Components used for the study

[0440] The plasmids were obtained from the pcDNA3 plasmid of INVITROGENE

[0441] pcDNA30RF− Plasmids

[0442] These plasmids are plasmids which do not carry a PWD circovirus nucleic acid insert and are used as a negative control plasmid.

[0443] pcDNA30RF1+ Plasmid and pcDNA30RF2+ Plasmid

[0444] The pcDNA30RF1+ and pcDNA30RF2+ plasmids are plasmids which carry a nucleic acid insert of the sequence of the PWD circovirus of TYPE B, respectively an insert comprising the nucleic acid fragment SEQ ID No. 23 (ORF′1) coding for the Rep protein of sequence SEQ ID No. 24 and an insert comprising the nucleic acid fragment SEQ ID No. 25 (ORF′2) coding for the protein of sequence SEQ ID No. 26, probably corresponding to the capsid protein, these nucleic constructs comprising the ATG initiation codon of the coding sequence of the corresponding protein.

[0445] GMCSF+ Plasmid

[0446] GM-CSF (granulocyte/macrophage colony stimulating factor) is a cytokine which occurs in the development, the maturation and the activation of macrophages, granulocytes and dendritic cells which present an antigen. The beneficial contribution of the GM-CSF in vaccination is considered to be a cellular activation with, especially, the recruitment and the differentiation of cells which present an antigen.

[0447] This pcDNA3-GMCSF+ plasmid carries a nucleic acid insert coding for the granulocyte/macrophage colony stimulation factor, the GM-CSF protein.

[0448] The gene coding for this GM-CSF protein was cloned and sequenced by Inumaru et al. (Immunol. Cell Biol., 1995, 73 (5), 474-476). The pcDNA3GMCSF+ plasmid was obtained by Dr. B. Charley of INRA of Jouy-en-Josas (78, France).

[0449] Recombinant Baculoviruses

[0450] The so-called ORF-baculoviruses are viruses not carrying any insert comprising a nucleic acid fragment capable of expressing a PWD circovirus protein.

[0451] The so-called ORFI+ (BAC ORFI+) or ORF2+ (BAC ORF2+) baculoviruses are recombinant baculoviruses respectively carrying an insert comprising a nucleic acid fragment SEQ ID No. 23 (ORF′1) and an insert comprising the nucleic acid fragment SEQ ID No. 25 (ORF′2).

[0452] Adjuvant

[0453] The adjuvant supplied by the Seppic Company, a subsidiary of AIR LIQUIDE, is the adjuvant corresponding to the reference AIF SEPPIC.

[0454] b) Vaccination Protocol

[0455] Weaned piglets aged 3 weeks are divided into four batches A, B, C and D each comprising 8 piglets.

[0456] Batches A, B and C, aged 3 weeks, each receive a first injection (injection M1) of 1 ml containing 200 micrograms of plasmids (naked DNA) in PBS, pH: 7.2, by the intramuscular route for each of the plasmids mentioned below for each batch, then, at the age of 5 weeks, a second injection (injection M2) comprising these same plasmids. A third injection is carried out simultaneously on the other side of the neck. This third injection comprises 1 ml of a suspension containing 5.106 cells infected by recombinant baculoviruses and 1 ml of AIF SEPPIC adjuvant.

[0457] Batch A (F1) (control batch):

[0458] first injection

[0459] pcDNA30RF1− plasmid, pcDNA30RF2− plasmid and GMCSF+ plasmid.

[0460] second and third injection (simultaneous)

[0461] pcDNA30RF1− plasmid, pcDNA30RF2− plasmid and GMCSF+ plasmid;

[0462] Cells transformed by baculoviruses not containing any nucleic acid insert coding for a PWD circovirus protein;

[0463] AIF SEPPIC adjuvant.

[0464] Batch B (F2) (control batch):

[0465] first injection

[0466] pcDNA30RF1− plasmid, pcDNA30RF2− plasmid and GMCSF+ plasmid;

[0467] second and third injection (simultaneous)

[0468] pcDNA30RF1− plasmid, pcDNA30RF2− plasmid and GMCSF+ plasmid;

[0469] Cells transformed by baculoviruses not containing any nucleic acid insert coding for a PWD circovirus protein;

[0470] AIF SEPPIC adjuvant.

[0471] Batch C (F3):

[0472] first injection

[0473] pcDNA30RF1+ plasmid, pcDNA30RF2+ plasmid and GMCSF+ plasmid;

[0474] second and third injection (simultaneous)

[0475] pcDNA30RF1+ plasmid, pcDNA30RF2+ plasmid and GMCSF+ plasmid;

[0476] Cells transformed by BAC ORF1+ and BAC ORF2+ recombinant baculoviruses capable of respectively expressing the Rep protein of sequence SEQ ID No. 24 and the protein of sequence SEQ ID No. 26 of the PWD circovirus of TYPE B.

[0477] Batch D (F4) (control batch): no injection

[0478] The batches of piglets B, C and D are infected (tested) at the age of 6 weeks although batch A is not subjected to the test.

[0479] 3) Observation of the Batches

[0480] counting of coughing/sneezing: 15 minutes/batch/day;

[0481] consistency of fecal matter: every day;

[0482] regular recordings: weekly taking of blood, weighing;

[0483] weighing of food refuse: 3 times per week;

[0484] calculation of the daily mean gain in weight (dmg);

[0485] The daily mean gains were calculated for each of the batches over a period of 28 days following testing (cf. FIG. 10), an intermediate calculation of the dmg was likewise carried out for each of the batches over the first and second periods of 14 days. The results obtained are reported below in Table 6. TABLE 6 Daily mean gains F1 F2 F3 F4  d0-d14 411 g 450 g 511 g 461 g d14-d28 623 g 362 g 601 g 443 g  d0-d28 554 g 406 g 556 g 452 g

[0486] Measurement of Hyperthermia

[0487] The measurement of hyperthermia, of greater than 41° C. (cf. FIG. 11) and greater than 40.2° C., was carried out for each of the batches over a total period of 28 days following testing. The results obtained, corresponding to the ratio expressed as a percentage between the number of recordings of heat of greater than 41° C. (or greater than 40.2° C.) and the total number of recordings of heat carried out on all of the pigs per one-week period are reported below in Tables 7 and 8, respectively for the hyperthermia measurements of greater than 41° C. and greater than 40.2° C. TABLE 7 Hyperthermia > 41° C. F1 F2 F3 F4 W1 4.1 0. 0. 0. W2 10.7 16. 0. 8.9 W3 4.7 27. 0. 45. W4 0. 0. 0. 7.5

[0488] TABLE 8 Hyperthermia > 40.2 F1 F2 F3 F4 W1 29.1 10.41 29.1 20.8 W2 28.5 39.2 10.7 37.5 W3 14.3 68.7 25.0 81.2 W4 3.3 17.5 20.0 55

[0489] 4) Conclusion

[0490] The recordings carried out clearly show that the animals which received the three injections of a vaccine composition comprising nucleic acid fragments of PWD circovirus according to the invention and/or capable of expressing recombinant proteins of PWD circovirus, in particular of type B, did not exhibit hyperthermia (cf. FIG. 10). These animals additionally did not experience a decline in their growth, the dmgs being comparable to those of uninfected control animals (cf. FIG. 9). They did not exhibit any particular clinical sign.

[0491] These results demonstrate the efficacious protection of the piglets against infection with a PWD circovirus of the invention, the primary agent responsible for PWD or FPW, provided by a vaccine composition prepared from a nucleic acid fragment of the nucleic sequence of PWD circovirus according to the invention, in particular of type B, and/or from recombinant proteins encoded by these nucleic acid fragments.

[0492] These results in particular show that the proteins encoded by the ORF1 and ORF2 of PWD circovirus according to the invention are immunogenic proteins inducing an efficacious protective response for the prevention of infection by a PWD circovirus.

Example 6 Serological Diagnosis of PWD Circovirus by Immunodetermination Using Recombinant Proteins or Synthetic Peptides of PWD Circovirus

[0493] A—Serological Diagnosis With Recombinant Proteins

[0494] The identification and the sequencing of porcine PWD circovirus allow recombinant proteins of PWD circovirus to be produced by the techniques of genetic recombination well known to the person skilled in the art.

[0495] By these techniques, recombinant proteins encoded, in particular, by the ORF′2 of the PWD circovirus, type B, were expressed by transformed Sf9 insect cells and then isolated.

[0496] These recombinant proteins encoded by the ORF′2 are extracted, after culture of the transformed Sf9 cells, by thermal cell lysis by means of 3 cycles of freezing/thawing to −70° C./+37° C. Healthy Sf9 cells or nontransformed control Sf9 cells are also lyzed.

[0497] These two antigenic fractions originating from nontransformed control Sf9 cells and Sf9 cells expressing the ORF′2 are precipitated at 4° C. by a 60% plus or minus 5% saturated ammonium sulfate solution. Determination of total proteins is carried out with the aid of the Biorad kit. 500 ng of control Sf9 proteins and of semipurified Sf9 proteins expressing the ORF′2, in solution in 0.05 M bicarbonate buffer pH 9.6, are passively adsorbed at the bottom of 3 different cupules of a Nunc Maxisorp microplate by incubation for one night at +4° C.

[0498] The reactivity of pig sera with respect to each of these antigenic fractions is evaluated by an indirect ELISA reaction of which the experimental protocol is detailed below:

[0499] Saturation step: 200 μl/cupule of PBS1X/3% semi-skimmed milk, 1 h 30 incubation at 37° C.

[0500] Washing: 200 μl/cupule of PBS1X/Tween 20: 0.05%, 3 rapid washes.

[0501] Serum incubation step: 100/1/cupule of serum diluted to {fraction (1/100)} in PBS1X/semi-skimmed milk, 1%/Tween 20: 0.05%, 1 h incubation at 37° C.

[0502] Washing: 200 μl/cupule of PBS1X/Tween 20: 0.05%, 2 rapid washes followed by 2 washes of 5 min.

[0503] Conjugate incubation step: 50 μl/cupule of rabbit anti-pig conjugate diluted to {fraction (1/1000)} in PBS1X/semi-skimmed milk, 1%/Tween 20: 0.05%, 1 h incubation at 37° C.

[0504] Washing: 200 μl/cupule of PBS1X/Tween 20: 0.05%, 2 rapid washes followed by 2 washes of 5 min.

[0505] Visualization step: 100 μl/cupule of OPD substrate/citrate buffer/H₂O₂, 15 min incubation at 37° C.

[0506] Stopping of reaction: 50 μl/cupule of 1 N H₂SO₄.

[0507] Reading in a spectrophotometer at 490 nm.

[0508] Results

[0509] The results obtained are shown below in Table 9. TABLE 9 Reactivity of Pig Reactivity of Pig Serum Serum not inoculated inoculated with Antigens with Circovirus Circovirus Purified Sf9 control 0.076 0.088 Sf9 expressing purified 0.071 1.035 ORF'2

[0510] The results are expressed in optical density measured in a spectrophotometer at 490 nm during analysis by ELISA of the reactivity of pig sera which are or are not inoculated with the type B PWD circovirus according to the protocol indicated above.

[0511] B—Serological Diagnosis by Synthetic Peptide

[0512] The epitopic mapping of the proteins encoded, for example, by the nucleic sequences ORF1 and ORF2 of the two types of PWD circovirus (types A and B) additionally allowed immunogenic circoviral epitopes to be identified on the proteins encoded by the nucleic sequences ORF′1 and ORF′2 as well as the specific epitopes of the protein encoded by the nucleic sequence ORF′2 of the type B PWD circovirus. Four specific epitopes of the type B PWD circovirus and one epitope common to the two types of PWD circovirus situated on the protein encoded by the nucleic sequence ORF′2 were synthesized in peptide form. The equivalent peptides in the circovirus of type A were likewise synthesized. All these peptides were evaluated as diagnostic antigens within the context of carrying out a serological test.

[0513] Results

[0514] The results obtained are shown in Table 10 below. TABLE 10 Results of the evaluation as a diagnostic antigen of synthetic peptides encoded by the nucleic se- quences ORF2 and ORF′2 of PWD circovirus of type A and B. Infected pig serum reactivity Circovirus B Type Conventional Conventional Pep- PWD SPF 1 2 Epitopic de circovirus Position AA sequence D0/D54 D0/D42 D0/D42 specificity SEQ ID NO: 29 121 B 71-85 VDMMRFNINDFLPPG +/−, +++ +/−, +++ −, +++ Circovirus B SEQ ID NO: 55 177 B 70-84 NVNELRFNIGQFLPP +/−, + +/−, +/− +/−, − SEQ ID NO: 30 131 B 115-129 QGDRGVGSSAVILDD +/−, +/− ++, ++ +/−, + Circovirus B SEQ ID NO: 56 188 A 114-127 TSNQRGVGSTVVIL +/−, − −, +/− +/−, +/− SEQ ID NO: 31 133 B 119-134 GVGSSAVILDDNVFTK −, ++ ++, +++ +/−, ++ SEQ ID NO: 57 189 A 118-132 RGVGSTVVILDANFV +/−, − −, +/− +/−, +/− SEQ ID NO: 58 146 B 171-185 FTIDYFQPNNKRNQL −, +/− −, ++ −, ++ Circovirus A&B SEQ ID NO: 59 202 A 170-184 DQTIDWFQPNNKRNQ +++, +/−, ++ +, ++ +++ SEQ ID NO: 32 152 B 195-209 VDHVGLGTAFENSIY −, ++ +++, +++ +/−, + Circovirus B SEQ ID NO: 60 208 A 194-208 NVEHTGLGYALQNAT −,− −, − −, −

Example 7 Characterization of the Specific Epitopes of the PWD Circovirus of Type B

[0515] The proteins encoded by the ORF2 of the porcine circoviruses of type A and B were chosen for this study. For each of the ORF2s (types A and B), 56 peptides of 15 amino acids which overlap every 4 amino acids were synthesized, thus covering the whole of the protein (cf. Table 11 below). TABLE 11 Sequence of amino acids of the 56 peptides of 15 amino acids synthesized from the nucleic sequence ORF′2 (type B) and ORF2 (type A) of PWD circovirus with their corresponding spot number (cf. FIG. 12) Type B ORF′2 Type A ORF2 Spot No. Sequence Spot No. Sequence SEQ ID NO:61 107 HRPRSHLGQILRRRP SEQ ID NO:84 163 TRPRSHLGNILRRRP SEQ ID NO:62 108 SHLGQILRRRPWLVH SEQ ID NO:85 164 SHLGNILRRRPYLVH SEQ ID NO:63 109 QILRRRPWLVHPRHR SEQ ID NO:86 165 NILRRRPYLVHPAFR SEQ ID NO:64 110 RRPWLVHPRHRYRWR SEQ ID NO:87 166 RRPYLVHPAFRNRYR SEQ ID NO:65 111 LVHPRHRYRWRRKNG SEQ ID NO:88 167 LVHPAFRNRYRWRRK SEQ ID NO:66 112 RHRYRWRRKNGIFNT SEQ ID NO:89 168 AFRNRYRWRRKTGIF SEQ ID NO:67 113 RWRRKNGIFNTRLSR SEQ ID NO:90 169 RYRWRRKTGIFNSRL SEQ ID NO:68 114 KNGIFNTRLSRTFGY SEQ ID NO:91 170 RRKTGIFNSRLSREF SEQ ID NO:69 115 FNTRLSRTFGYTVKR SEQ ID NO:92 171 GIFNSRLSREFVLTI SEQ ID NO:70 116 LSRTFGYTVKRTTVR SEQ ID NO:93 172 SRLSREFVLTIRGGH SEQ ID NO:71 117 FGYTVKRTTVRTPSW SEQ ID NO:94 173 REFVLTIRGGHSQPS SEQ ID NO:72 118 VKRTTVRTPSWAVDM SEQ ID NO:95 174 LTIRGGHSOPSWNVN SEQ ID NO:73 119 TVRTPSWAVDMMRFN SEQ ID NO:96 175 GGHSQPSWNVNELRF SEQ ID NO:74 120 PSWAVDMMRFNINDF SEQ ID NO:97 176 QPSWNVNELRFNIGO SEQ ID NO:29 121 VDMMRFNINDFLPPG SEQ ID NO:98 177 NVNELRFNIGQFLPP SEQ ID NO:75 122 RFNINDFLPPGGGSN SEQ ID NO:99 178 LRFNIGQFLPPSGGT SEQ ID NO:76 123 NDFLPPGGGSNPRSV SEQ ID NO:100 179 IGQFLPPSGGTNPLP SEQ ID NO:77 124 PPGGGSNPRSVPFEY SEQ ID NO:101 180 LPPSGGTNPLPLPFQ SEQ ID NO:78 125 GSNPRSVPFEYYRIR SEQ ID NO:102 181 GGTNPLPLPFQYYRI SEQ ID NO:79 126 RSVPFEYYRIRKVKV SEQ ID NO:103 182 PLPLPFQYYRIRKAK SEQ ID NO:80 127 FEYYRIRKVKVEFWP SEQ ID NO:104 183 PFQYYRIRKAKYEFY SEQ ID NO:81 128 RIRKVKVEFWPCSPI SEQ ID NO:105 184 YRIRKAKYEFYPRDP SEQ ID NO:82 129 VKVEFWPCSPITQGD SEQ ID NO:106 185 KAKYEFYPRDPITSN SEQ ID NO:83 130 FWPCSPITQGDRGVG SEQ ID NO:107 186 EFYPRDPITSNQRGV SEQ ID NO:30 131 SPITQGDRGVGSSAV SEQ ID NO:108 187 RDPITSNQRGVGSTV SEQ ID NO:31 132 QGDRGVGSSAVILDD SEQ ID NO:109 188 TSNQRGVGSTVVILD SEQ ID NO:110 133 GVGSSAVILDDNFVT SEQ ID NO:136 189 RGVGSTVVILDANFV SEQ ID NO:111 134 SAVILDDNFVTKATA SEQ ID NO:137 190 STVVILDANFVTPST SEQ ID NO:112 135 LDDNFVTKATALTYD SEQ ID NO:138 191 ILDANFVTPSTNLAY SEQ ID NO:113 136 FVTKATALTYDPYVN SEQ ID NO:139 192 NFVTPSTNLAYDPYI SEQ ID NO:114 137 ATALTYDPYVNYSSR SEQ ID NO:140 193 PSTNLAYDPYINYSS SEQ ID NO:115 138 TYDPYVNYSSRIITIT SEQ ID NO:141 194 LAYDPYINYSSRHTI SEQ ID NO:116 139 YVNYSSRHTITQPFS SEQ ID NO:142 195 PYINYSSRHTIRQPF SEQ ID NO:117 140 SSRHTITQPFSYHSR SEQ ID NO:143 196 YSSRIITIRQPFTYHS SEQ ID NO:118 141 TITQPFSYHSRYFTP SEQ ID NO:144 197 HTIRQPFTYHSRYFT SEQ ID NO:119 142 PFSYHSRYFTPKPVL SEQ ID NO:145 198 QPFTYHSRYFTPKPE SEQ ID NO:120 143 HSRYFTPKPVLDFTI SEQ ID NO:146 199 YHSRYFTPKPELDQT SEQ ID NO:121 144 FTPKPVLDFTIDYYFQ SEQ ID NO:147 200 YFTPKPELDQTIDWF SEQ ID NO:122 145 PVLDFTIDYFQPNNK SEQ ID NO:148 201 KPELDQTIDWFQPNN SEQ ID NO:123 146 FTIDYFQPNNKRNQL SEQ ID NO:149 202 DQTIDWFQPNNKRNQ SEQ ID NO:124 147 YFQPNNKRNQLWLRL SEQ ID NO:150 203 DWFQPNNKRNQLWLH SEQ ID NO:125 148 NNKRNQLWLRLQTAG SEQ ID NO:151 204 PNNKRNQLWLHLNTH SEQ ID NO:126 149 NQLWLRLQTAGNVDH SEQ ID NO:152 205 RNQLWLHLNTHTNVE SEQ ID NO:127 150 LRLQTAGNVDHVGLG SEQ ID NO:153 206 WLHLNTHTNVEHTGL SEQ ID NO:128 151 TAGNVDHVGLGTAFE SEQ ID NO:154 207 NTHTNVEHTGLGYAL SEQ ID NO:32 152 VDHVGLGTAFENSIY SEQ ID NO:155 208 NVEHTGLGYALQNAT SEQ ID NO:129 153 GLGTAFENSIYDQEY SEQ ID NO:156 209 TGLGYALQNATTAQN SEQ ID NO:130 154 AFENSIYDQEYNIRV SEQ ID NO:157 210 YALQNATTAQNYVVR SEQ ID NO:131 155 SIYDQEYNIRVTMYV SEQ ID NO:158 211 NATTAQNYVVRLTIY SEQ ID NO:132 156 QEYNIRVTMYVQFRE SEQ ID NO:159 212 AQNYVVRLTIYVQFR SEQ ID NO:133 157 IRVTMYVQFREFNFK SEQ ID NO:160 213 VVRLTIYVQFREFIL SEQ ID NO:134 158 MYVQFREFNFKDPPL SEQ ID NO:161 214 TIYVQFREFILKDPL SEQ ID NO:135 159 VQFREFNFKDPPLNP SEQ ID NO:162 215 YVQFREFILKDPLNE

[0516] These peptides were synthesized according to the “spot” method which consists in simultaneous synthesis of a large number of peptides on a cellulose solid support, each site of synthesis of a peptide constituting a spot (System, NIMES). This method involves orientation of the peptides on the plate, these being fixed covalently by the carboxy-terminal end. A spot represents approximately 50 nmol of peptide.

[0517] The reference of the spots and corresponding peptide sequences is given in Table 11.

[0518] These membranes were used for immunoreactivity tests with respect to serum of SPF pigs which were or were not infected experimentally with the type B PWD circoviral strain as well as with respect to sera of infected pigs from conventional farms (conventional farms 1 or 2). This study allowed specific immunoreactive peptides of the circovirus of type B corresponding to the spots No. 121, No. 132, No. 133 and No. 152 (respectively of amino acid sequences SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31 and SEQ ID No. 32) to be demonstrated. An illustration is shown in FIG. 12 where the membranes are visualized with an infected pig serum coming from a conventional farm. Nonspecific immunoreactive peptides of type [lacuna] were likewise demonstrated, among which we shall keep the peptide No. 146 SEQ ID No. 123 which is strongly immunogenic.

[0519] A comparison between the peptide sequences of circoviruses of type A and B (FIG. 13) indicates a divergence ranging from 20 to 60% for the specific immunoreactive peptides of the type B, and a weaker divergence (13%) between the nonspecific peptides.

Example 8 Protection of Swine From Post-Weaning Multisystemic Wasting Syndrome (PMWS) Conferred by Procine Circovirus Type B (PCV-B) ORF′2 Protein

[0520] The ORF′1-encoded protein (REP) and ORF′2-encoded putative capsid protein of PCV-B were expressed, either in insect cells by recombinant baculovirus vectors, or in mammalian cell lines by transfection with plasmidic expression vectors. These two circovirus-derived proteins were detectable in both expression system. As evaluated by weight gains, hyperthermia and absence of lesions following challenge, the pigs were protected against a virulent circovirus challenge after one first DNA immunization with plasmids directing ORF′2 protein and GM-CSF expression and a second injection, 15 days later, with the same plasmid preparation plus the ORF′2 recombinant protein. A lower level of protection was observed when the pigs were vaccinated with ORF′1 protein, as opposed to pigs vaccinated with ORF′2 protein.

[0521] A. Development of an Experimental Model of PMWS in Swine:

[0522] Eight 3 week-old SPF pigs were inoculated intratracheally (5 ml) and intramuscularly (1 ml).

[0523] B. Production and Control of PCV-B Plasmids:

[0524] PCV-B ORF′1 and ORF′2 genes, isolated from PCV-B challenge strain, have been cloned into vector plasmid pcDNA3.1. All constructs have been validated through a partial sequencing of the PCV-B genes in the final plasmids and expression control by immunoperoxidase on PK15 cells respectively transfected with each plasmid, using swine polyclonal antibodies. Plasmid encoding GM-CSF has been co-administred.

[0525] C. Construction of Recombinant Baculoviruses:

[0526] ORF′1 and ORF′2 proteins were expressed under polyhedrin promoter control. Recombinant proteins were detected by western-blot using swine polyclonal antibodies.

[0527] D. Vaccination and Challenge:

[0528] Four groups of 7 pigs were vaccinated intramuscularly at day 0 (Do), two weeks later, they received the same plasmid preparation plus the recombinant baculovirus.

[0529] E. Monitoring:

[0530] All groups of pigs were housed in isolated experimental units with air filtration and low air pressure. Clinical observations and rectal temperatures were recorded every day. The pigs were weighed weekly.

[0531] F. Conclusions

[0532] Expression of PCV-B ORF′2 or PCV-B ORF′1 in swine resulted in a significantly enhanced level of protection as evaluated by weight evolution and body temperature evolution following challenge with PCV-B circovirus. These results are summarized in FIGS. 14 and 15.

[0533] The invention described herein may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The specific embodiments previously described are therefore to be considered as illustrative of, and not limiting, the scope of the invention. Additionally, the disclosure of all publications and patent applications cited above and below, including International Patent Application No. PCT/FR98/02634, filed Dec. 4, 1998, and published as International Publication No. WO 99/29871 on Jun. 17, 1999, are expressly incorporated herein by reference in their entireties to the same extent as if each were incorporated by reference individually.

BIBLIOGRAPHIC REFERENCES

[0534] Allan, G. M. et al., 1995, Vet. Microbiol., 44: 49-64.

[0535] Barany, F., 1911, PNAS. USA, 88: 189-193.

[0536] Boulton, L. H. et al., 1997, J. Gen. Virol., 78 (Pt 6), 1265-1270.

[0537] Buckholz, R. G., 1993, Yeast systems for the expression of heterologous gene products. Curr. Op. Biotechnology 4: 538-542.

[0538] Burg, J. L. et al., 1996, Mol. and Cell. Probes, 10: 257-271.

[0539] Chu, B. C. F. et al., 1986, NAR, 14: 5591-5603.

[0540] Chu, P. W. G. et al., 1993, Virus Research, 27: 161-171.

[0541] Clark, E. G., 1997, American Association of Swine Practitioners, 499-501.

[0542] Daft, B. et al., 1996, American Association of Veterinary Laboratory Diagnosticians, 32.

[0543] Derse, D. et al., 1995, J. Virol., 69(3): 1907-1912.

[0544] Duck, P. et al., 1990, Biotechniques, 9: 142-147.

[0545] Dulac, G. C. et al., 1989, Can. J. Vet. Res., 53: 431-433.

[0546] Edwards, C. P., and Aruffo, A., 1993, Current applications of COS cell based transient expression systems. Curr. Op. Biotechnology 4: 558-563.

[0547] Edwards, S. et al., 1994, Vet. Rec., 134: 680-681.

[0548] Erlich, H. A., 1989, In PCR Technology. Principles and Applications for DNA Amplification. New York: Stockton Press. Felgner, et al., 1987, Proc. Natl. Acad. Sci., 84: 7413.

[0549] Fontes, E. P. B. et al., 1994, J. Biol. Chem., Vol. 269, No. 11: 8459-8465.

[0550] Fraley et al., 1980, J. Biol. Chem., 255: 10431.

[0551] Guateli, J. C. et al., 1990, PNAS. USA, 87: 1874-1878.

[0552] Hackland, A. F. et al., 1994, Arch. Virol., 139: 1-22.

[0553] Hanson, S. F. et al., 1995, Virology, 211: 1-9.

[0554] Harding, J. C., 1997, American Association of Swine Practitioners, 503.

[0555] Harding, R. M. et al., 1993, Journal of General Virology, 74: 323-328.

[0556] Harding, J. C. and Clark, E. G., 1997, Swine Health and Production, Vol. 5, No. 5: 201203.

[0557] Heyraud-Nitschke, F. et al., 1995, Nucleic Acids Research, Vol. 23, No. 6.

[0558] Horner, G. W., 1991, Surveillance 18(5): 23.

[0559] Houben-Weyl, 1974, in Methode der Organischen Chemie, E. Wunsch Ed., Volume 15-1 and 15-II, Thieme, Stuttgart.

[0560] Huygen, K. et al., 1996, Nature Medicine, 2(8): 893-898.

[0561] Innis, M. A. et al., 1990, in PCR Protocols. A guide to Methods and Applications, San Diego, Academic Press.

[0562] Kaneda, et al., 1989, Science, 243: 375.

[0563] Kievitis, T. et al., 1991, J. Virol. Methods, 35: 273-286.

[0564] Kohler, G. et al., 1975, Nature, 256(5517): 495-497.

[0565] Kwoh, D. Y. et al., 1989, PNAS. USA, 86: 1173-1177.

[0566] Ladany, S. et al., 1989, J. Clin. Microbiol. 27: 2778-2783.

[0567] Lazarowitz, S. G. et al., 1989, The EMBO Journal, Vol. 8 No. 4: 1023-1032.

[0568] Luckow, V. A., 1993, Baculovirus systems for the expression of human gene products. Curr. Op. Biotechnology 4: 564-572.

[0569] Mankertz, A. et al., 1997, J. Virol., 71: 2562-2566.

[0570] Matthews, J. A. et al., 1988, Anal. Biochem., 169: 1-25.

[0571] McNeilly, F. et al., 1996, Vet. Immunol. Immunopathol., 49: 295-306.

[0572] Meehan, B. M. et al., 1997, J. Gen. Virol. 78: 221-227.

[0573] Merrifield, R. D., 1966, J. Am. Chem. Soc., 88(21): 5051-5052.

[0574] Midoux, 1993, Nucleic Acids Research, 21: 871-878.

[0575] Miele, E. A. et al., 1983, J. Mol. Biol., 171: 281-295.

[0576] Murphy, F. A. et al., 1995, Sixth Report of the International Committee on Taxonomy of Viruses. Springer-Verlag Wien New York.

[0577] Nayar, G. P. et al., 1997, Can. Vet. J. 38(6): 385-386.

[0578] Olins, P. O., and Lee, S. C., 1993, Recent advances in heterologous gene expression in E. coli. Curr. Op. Biotechnology 4: 520-525.

[0579] Pagano et al., 1967, J. Virol., 1: 891.

[0580] Rolfs, A. et al., 1991, In PCR Topics. Usage of Polymerase Chain reaction in Genetic and Infectious Disease. Berlin: Springer-Verlag.

[0581] Sambrook, J. et al., 1989, In Molecular cloning: A Laboratory Manual. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press.

[0582] Sanchez-Pescador, R., 1988, J. Clin. Microbiol., 26(10): 1934-1938.

[0583] Segev D., 1992, in “Non-radioactive Labeling and Detection of Biomolecules”. Kessler C.

[0584] Springer Verlag, Berlin, New-York: 197-205.

[0585] Shiver, J. W., 1995, in Vaccines 1995, eds Chanock, R. M. Brown, F. Ginsberg, H. S. &

[0586] Norrby, E., pp. 95-98, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.

[0587] Tascon, R. E. et al., 1996, Nature Medicine, 2(8): 888-892.

[0588] Tischer, I. et al., 1982, Nature, 295: 64-66.

[0589] Tischer, I. et al., 1986, Arch. Virol., 91: 271-276.

[0590] Tischer, I. et al., 1988, Zentralbl Bakteriol Mikrobiol Hyg [A] 270: 280-287.

[0591] Tischer, I. et al., 1995, Arch. Virol., 140: 737-743.

[0592] Urdea, M. S., 1988, Nucleic Acids Research, II: 4937-4957.

[0593] Walker, G. T. et al., 1992, NAR 20: 1691-1696.

[0594] Walker, G. T. et al., 1992, PNAS. USA, 89: 392-396.

[0595] White, B. A. et al., 1997, Methods in Molecular Biology, 67, Humana Press, Towota.

[0596] Zhao, T. M. et al., 1996, Proc. Natl. Acad. Sci., USA 93(13): 6653-6648.

1 170 1 1759 DNA Type A PWD circovirus CDS (1)..(78) CDS (82)..(99) CDS (106)..(156) CDS (160)..(195) CDS (199)..(231) CDS (235)..(246) CDS (250)..(315) CDS (319)..(330) CDS (334)..(489) CDS (493)..(525) CDS (529)..(591) CDS (595)..(600) CDS (604)..(606) CDS (610)..(627) CDS (634)..(636) CDS (640)..(681) CDS (685)..(708) CDS (712)..(726) CDS (730)..(753) CDS (757)..(933) CDS (937)..(969) CDS (973)..(1047) CDS (1051)..(1056) CDS (1060)..(1071) CDS (1075)..(1236) CDS (1240)..(1257) CDS (1261)..(1293) CDS (1297)..(1350) CDS (1354)..(1380) CDS (1384)..(1386) CDS (1390)..(1416) CDS (1420)..(1425) CDS (1429)..(1497) CDS (1501)..(1512) CDS (1516)..(1551) CDS (1555)..(1566) CDS (1570)..(1581) CDS (1585)..(1620) CDS (1624)..(1752) CDS (1756)..(1758) 1 acc agc gca ctt cgg cag cgg cag cac ctc ggc agc gtc agt gaa aat 48 Thr Ser Ala Leu Arg Gln Arg Gln His Leu Gly Ser Val Ser Glu Asn 1 5 10 15 gcc aag caa gaa aag cgg ccc gca acc cca taa gag gtg ggt gtt cac 96 Ala Lys Gln Glu Lys Arg Pro Ala Thr Pro Glu Val Gly Val His 20 25 30 cct taataa tcc ttc cga gga gga gaa aaa caa aat acg gga gct tcc 144 Pro Ser Phe Arg Gly Gly Glu Lys Gln Asn Thr Gly Ala Ser 35 40 45 aat ctc cct ttt tga tta ttt tgt ttg tgg cga gga agg ttt gga aga 192 Asn Leu Pro Phe Leu Phe Cys Leu Trp Arg Gly Arg Phe Gly Arg 50 55 60 ggg tag aac tcc tca cct cca ggg gtt tgc gaa ttt tgc taa gaa gca 240 Gly Asn Ser Ser Pro Pro Gly Val Cys Glu Phe Cys Glu Ala 65 70 gac ttt taa caa ggt gaa gtg gta ttt tgg tgc ccg ctg cca cat cga 288 Asp Phe Gln Gly Glu Val Val Phe Trp Cys Pro Leu Pro His Arg 75 80 85 gaa agc gaa agg aac cga cca gca gaa taa aga ata ctg cag taa aga 336 Glu Ser Glu Arg Asn Arg Pro Ala Glu Arg Ile Leu Gln Arg 90 95 100 agg cca cat act tat cga gtg tgg agc tcc gcg gaa cca ggg gaa gcg 384 Arg Pro His Thr Tyr Arg Val Trp Ser Ser Ala Glu Pro Gly Glu Ala 105 110 115 cag cga cct gtc tac tgc tgt gag tac cct ttt gga gac ggg gtc ttt 432 Gln Arg Pro Val Tyr Cys Cys Glu Tyr Pro Phe Gly Asp Gly Val Phe 120 125 130 135 ggt gac tgt agc cga gca gtt tcc tgt aac gta tgt gag aaa ttt ccg 480 Gly Asp Cys Ser Arg Ala Val Ser Cys Asn Val Cys Glu Lys Phe Pro 140 145 150 cgg gct ggc tga act ttt gaa agt gag cgg gaa gat gca gaa gcg tga 528 Arg Ala Gly Thr Phe Glu Ser Glu Arg Glu Asp Ala Glu Ala 155 160 165 ttg gaa gac agc tgt aca cgt cat agt ggg ccc gcc cgg ttg tgg gaa 576 Leu Glu Asp Ser Cys Thr Arg His Ser Gly Pro Ala Arg Leu Trp Glu 170 175 180 gag cca gtg ggc ccg taa ttt tgc tga gcc tag gga cac cta ctg gaa 624 Glu Pro Val Gly Pro Phe Cys Ala Gly His Leu Leu Glu 185 190 gcc tagtag aaa taa gtg gtg gga tgg ata tca tgg aga aga agt tgt 672 Ala Lys Val Val Gly Trp Ile Ser Trp Arg Arg Ser Cys 195 200 205 tgt ttt gga tga ttt tta tgg ctg gtt acc ttg gga tga tct act gag 720 Cys Phe Gly Phe Leu Trp Leu Val Thr Leu Gly Ser Thr Glu 210 215 220 act gtg tga ccg gta tcc att gac tgt aga gac taa agg ggg tac tgt 768 Thr Val Pro Val Ser Ile Asp Cys Arg Asp Arg Gly Tyr Cys 225 230 235 tcc ttt ttt ggc ccg cag tat ttt gat tac cag caa tca ggc ccc cca 816 Ser Phe Phe Gly Pro Gln Tyr Phe Asp Tyr Gln Gln Ser Gly Pro Pro 240 245 250 gga atg gta ctc ctc aac tgc tgt ccc agc tgt aga agc tct cta tcg 864 Gly Met Val Leu Leu Asn Cys Cys Pro Ser Cys Arg Ser Ser Leu Ser 255 260 265 gag gat tac tac ttt gca att ttg gaa gac tgc tgg aga aca atc cac 912 Glu Asp Tyr Tyr Phe Ala Ile Leu Glu Asp Cys Trp Arg Thr Ile His 270 275 280 gga ggt acc cga agg ccg att tga agc agt gga ccc acc ctg tgc cct 960 Gly Gly Thr Arg Arg Pro Ile Ser Ser Gly Pro Thr Leu Cys Pro 285 290 295 ttt ccc ata taa aat aaa tta ctg agt ctt ttt tgt tat cac atc gta 1008 Phe Pro Ile Asn Lys Leu Leu Ser Leu Phe Cys Tyr His Ile Val 300 305 310 atg gtt ttt att ttt att cat tta gag ggt ctt tca gga taa att ctc 1056 Met Val Phe Ile Phe Ile His Leu Glu Gly Leu Ser Gly Ile Leu 315 320 325 tga att gta cat aaa tag tca acc tta cca cat aat ttt ggg ctg tgg 1104 Ile Val His Lys Ser Thr Leu Pro His Asn Phe Gly Leu Trp 330 335 340 ttg cat ttt gga gcg cat agc cca ggc ctg tgt gct cga cat tgg tgt 1152 Leu His Phe Gly Ala His Ser Pro Gly Leu Cys Ala Arg His Trp Cys 345 350 355 ggg tat tta aat gga gcc aca gct ggt ttc ttt tat tat ttg gct gga 1200 Gly Tyr Leu Asn Gly Ala Thr Ala Gly Phe Phe Tyr Tyr Leu Ala Gly 360 365 370 acc aat caa ttg ttt ggt cta gct ctg gtt tgg ggg tga agt acc tgg 1248 Thr Asn Gln Leu Phe Gly Leu Ala Leu Val Trp Gly Ser Thr Trp 375 380 385 agt ggt agg taa agg gct gcc tta tgg tgt ggc ggg agg agt agt taa 1296 Ser Gly Arg Arg Ala Ala Leu Trp Cys Gly Gly Arg Ser Ser 390 395 400 tat agg ggt cat agg cca agt tgg tgg agg ggg tta caa agt tgg cat 1344 Tyr Arg Gly His Arg Pro Ser Trp Trp Arg Gly Leu Gln Ser Trp His 405 410 415 cca aga taa caa cag tgg acc caa cac ctc ttt gat tag agg tga tgg 1392 Pro Arg Gln Gln Trp Thr Gln His Leu Phe Asp Arg Trp 420 425 430 ggt ctc tgg ggt aaa att cat att tag cct ttc taa tac ggt agt att 1440 Gly Leu Trp Gly Lys Ile His Ile Pro Phe Tyr Gly Ser Ile 435 440 445 gga aag gta ggg gta ggg ggt tgg tgc cgc ctg agg ggg gga gga act 1488 Gly Lys Val Gly Val Gly Gly Trp Cys Arg Leu Arg Gly Gly Gly Thr 450 455 460 ggc cga tgt tga atc tca gct cgt taa cat tcc aag atg gct gcg agt 1536 Gly Arg Cys Ile Ser Ala Arg His Ser Lys Met Ala Ala Ser 465 470 475 gtc ctc ctc tta tgg tga gta caa att ctc tag aaa ggc ggg aat tga 1584 Val Leu Leu Leu Trp Val Gln Ile Leu Lys Gly Gly Asn 480 485 aga tac ccg tct ttc ggc gcc atc tgt aac ggt ttc tga agg cgg ggt 1632 Arg Tyr Pro Ser Phe Gly Ala Ile Cys Asn Gly Phe Arg Arg Gly 490 495 500 gta cca aat atg gtc ttc tcc gga gga tgt ttc caa gat ggc tgc ggg 1680 Val Pro Asn Met Val Phe Ser Gly Gly Cys Phe Gln Asp Gly Cys Gly 505 510 515 520 ggc ggg tcc gtc ttc tgc ggt aac gcc tcc ttg gcc acg tca tcc tat 1728 Gly Gly Ser Val Phe Cys Gly Asn Ala Ser Leu Ala Thr Ser Ser Tyr 525 530 535 aaa agt gaa aga agt gcg ctg ctg tag tat t 1759 Lys Ser Glu Arg Ser Ala Leu Leu Tyr 540 545 2 545 PRT Type A PWD circovirus 2 Thr Ser Ala Leu Arg Gln Arg Gln His Leu Gly Ser Val Ser Glu Asn 1 5 10 15 Ala Lys Gln Glu Lys Arg Pro Ala Thr Pro Glu Val Gly Val His Pro 20 25 30 Ser Phe Arg Gly Gly Glu Lys Gln Asn Thr Gly Ala Ser Asn Leu Pro 35 40 45 Phe Leu Phe Cys Leu Trp Arg Gly Arg Phe Gly Arg Gly Asn Ser Ser 50 55 60 Pro Pro Gly Val Cys Glu Phe Cys Glu Ala Asp Phe Gln Gly Glu Val 65 70 75 80 Val Phe Trp Cys Pro Leu Pro His Arg Glu Ser Glu Arg Asn Arg Pro 85 90 95 Ala Glu Arg Ile Leu Gln Arg Arg Pro His Thr Tyr Arg Val Trp Ser 100 105 110 Ser Ala Glu Pro Gly Glu Ala Gln Arg Pro Val Tyr Cys Cys Glu Tyr 115 120 125 Pro Phe Gly Asp Gly Val Phe Gly Asp Cys Ser Arg Ala Val Ser Cys 130 135 140 Asn Val Cys Glu Lys Phe Pro Arg Ala Gly Thr Phe Glu Ser Glu Arg 145 150 155 160 Glu Asp Ala Glu Ala Leu Glu Asp Ser Cys Thr Arg His Ser Gly Pro 165 170 175 Ala Arg Leu Trp Glu Glu Pro Val Gly Pro Phe Cys Ala Gly His Leu 180 185 190 Leu Glu Ala Lys Val Val Gly Trp Ile Ser Trp Arg Arg Ser Cys Cys 195 200 205 Phe Gly Phe Leu Trp Leu Val Thr Leu Gly Ser Thr Glu Thr Val Pro 210 215 220 Val Ser Ile Asp Cys Arg Asp Arg Gly Tyr Cys Ser Phe Phe Gly Pro 225 230 235 240 Gln Tyr Phe Asp Tyr Gln Gln Ser Gly Pro Pro Gly Met Val Leu Leu 245 250 255 Asn Cys Cys Pro Ser Cys Arg Ser Ser Leu Ser Glu Asp Tyr Tyr Phe 260 265 270 Ala Ile Leu Glu Asp Cys Trp Arg Thr Ile His Gly Gly Thr Arg Arg 275 280 285 Pro Ile Ser Ser Gly Pro Thr Leu Cys Pro Phe Pro Ile Asn Lys Leu 290 295 300 Leu Ser Leu Phe Cys Tyr His Ile Val Met Val Phe Ile Phe Ile His 305 310 315 320 Leu Glu Gly Leu Ser Gly Ile Leu Ile Val His Lys Ser Thr Leu Pro 325 330 335 His Asn Phe Gly Leu Trp Leu His Phe Gly Ala His Ser Pro Gly Leu 340 345 350 Cys Ala Arg His Trp Cys Gly Tyr Leu Asn Gly Ala Thr Ala Gly Phe 355 360 365 Phe Tyr Tyr Leu Ala Gly Thr Asn Gln Leu Phe Gly Leu Ala Leu Val 370 375 380 Trp Gly Ser Thr Trp Ser Gly Arg Arg Ala Ala Leu Trp Cys Gly Gly 385 390 395 400 Arg Ser Ser Tyr Arg Gly His Arg Pro Ser Trp Trp Arg Gly Leu Gln 405 410 415 Ser Trp His Pro Arg Gln Gln Trp Thr Gln His Leu Phe Asp Arg Trp 420 425 430 Gly Leu Trp Gly Lys Ile His Ile Pro Phe Tyr Gly Ser Ile Gly Lys 435 440 445 Val Gly Val Gly Gly Trp Cys Arg Leu Arg Gly Gly Gly Thr Gly Arg 450 455 460 Cys Ile Ser Ala Arg His Ser Lys Met Ala Ala Ser Val Leu Leu Leu 465 470 475 480 Trp Val Gln Ile Leu Lys Gly Gly Asn Arg Tyr Pro Ser Phe Gly Ala 485 490 495 Ile Cys Asn Gly Phe Arg Arg Gly Val Pro Asn Met Val Phe Ser Gly 500 505 510 Gly Cys Phe Gln Asp Gly Cys Gly Gly Gly Ser Val Phe Cys Gly Asn 515 520 525 Ala Ser Leu Ala Thr Ser Ser Tyr Lys Ser Glu Arg Ser Ala Leu Leu 530 535 540 Tyr 545 3 577 PRT Type A PWD circovirus 3 Pro Ala His Phe Gly Ser Gly Ser Thr Ser Ala Ala Ser Val Lys Met 1 5 10 15 Pro Ser Lys Lys Ser Gly Pro Gln Pro His Lys Arg Trp Val Phe Thr 20 25 30 Leu Asn Asn Pro Ser Glu Glu Glu Lys Asn Lys Ile Arg Glu Leu Pro 35 40 45 Ile Ser Leu Phe Asp Tyr Phe Val Cys Gly Glu Glu Gly Leu Glu Glu 50 55 60 Gly Arg Thr Pro His Leu Gln Gly Phe Ala Asn Phe Ala Lys Lys Gln 65 70 75 80 Thr Phe Asn Lys Val Lys Trp Tyr Phe Gly Ala Arg Cys His Ile Glu 85 90 95 Lys Ala Lys Gly Thr Asp Gln Gln Asn Lys Glu Tyr Cys Ser Lys Glu 100 105 110 Gly His Ile Leu Ile Glu Cys Gly Ala Pro Arg Asn Gln Gly Lys Arg 115 120 125 Ser Asp Leu Ser Thr Ala Val Ser Thr Leu Leu Glu Thr Gly Ser Leu 130 135 140 Val Thr Val Ala Glu Gln Phe Pro Val Thr Tyr Val Arg Asn Phe Arg 145 150 155 160 Gly Leu Ala Glu Leu Leu Lys Val Ser Gly Lys Met Gln Lys Arg Asp 165 170 175 Trp Lys Thr Ala Val His Val Ile Val Gly Pro Pro Gly Cys Gly Lys 180 185 190 Ser Gln Trp Ala Arg Asn Phe Ala Glu Pro Arg Asp Thr Tyr Trp Lys 195 200 205 Pro Ser Arg Asn Lys Trp Trp Asp Gly Tyr His Gly Glu Glu Val Val 210 215 220 Val Leu Asp Asp Phe Tyr Gly Trp Leu Pro Trp Asp Asp Leu Leu Arg 225 230 235 240 Leu Cys Asp Arg Tyr Pro Leu Thr Val Glu Thr Lys Gly Gly Thr Val 245 250 255 Pro Phe Leu Ala Arg Ser Ile Leu Ile Thr Ser Asn Gln Ala Pro Gln 260 265 270 Glu Trp Tyr Ser Ser Thr Ala Val Pro Ala Val Glu Ala Leu Tyr Arg 275 280 285 Arg Ile Thr Thr Leu Gln Phe Trp Lys Thr Ala Gly Glu Gln Ser Thr 290 295 300 Glu Val Pro Glu Gly Arg Phe Glu Ala Val Asp Pro Pro Cys Ala Leu 305 310 315 320 Phe Pro Tyr Lys Ile Asn Tyr Val Phe Phe Val Ile Thr Ser Trp Phe 325 330 335 Leu Phe Leu Phe Ile Arg Val Phe Gln Asp Lys Phe Ser Glu Leu Tyr 340 345 350 Ile Asn Ser Gln Pro Tyr His Ile Ile Leu Gly Cys Gly Cys Ile Leu 355 360 365 Glu Arg Ile Ala Gln Ala Cys Val Leu Asp Ile Gly Val Gly Ile Met 370 375 380 Glu Pro Gln Leu Val Ser Phe Ile Ile Trp Leu Glu Pro Ile Asn Cys 385 390 395 400 Leu Val Leu Trp Phe Gly Gly Glu Val Pro Gly Val Val Gly Lys Gly 405 410 415 Leu Pro Tyr Gly Val Ala Gly Gly Val Val Asn Ile Gly Val Ile Gly 420 425 430 Gln Val Gly Gly Gly Gly Tyr Lys Val Gly Ile Gln Asp Asn Asn Ser 435 440 445 Gly Pro Asn Thr Ser Leu Ile Arg Gly Asp Gly Val Ser Gly Val Lys 450 455 460 Phe Ile Phe Ser Leu Ser Asn Thr Val Val Leu Glu Arg Gly Val Gly 465 470 475 480 Ala Ala Gly Gly Glu Glu Leu Ala Asp Val Glu Ser Gln Leu Val Asn 485 490 495 Ile Pro Arg Trp Leu Arg Val Ser Ser Ser Tyr Gly Glu Tyr Lys Phe 500 505 510 Ser Arg Lys Ala Gly Ile Glu Asp Thr Arg Leu Ser Ala Pro Ser Val 515 520 525 Thr Val Ser Glu Gly Gly Val Tyr Gln Ile Trp Ser Ser Pro Glu Asp 530 535 540 Val Ser Lys Met Ala Ala Gly Ala Gly Pro Ser Ser Ala Val Thr Pro 545 550 555 560 Pro Trp Pro Arg His Pro Ile Lys Val Lys Glu Val Arg Cys Cys Ser 565 570 575 Ile 4 553 PRT Type A PWD circovirus 4 Gln Arg Thr Ser Ala Ala Ala Ala Pro Arg Gln Arg Gln Lys Cys Gln 1 5 10 15 Ala Arg Lys Ala Ala Arg Asn Pro Ile Arg Gly Gly Cys Ser Pro Leu 20 25 30 Leu Pro Arg Arg Arg Lys Thr Lys Tyr Gly Ser Phe Gln Ser Pro Phe 35 40 45 Leu Ile Ile Leu Phe Val Ala Arg Lys Val Trp Lys Arg Val Glu Leu 50 55 60 Leu Thr Ser Arg Gly Leu Arg Ile Leu Leu Arg Ser Arg Leu Leu Thr 65 70 75 80 Arg Ser Gly Ile Leu Val Pro Ala Ala Thr Ser Arg Lys Arg Lys Glu 85 90 95 Pro Thr Ser Arg Ile Lys Asn Thr Ala Val Lys Lys Ala Thr Tyr Leu 100 105 110 Ser Ser Val Glu Leu Arg Gly Thr Arg Gly Ser Ala Ala Thr Cys Leu 115 120 125 Leu Leu Val Pro Phe Trp Arg Arg Gly Leu Trp Leu Pro Ser Ser Phe 130 135 140 Leu Arg Met Glu Ile Ser Ala Gly Trp Leu Asn Phe Lys Ala Gly Arg 145 150 155 160 Cys Arg Ser Val Ile Gly Arg Gln Leu Tyr Thr Ser Trp Ala Arg Pro 165 170 175 Val Val Gly Arg Ala Ser Gly Pro Val Ile Leu Leu Ser Leu Gly Thr 180 185 190 Pro Thr Gly Ser Leu Val Glu Ile Ser Gly Gly Met Asp Ile Met Glu 195 200 205 Lys Lys Leu Leu Phe Trp Met Ile Phe Met Ala Gly Tyr Leu Gly Met 210 215 220 Ile Tyr Asp Cys Val Thr Gly Ile His Leu Arg Leu Lys Gly Val Leu 225 230 235 240 Phe Leu Phe Trp Pro Ala Val Phe Leu Pro Ala Ile Arg Pro Pro Arg 245 250 255 Asn Gly Thr Pro Gln Leu Leu Ser Gln Leu Lys Leu Ser Ile Gly Gly 260 265 270 Leu Leu Leu Cys Asn Phe Gly Arg Leu Leu Glu Asn Asn Pro Arg Arg 275 280 285 Tyr Pro Lys Ala Asp Leu Lys Gln Trp Thr His Pro Val Pro Phe Ser 290 295 300 His Ile Lys Ile Thr Glu Ser Phe Leu Leu Ser His Arg Asn Gly Phe 305 310 315 320 Tyr Phe Tyr Ser Phe Arg Gly Ser Phe Arg Ile Asn Ser Leu Asn Cys 325 330 335 Thr Ile Val Asn Leu Thr Thr Phe Trp Ala Val Val Ala Phe Trp Ser 340 345 350 Ala Pro Arg Pro Val Cys Ser Thr Leu Val Trp Val Phe Lys Trp Ser 355 360 365 His Ser Trp Phe Leu Leu Leu Phe Gly Trp Asn Gln Ser Ile Val Trp 370 375 380 Ser Ser Ser Gly Leu Gly Val Lys Tyr Leu Glu Trp Val Lys Gly Cys 385 390 395 400 Leu Met Val Trp Arg Glu Glu Leu Ile Gly Ser Ala Lys Leu Val Glu 405 410 415 Gly Val Thr Lys Leu Ala Ser Lys Ile Thr Thr Val Asp Pro Thr Pro 420 425 430 Leu Leu Glu Val Met Gly Ser Leu Gly Asn Ser Tyr Leu Ala Phe Leu 435 440 445 Ile Arg Tyr Trp Lys Gly Arg Gly Arg Gly Leu Val Pro Pro Glu Gly 450 455 460 Gly Arg Asn Trp Pro Met Leu Asn Leu Ser Ser Leu Thr Phe Gln Asp 465 470 475 480 Gly Cys Glu Cys Pro Pro Leu Met Val Ser Thr Asn Ser Leu Glu Arg 485 490 495 Arg Glu Leu Lys Ile Pro Val Phe Arg Arg His Leu Arg Phe Leu Lys 500 505 510 Ala Gly Cys Thr Lys Tyr Gly Leu Leu Arg Arg Met Phe Pro Arg Trp 515 520 525 Leu Arg Gly Arg Val Arg Leu Leu Arg Arg Leu Leu Gly His Val Ile 530 535 540 Leu Lys Lys Lys Cys Ala Ala Val Val 545 550 5 1759 DNA Type A PWD circovirus 5 aatactacag cagcgcactt ctttcacttt tataggatga cgtggccaag gaggcgttac 60 cgcagaagac ggacccgccc ccgcagccat cttggaaacg tcctccggag aagaccatat 120 ttggtacacc ccgccttcag aaaccgttac agatggcgcc gaaagacggg tatcttcaat 180 tcccgccttt ctagagaatt tgtactcacc ataagaggag gacactcgca gccatcttgg 240 aatgttaacg agctgagatt caacatcggc cagttcctcc ccccctcagg cggcaccaac 300 cccctacccc tacctttcca atactaccgt attagaaagg ctaaatatga attttacccc 360 agagacccca tcacctctaa tcaaagaggt gttgggtcca ctgttgttat cttggatgcc 420 aactttgtaa ccccctccac caacttggcc tatgacccct atattaacta ctcctcccgc 480 cacaccataa ggcagccctt tacctaccac tccaggtact tcacccccaa accagagcta 540 gaccaaacaa ttgattggtt ccagccaaat aataaaagaa accagctgtg gctccattta 600 aatacccaca ccaatgtcga gcacacaggc ctgggctatg cgctccaaaa tgcaaccaca 660 gcccaaaatt atgtggtaag gttgactatt tatgtacaat tcagagaatt tatcctgaaa 720 gaccctctaa atgaataaaa ataaaaacca ttacgatgtg ataacaaaaa agactcagta 780 atttatttta tatgggaaaa gggcacaggg tgggtccact gcttcaaatc ggccttcggg 840 tacctccgtg gattgttctc cagcagtctt ccaaaattgc aaagtagtaa tcctccgata 900 gagagcttct acagctggga cagcagttga ggagtaccat tcctgggggg cctgattgct 960 ggtaatcaaa atactgcggg ccaaaaaagg aacagtaccc cctttagtct ctacagtcaa 1020 tggataccgg tcacacagtc tcagtagatc atcccaaggt aaccagccat aaaaatcatc 1080 caaaacaaca acttcttctc catgatatcc atcccaccac ttatttctac taggcttcca 1140 gtaggtgtcc ctaggctcag caaaattacg ggcccactgg ctcttcccac aaccgggcgg 1200 gcccactatg acgtgtacag ctgtcttcca atcacgctgc tgcatcttcc cgctcacttt 1260 caaaagttca gccagcccgc ggaaatttct cacatacgtt acaggaaact gctcggctac 1320 agtcaccaaa gaccccgtct ccaaaagggt actcacagca gtagacaggt cgctgcgctt 1380 cccctggttc cgcggagctc cacactcgat aagtatgtgg ccttctttac tgcagtattc 1440 tttattctgc tggtcggttc ctttcgcttt ctcgatgtgg cagcgggcac caaaatacca 1500 cttcaccttg ttaaaagtct gcttcttagc aaaattcgca aacccctgga ggtgaggagt 1560 tctaccctct tccaaacctt cctcgccaca aacaaaataa tcaaaaaggg agattggaag 1620 ctcccgtatt ttgtttttct cctcctcgga aggattatta agggtgaaca cccacctctt 1680 atggggttgc gggccgcttt tcttgcttgg cattttcact gacgctgccg aggtgctgcc 1740 gctgccgaag tgcgctggt 1759 6 567 PRT Type A PWD circovirus 6 Gly Ala Cys Lys Pro Leu Pro Leu Val Glu Ala Ala Asp Thr Phe Ile 1 5 10 15 Gly Leu Leu Phe Leu Pro Gly Cys Gly Trp Leu Leu His Thr Asn Val 20 25 30 Arg Leu Leu Gly Glu Ser Ser Ser Phe Phe Leu Ile Arg Ser Ser Gly 35 40 45 Ile Glu Arg Lys Ser Lys Thr Gln Pro Ser Ser Pro Lys Ser Ser Pro 50 55 60 Leu Val Gly Arg Trp Pro Asn Ala Phe Lys Ala Leu Phe Cys Val Lys 65 70 75 80 Leu Leu Thr Phe His Tyr Lys Pro Ala Arg Gln Trp Met Ser Phe Ala 85 90 95 Phe Pro Val Ser Trp Cys Phe Leu Ser Tyr Gln Leu Leu Ser Pro Trp 100 105 110 Met Ser Ile Ser His Pro Ala Gly Arg Phe Trp Pro Phe Arg Leu Ser 115 120 125 Arg Asp Val Ala Thr Leu Val Arg Lys Ser Val Pro Asp Lys Thr Val 130 135 140 Thr Ala Ser Cys Asn Gly Thr Val Tyr Thr Leu Phe Lys Arg Pro Ser 145 150 155 160 Ala Ser Ser Lys Phe Thr Leu Pro Phe Ile Cys Cys Arg Ser Gln Phe 165 170 175 Val Ala Thr Cys Thr Met Thr Pro Gly Gly Pro Gln Pro Phe Leu Trp 180 185 190 His Ala Arg Leu Lys Ala Ser Gly Leu Ser Val Gln Phe Gly Leu Leu 195 200 205 Phe Leu His His Ser Pro Tyr Pro Ser Ser Thr Thr Thr Lys Ser Ser 210 215 220 Lys Pro Gln Asn Gly Gln Ser Ser Arg Ser Leu Ser His Ser Arg Tyr 225 230 235 240 Gly Asn Val Thr Ser Val Leu Pro Pro Val Thr Gly Lys Lys Ala Arg 245 250 255 Leu Ile Lys Ile Val Leu Leu Ala Gly Trp Ser His Tyr Glu Glu Val 260 265 270 Ala Thr Gly Ala Thr Ser Ala Arg Arg Leu Ile Val Val Lys Cys Asn 275 280 285 Gln Phe Val Ala Pro Ser Cys Asp Val Ser Thr Gly Ser Pro Arg Asn 290 295 300 Ser Ala Thr Ser Gly Gly Gln Ala Arg Lys Gly Tyr Leu Ile Phe Gln 305 310 315 320 Thr Lys Lys Thr Ile Val Asp Tyr His Asn Lys Asn Lys Asn Met Leu 325 330 335 Thr Lys Ser Leu Asn Glu Ser Asn Tyr Met Phe Leu Gly Trp Met Ile 340 345 350 Lys Pro Gln Pro Gln Met Lys Ser Arg Met Ala Trp Ala Gln Thr Ser 355 360 365 Ser Met Pro Thr Pro Ile Ile Ser Gly Cys Ser Thr Glu Lys Ile Ile 370 375 380 Gln Ser Ser Gly Ile Leu Gln Lys Thr Ser Gln Asn Pro Pro Ser Thr 385 390 395 400 Gly Pro Thr Thr Pro Leu Pro Ser Gly Pro Thr Ala Pro Pro Thr Thr 405 410 415 Leu Ile Pro Thr Met Pro Trp Thr Pro Pro Pro Pro Leu Thr Pro Met 420 425 430 Trp Ser Leu Leu Leu Pro Gly Leu Val Glu Lys Ile Leu Pro Ser Pro 435 440 445 Thr Glu Pro Thr Phe Asn Met Asn Leu Arg Glu Leu Val Thr Thr Asn 450 455 460 Ser Leu Tyr Pro Tyr Pro Thr Pro Ala Ala Gln Pro Pro Ser Ser Ser 465 470 475 480 Ala Ser Thr Ser Asp Ser Thr Leu Met Gly Leu His Ser Arg Thr Asp 485 490 495 Glu Glu Pro Ser Tyr Leu Asn Glu Leu Phe Ala Pro Ile Ser Ser Val 500 505 510 Arg Arg Glu Ala Gly Asp Thr Val Thr Glu Ser Pro Pro Thr Tyr Trp 515 520 525 Ile His Asp Glu Gly Ser Ser Thr Glu Leu Ile Ala Ala Pro Ala Pro 530 535 540 Gly Asp Glu Ala Thr Val Gly Gly Gln Gly Arg Gly Ile Phe Thr Phe 545 550 555 560 Ser Thr Arg Gln Gln Leu Ile 565 7 580 PRT Type A PWD circovirus 7 Trp Arg Val Glu Ala Ala Ala Ala Gly Arg Cys Arg His Phe His Trp 1 5 10 15 Ala Leu Phe Ala Ala Arg Leu Gly Met Leu Pro Pro His Glu Gly Lys 20 25 30 Ile Ile Arg Gly Leu Leu Leu Phe Val Phe Tyr Pro Leu Lys Trp Asp 35 40 45 Gly Lys Lys Ile Ile Lys Asn Thr Ala Leu Phe Thr Gln Phe Leu Thr 50 55 60 Ser Ser Arg Val Glu Leu Pro Lys Arg Ile Lys Ser Leu Leu Leu Ser 65 70 75 80 Lys Val Leu His Leu Pro Ile Lys Thr Gly Ala Ala Val Asp Leu Phe 85 90 95 Arg Phe Ser Gly Val Leu Leu Ile Phe Phe Val Ala Thr Phe Phe Ala 100 105 110 Val Tyr Lys Asp Leu Thr Ser Ser Arg Pro Val Leu Pro Leu Ala Ala 115 120 125 Val Gln Arg Ser Ser His Thr Gly Lys Gln Leu Arg Pro Arg Gln His 130 135 140 Ser Tyr Gly Leu Leu Lys Arg Tyr Arg Ile His Ser Ile Glu Ala Pro 145 150 155 160 Gln Ser Phe Lys Gln Phe His Ala Pro Leu His Leu Leu Thr Ile Pro 165 170 175 Leu Cys Ser Tyr Val Asp Tyr His Ala Arg Gly Thr Thr Pro Leu Ala 180 185 190 Leu Pro Gly Thr Ile Lys Ser Leu Arg Pro Val Gly Val Pro Leu Arg 195 200 205 Thr Ser Ile Leu Pro Pro Ile Ser Ile Met Ser Phe Phe Asn Asn Asn 210 215 220 Gln Ile Ile Lys Ile Ala Pro Arg Pro Ile Ile Gln Ser Gln Thr Val 225 230 235 240 Pro Ile Trp Gln Ser Tyr Leu Ser Phe Pro Thr Ser Asn Arg Lys Gln 245 250 255 Gly Ala Thr Asn Gln Asn Gly Ala Ile Leu Gly Gly Leu Phe Pro Val 260 265 270 Gly Ser Ser Asp Trp Ser Tyr Phe Ser Glu Ile Pro Pro Asn Ser Ser 275 280 285 Gln Leu Lys Pro Leu Ser Ser Ser Phe Leu Gly Arg Leu Tyr Gly Phe 290 295 300 Ala Ser Lys Phe Cys His Val Trp Gly Thr Gly Lys Glu Trp Ile Phe 305 310 315 320 Tyr Ile Val Ser Asp Lys Lys Asn Asp Cys Arg Leu Pro Lys Lys Glu 325 330 335 Asn Leu Pro Asp Lys Leu Ile Phe Glu Arg Phe Gln Val Tyr Ile Thr 340 345 350 Leu Arg Val Val Tyr Asn Gln Ala Thr Thr Ala Asn Gln Leu Ala Tyr 355 360 365 Gly Leu Gly Thr His Glu Val Asn Thr His Thr Asn Leu His Leu Trp 370 375 380 Leu Gln Asn Arg Lys Asn Asn Pro Gln Phe Trp Asp Ile Thr Gln Asp 385 390 395 400 Leu Glu Pro Lys Pro Thr Phe Tyr Arg Ser His Tyr Thr Phe Pro Gln 405 410 415 Arg Ile Thr His Arg Ser Ser Tyr Asn Ile His Pro Asp Tyr Ala Leu 420 425 430 Asn Thr Ser Pro Thr Val Phe Asn Ala Asp Leu Ile Val Val Thr Ser 435 440 445 Gly Val Gly Arg Gln Asn Ser Thr Ile Pro Asp Arg Pro Tyr Phe Glu 450 455 460 Tyr Lys Ala Lys Arg Ile Arg Tyr Tyr Gln Phe Pro Leu Pro Leu Pro 465 470 475 480 Asn Thr Gly Gly Ser Pro Pro Leu Phe Gln Gly Ile Asn Phe Arg Leu 485 490 495 Glu Asn Val Asn Trp Ser Pro Gln Ser His Gly Gly Arg Ile Thr Leu 500 505 510 Val Phe Glu Arg Ser Leu Arg Ser Asn Phe Ile Gly Thr Lys Arg Arg 515 520 525 Trp Arg Tyr Arg Asn Arg Phe Ala Pro His Val Leu Tyr Pro Arg Arg 530 535 540 Arg Leu Ile Asn Gly Leu His Ser Arg Pro Arg Thr Arg Arg Arg Arg 545 550 555 560 Tyr Arg Arg Arg Pro Trp Thr Met Arg Tyr Phe His Phe Phe His Ala 565 570 575 Ala Thr Thr Asn 580 8 557 PRT Type A PWD circovirus 8 Leu Ala Ser Arg Cys Arg Cys Cys Arg Pro Leu Thr Leu Ser Phe Ala 1 5 10 15 Leu Cys Ser Phe Arg Gly Ala Val Gly Tyr Ser Thr Pro Thr Gly Tyr 20 25 30 Asp Lys Arg Pro Pro Ser Phe Cys Phe Val Pro Ala Glu Leu Arg Gly 35 40 45 Lys Gln Asn Asn Gln Lys His Arg Pro Leu Asn Pro Leu Pro Tyr Phe 50 55 60 Glu Glu Gly Gly Pro Thr Gln Ser Asn Gln Ser Ala Ser Lys Cys Pro 65 70 75 80 Ser Thr Thr Asn Gly His Gly Ser Gly Cys Arg Ser Leu Ser Leu Phe 85 90 95 Arg Gly Ala Ser Tyr Leu Ile Ser Cys Tyr Leu Leu Gly Cys Val Arg 100 105 110 Thr His Leu Glu Ala Ser Gly Pro Ser Ala Cys Arg Gly Thr Gln Gln 115 120 125 Ser Tyr Gly Lys Pro Ser Pro Thr Lys Pro Ser Gln Leu Arg Ala Thr 130 135 140 Glu Gln Leu Thr His Ser Phe Asn Gly Arg Ala Pro Gln Val Lys Ser 145 150 155 160 Leu Ser Arg Ser Ser Ala Ala Ala His Asn Ser Ser Leu Gln Val Arg 165 170 175 Leu Pro Gly Ala Arg Asn His Ser Ser Gly Thr Pro Gly Tyr Asn Gln 180 185 190 Gln Ala Pro Cys Arg Ser Ser Ala Tyr Phe Tyr Thr Thr Pro His Ile 195 200 205 Asp His Leu Leu Leu Gln Gln Lys Pro His Asn Lys His Ser Thr Val 210 215 220 Lys Pro His Asp Val Ser Val Thr His Gly Thr Asp Met Ser Gln Leu 225 230 235 240 Ser Leu Pro Tyr Gln Glu Lys Lys Pro Gly Cys Tyr Lys Ser Trp Cys 245 250 255 Asp Pro Gly Gly Pro Ile Thr Ser Arg Leu Gln Gln Gly Leu Gln Leu 260 265 270 Leu Glu Arg Asp Ser Ser Lys Ala Ile Lys Ser Ser Gln Gln Leu Val 275 280 285 Ile Trp Pro Pro Val Arg Leu Gly Ile Gln Leu Leu Pro Gly Val Arg 290 295 300 His Gly Lys Gly Met Tyr Phe Leu Asn Ser Leu Arg Lys Gln Met Thr 305 310 315 320 Ile Thr Lys Ile Lys Ile Lys Ser Pro Arg Glu Pro Tyr Ile Arg Gln 325 330 335 Ile Thr Cys Leu Tyr Asp Val Lys Gly Cys Leu Lys Pro Ser His Asn 340 345 350 Cys Lys Pro Ala Cys Leu Gly Pro Arg His Ala Arg Cys Gln His Pro 355 360 365 Tyr Lys Phe Pro Ala Val Val Pro Lys Lys Lys Ala Pro Val Leu Asn 370 375 380 Asn Pro Arg Ala Arg Thr Gln Pro His Leu Val Gln Leu Pro Leu Tyr 385 390 395 400 Leu Ala Ala Lys His His Pro Pro Leu Leu Leu Tyr Leu Pro Leu Gly 405 410 415 Leu Gln His Leu Pro Asn Cys Leu Gln Cys Gly Leu Tyr Cys Cys His 420 425 430 Val Trp Cys Arg Lys Ser Leu His His Pro Arg Gln Pro Leu Ile Ile 435 440 445 Gly Lys Tyr Pro Leu Ile Pro Phe Thr Pro Thr Pro Pro Gln His Arg 450 455 460 Arg Leu Pro Pro Pro Val Pro Arg His Gln Ile Glu Ala Arg Cys Glu 465 470 475 480 Leu Ile Ala Ala Leu Thr Arg Arg Lys His His Thr Cys Ile Arg Phe 485 490 495 Pro Pro Phe Gln Leu Tyr Gly Asp Lys Pro Ala Met Gln Leu Pro Lys 500 505 510 Gln Leu Arg Pro Thr Gly Phe Ile Thr Lys Glu Pro Pro His Lys Trp 515 520 525 Ser Pro Gln Pro Pro Pro Asp Thr Lys Gln Pro Leu Ala Glu Lys Ala 530 535 540 Val Asp Asp Leu Leu Ser Leu Leu Ala Ser Ser Tyr Tyr 545 550 555 9 939 DNA Type A PWD circovirus CDS (1)..(936) 9 atg cca agc aag aaa agc ggc ccg caa ccc cat aag agg tgg gtg ttc 48 Met Pro Ser Lys Lys Ser Gly Pro Gln Pro His Lys Arg Trp Val Phe 1 5 10 15 acc ctt aat aat cct tcc gag gag gag aaa aac aaa ata cgg gag ctt 96 Thr Leu Asn Asn Pro Ser Glu Glu Glu Lys Asn Lys Ile Arg Glu Leu 20 25 30 cca atc tcc ctt ttt gat tat ttt gtt tgt ggc gag gaa ggt ttg gaa 144 Pro Ile Ser Leu Phe Asp Tyr Phe Val Cys Gly Glu Glu Gly Leu Glu 35 40 45 gag ggt aga act cct cac ctc cag ggg ttt gcg aat ttt gct aag aag 192 Glu Gly Arg Thr Pro His Leu Gln Gly Phe Ala Asn Phe Ala Lys Lys 50 55 60 cag act ttt aac aag gtg aag tgg tat ttt ggt gcc cgc tgc cac atc 240 Gln Thr Phe Asn Lys Val Lys Trp Tyr Phe Gly Ala Arg Cys His Ile 65 70 75 80 gag aaa gcg aaa gga acc gac cag cag aat aaa gaa tac tgc agt aaa 288 Glu Lys Ala Lys Gly Thr Asp Gln Gln Asn Lys Glu Tyr Cys Ser Lys 85 90 95 gaa ggc cac ata ctt atc gag tgt gga gct ccg cgg aac cag ggg aag 336 Glu Gly His Ile Leu Ile Glu Cys Gly Ala Pro Arg Asn Gln Gly Lys 100 105 110 cgc agc gac ctg tct act gct gtg agt acc ctt ttg gag acg ggg tct 384 Arg Ser Asp Leu Ser Thr Ala Val Ser Thr Leu Leu Glu Thr Gly Ser 115 120 125 ttg gtg act gta gcc gag cag ttt cct gta acg tat gtg aga aat ttc 432 Leu Val Thr Val Ala Glu Gln Phe Pro Val Thr Tyr Val Arg Asn Phe 130 135 140 cgc ggg ctg gct gaa ctt ttg aaa gtg agc ggg aag atg cag cag cgt 480 Arg Gly Leu Ala Glu Leu Leu Lys Val Ser Gly Lys Met Gln Gln Arg 145 150 155 160 gat tgg aag aca gct gta cac gtc ata gtg ggc ccg ccc ggt tgt ggg 528 Asp Trp Lys Thr Ala Val His Val Ile Val Gly Pro Pro Gly Cys Gly 165 170 175 aag agc cag tgg gcc cgt aat ttt gct gag cct agg gac acc tac tgg 576 Lys Ser Gln Trp Ala Arg Asn Phe Ala Glu Pro Arg Asp Thr Tyr Trp 180 185 190 aag cct agt aga aat aag tgg tgg gat gga tat cat gga gaa gaa gtt 624 Lys Pro Ser Arg Asn Lys Trp Trp Asp Gly Tyr His Gly Glu Glu Val 195 200 205 gtt gtt ttg gat gat ttt tat ggc tgg tta cct tgg gat gat cta ctg 672 Val Val Leu Asp Asp Phe Tyr Gly Trp Leu Pro Trp Asp Asp Leu Leu 210 215 220 aga ctg tgt gac cgg tat cca ttg act gta gag act aaa ggg ggt act 720 Arg Leu Cys Asp Arg Tyr Pro Leu Thr Val Glu Thr Lys Gly Gly Thr 225 230 235 240 gtt cct ttt ttg gcc cgc agt att ttg att acc agc aat cag gcc ccc 768 Val Pro Phe Leu Ala Arg Ser Ile Leu Ile Thr Ser Asn Gln Ala Pro 245 250 255 cag gaa tgg tac tcc tca act gct gtc cca gct gta gaa gct ctc tat 816 Gln Glu Trp Tyr Ser Ser Thr Ala Val Pro Ala Val Glu Ala Leu Tyr 260 265 270 cgg agg att act act ttg caa ttt tgg aag act gct gga gaa caa tcc 864 Arg Arg Ile Thr Thr Leu Gln Phe Trp Lys Thr Ala Gly Glu Gln Ser 275 280 285 acg gag gta ccc gaa ggc cga ttt gaa gca gtg gac cca ccc tgt gcc 912 Thr Glu Val Pro Glu Gly Arg Phe Glu Ala Val Asp Pro Pro Cys Ala 290 295 300 ctt ttc cca tat aaa ata aat tac tga 939 Leu Phe Pro Tyr Lys Ile Asn Tyr 305 310 10 312 PRT Type A PWD circovirus 10 Met Pro Ser Lys Lys Ser Gly Pro Gln Pro His Lys Arg Trp Val Phe 1 5 10 15 Thr Leu Asn Asn Pro Ser Glu Glu Glu Lys Asn Lys Ile Arg Glu Leu 20 25 30 Pro Ile Ser Leu Phe Asp Tyr Phe Val Cys Gly Glu Glu Gly Leu Glu 35 40 45 Glu Gly Arg Thr Pro His Leu Gln Gly Phe Ala Asn Phe Ala Lys Lys 50 55 60 Gln Thr Phe Asn Lys Val Lys Trp Tyr Phe Gly Ala Arg Cys His Ile 65 70 75 80 Glu Lys Ala Lys Gly Thr Asp Gln Gln Asn Lys Glu Tyr Cys Ser Lys 85 90 95 Glu Gly His Ile Leu Ile Glu Cys Gly Ala Pro Arg Asn Gln Gly Lys 100 105 110 Arg Ser Asp Leu Ser Thr Ala Val Ser Thr Leu Leu Glu Thr Gly Ser 115 120 125 Leu Val Thr Val Ala Glu Gln Phe Pro Val Thr Tyr Val Arg Asn Phe 130 135 140 Arg Gly Leu Ala Glu Leu Leu Lys Val Ser Gly Lys Met Gln Gln Arg 145 150 155 160 Asp Trp Lys Thr Ala Val His Val Ile Val Gly Pro Pro Gly Cys Gly 165 170 175 Lys Ser Gln Trp Ala Arg Asn Phe Ala Glu Pro Arg Asp Thr Tyr Trp 180 185 190 Lys Pro Ser Arg Asn Lys Trp Trp Asp Gly Tyr His Gly Glu Glu Val 195 200 205 Val Val Leu Asp Asp Phe Tyr Gly Trp Leu Pro Trp Asp Asp Leu Leu 210 215 220 Arg Leu Cys Asp Arg Tyr Pro Leu Thr Val Glu Thr Lys Gly Gly Thr 225 230 235 240 Val Pro Phe Leu Ala Arg Ser Ile Leu Ile Thr Ser Asn Gln Ala Pro 245 250 255 Gln Glu Trp Tyr Ser Ser Thr Ala Val Pro Ala Val Glu Ala Leu Tyr 260 265 270 Arg Arg Ile Thr Thr Leu Gln Phe Trp Lys Thr Ala Gly Glu Gln Ser 275 280 285 Thr Glu Val Pro Glu Gly Arg Phe Glu Ala Val Asp Pro Pro Cys Ala 290 295 300 Leu Phe Pro Tyr Lys Ile Asn Tyr 305 310 11 702 DNA Type A PWD circovirus CDS (1)..(699) 11 atg acg tgg cca agg agg cgt tac cgc aga aga cgg acc cgc ccc cgc 48 Met Thr Trp Pro Arg Arg Arg Tyr Arg Arg Arg Arg Thr Arg Pro Arg 1 5 10 15 agc cat ctt gga aac atc ctc cgg aga aga cca tat ttg gta cac ccc 96 Ser His Leu Gly Asn Ile Leu Arg Arg Arg Pro Tyr Leu Val His Pro 20 25 30 gcc ttc aga aac cgt tac aga tgg cgc cga aag acg ggt atc ttc aat 144 Ala Phe Arg Asn Arg Tyr Arg Trp Arg Arg Lys Thr Gly Ile Phe Asn 35 40 45 tcc cgc ctt tct aga gaa ttt gta ctc acc ata aga gga gga cac tcg 192 Ser Arg Leu Ser Arg Glu Phe Val Leu Thr Ile Arg Gly Gly His Ser 50 55 60 cag cca tct tgg aat gtt aac gag ctg aga ttc aac atc ggc cag ttc 240 Gln Pro Ser Trp Asn Val Asn Glu Leu Arg Phe Asn Ile Gly Gln Phe 65 70 75 80 ctc ccc ccc tca ggc ggc acc aac ccc cta ccc cta cct ttc caa tac 288 Leu Pro Pro Ser Gly Gly Thr Asn Pro Leu Pro Leu Pro Phe Gln Tyr 85 90 95 tac cgt att aga aag gct aaa tat gaa ttt tac ccc aga gac ccc atc 336 Tyr Arg Ile Arg Lys Ala Lys Tyr Glu Phe Tyr Pro Arg Asp Pro Ile 100 105 110 acc tct aat caa aga ggt gtt ggg tcc act gtt gtt atc ttg gat gcc 384 Thr Ser Asn Gln Arg Gly Val Gly Ser Thr Val Val Ile Leu Asp Ala 115 120 125 aac ttt gta acc ccc tcc acc aac ttg gcc tat gac ccc tat att aac 432 Asn Phe Val Thr Pro Ser Thr Asn Leu Ala Tyr Asp Pro Tyr Ile Asn 130 135 140 tac tcc tcc cgc cac acc ata agg cag ccc ttt acc tac cac tcc agg 480 Tyr Ser Ser Arg His Thr Ile Arg Gln Pro Phe Thr Tyr His Ser Arg 145 150 155 160 tac ttc acc ccc aaa cca gag cta gac caa aca att gat tgg ttc cag 528 Tyr Phe Thr Pro Lys Pro Glu Leu Asp Gln Thr Ile Asp Trp Phe Gln 165 170 175 cca aat aat aaa aga aac cag ctg tgg ctc cat tta aat acc cac acc 576 Pro Asn Asn Lys Arg Asn Gln Leu Trp Leu His Leu Asn Thr His Thr 180 185 190 aat gtc gag cac aca ggc ctg ggc tat gcg ctc caa aat gca acc aca 624 Asn Val Glu His Thr Gly Leu Gly Tyr Ala Leu Gln Asn Ala Thr Thr 195 200 205 gcc caa aat tat gtg gta agg ttg act att tat gta caa ttc aga gaa 672 Ala Gln Asn Tyr Val Val Arg Leu Thr Ile Tyr Val Gln Phe Arg Glu 210 215 220 ttt atc ctg aaa gac cct cta aat gaa taa 702 Phe Ile Leu Lys Asp Pro Leu Asn Glu 225 230 12 233 PRT Type A PWD circovirus 12 Met Thr Trp Pro Arg Arg Arg Tyr Arg Arg Arg Arg Thr Arg Pro Arg 1 5 10 15 Ser His Leu Gly Asn Ile Leu Arg Arg Arg Pro Tyr Leu Val His Pro 20 25 30 Ala Phe Arg Asn Arg Tyr Arg Trp Arg Arg Lys Thr Gly Ile Phe Asn 35 40 45 Ser Arg Leu Ser Arg Glu Phe Val Leu Thr Ile Arg Gly Gly His Ser 50 55 60 Gln Pro Ser Trp Asn Val Asn Glu Leu Arg Phe Asn Ile Gly Gln Phe 65 70 75 80 Leu Pro Pro Ser Gly Gly Thr Asn Pro Leu Pro Leu Pro Phe Gln Tyr 85 90 95 Tyr Arg Ile Arg Lys Ala Lys Tyr Glu Phe Tyr Pro Arg Asp Pro Ile 100 105 110 Thr Ser Asn Gln Arg Gly Val Gly Ser Thr Val Val Ile Leu Asp Ala 115 120 125 Asn Phe Val Thr Pro Ser Thr Asn Leu Ala Tyr Asp Pro Tyr Ile Asn 130 135 140 Tyr Ser Ser Arg His Thr Ile Arg Gln Pro Phe Thr Tyr His Ser Arg 145 150 155 160 Tyr Phe Thr Pro Lys Pro Glu Leu Asp Gln Thr Ile Asp Trp Phe Gln 165 170 175 Pro Asn Asn Lys Arg Asn Gln Leu Trp Leu His Leu Asn Thr His Thr 180 185 190 Asn Val Glu His Thr Gly Leu Gly Tyr Ala Leu Gln Asn Ala Thr Thr 195 200 205 Ala Gln Asn Tyr Val Val Arg Leu Thr Ile Tyr Val Gln Phe Arg Glu 210 215 220 Phe Ile Leu Lys Asp Pro Leu Asn Glu 225 230 13 621 DNA Type A PWD circovirus CDS (1)..(618) 13 atg ata tcc atc cca cca ctt att tct act agg ctt cca gta ggt gtc 48 Met Ile Ser Ile Pro Pro Leu Ile Ser Thr Arg Leu Pro Val Gly Val 1 5 10 15 cct agg ctc agc aaa att acg ggc cca ctg gct ctt ccc aca acc ggg 96 Pro Arg Leu Ser Lys Ile Thr Gly Pro Leu Ala Leu Pro Thr Thr Gly 20 25 30 cgg gcc cac tat gac gtg tac agc tgt ctt cca atc acg ctg ctg cat 144 Arg Ala His Tyr Asp Val Tyr Ser Cys Leu Pro Ile Thr Leu Leu His 35 40 45 ctt ccc gct cac ttt caa aag ttc agc cag ccc gcg gaa att tct cac 192 Leu Pro Ala His Phe Gln Lys Phe Ser Gln Pro Ala Glu Ile Ser His 50 55 60 ata cgt tac agg aaa ctg ctc ggc tac agt cac caa aga ccc cgt ctc 240 Ile Arg Tyr Arg Lys Leu Leu Gly Tyr Ser His Gln Arg Pro Arg Leu 65 70 75 80 caa aag ggt act cac agc agt aga cag gtc gct gcg ctt ccc ctg gtt 288 Gln Lys Gly Thr His Ser Ser Arg Gln Val Ala Ala Leu Pro Leu Val 85 90 95 ccg cgg agc tcc aca ctc gat aag tat gtg gcc ttc ttt act gca gta 336 Pro Arg Ser Ser Thr Leu Asp Lys Tyr Val Ala Phe Phe Thr Ala Val 100 105 110 ttc ttt att ctg ctg gtc ggt tcc ttt cgc ttt ctc gat gtg gca gcg 384 Phe Phe Ile Leu Leu Val Gly Ser Phe Arg Phe Leu Asp Val Ala Ala 115 120 125 ggc acc aaa ata cca ctt cac ctt gtt aaa agt ctg ctt ctt agc aaa 432 Gly Thr Lys Ile Pro Leu His Leu Val Lys Ser Leu Leu Leu Ser Lys 130 135 140 att cgc aaa ccc ctg gag gtg agg agt tct acc ctc ttc caa acc ttc 480 Ile Arg Lys Pro Leu Glu Val Arg Ser Ser Thr Leu Phe Gln Thr Phe 145 150 155 160 ctc gcc aca aac aaa ata atc aaa aag gga gat tgg aag ctc ccg tat 528 Leu Ala Thr Asn Lys Ile Ile Lys Lys Gly Asp Trp Lys Leu Pro Tyr 165 170 175 ttt gtt ttt ctc ctc ctc gga agg att att aag ggt gaa cac cca cct 576 Phe Val Phe Leu Leu Leu Gly Arg Ile Ile Lys Gly Glu His Pro Pro 180 185 190 ctt atg ggg ttg cgg gcc gct ttt ctt gct tgg cat ttt cac tga 621 Leu Met Gly Leu Arg Ala Ala Phe Leu Ala Trp His Phe His 195 200 205 14 206 PRT Type A PWD circovirus 14 Met Ile Ser Ile Pro Pro Leu Ile Ser Thr Arg Leu Pro Val Gly Val 1 5 10 15 Pro Arg Leu Ser Lys Ile Thr Gly Pro Leu Ala Leu Pro Thr Thr Gly 20 25 30 Arg Ala His Tyr Asp Val Tyr Ser Cys Leu Pro Ile Thr Leu Leu His 35 40 45 Leu Pro Ala His Phe Gln Lys Phe Ser Gln Pro Ala Glu Ile Ser His 50 55 60 Ile Arg Tyr Arg Lys Leu Leu Gly Tyr Ser His Gln Arg Pro Arg Leu 65 70 75 80 Gln Lys Gly Thr His Ser Ser Arg Gln Val Ala Ala Leu Pro Leu Val 85 90 95 Pro Arg Ser Ser Thr Leu Asp Lys Tyr Val Ala Phe Phe Thr Ala Val 100 105 110 Phe Phe Ile Leu Leu Val Gly Ser Phe Arg Phe Leu Asp Val Ala Ala 115 120 125 Gly Thr Lys Ile Pro Leu His Leu Val Lys Ser Leu Leu Leu Ser Lys 130 135 140 Ile Arg Lys Pro Leu Glu Val Arg Ser Ser Thr Leu Phe Gln Thr Phe 145 150 155 160 Leu Ala Thr Asn Lys Ile Ile Lys Lys Gly Asp Trp Lys Leu Pro Tyr 165 170 175 Phe Val Phe Leu Leu Leu Gly Arg Ile Ile Lys Gly Glu His Pro Pro 180 185 190 Leu Met Gly Leu Arg Ala Ala Phe Leu Ala Trp His Phe His 195 200 205 15 1767 DNA Type B PWD circovirus CDS (1)..(111) CDS (115)..(243) CDS (247)..(267) CDS (271)..(360) CDS (364)..(417) CDS (421)..(447) CDS (451)..(471) CDS (475)..(510) CDS (514)..(516) CDS (520)..(729) CDS (733)..(753) CDS (757)..(759) CDS (763)..(804) CDS (808)..(861) CDS (865)..(984) CDS (988)..(1173) CDS (1177)..(1233) CDS (1237)..(1359) CDS (1363)..(1476) CDS (1480)..(1737) CDS (1741)..(1767) 15 acc agc gca ctt cgg cag cgg cag cac ctc ggc agc acc tca gca gca 48 Thr Ser Ala Leu Arg Gln Arg Gln His Leu Gly Ser Thr Ser Ala Ala 1 5 10 15 aca tgc cca gca aga aga atg gaa gaa gcg gac ccc aac ccc ata aaa 96 Thr Cys Pro Ala Arg Arg Met Glu Glu Ala Asp Pro Asn Pro Ile Lys 20 25 30 ggt ggg tgt tca ctc tga ata atc ctt ccg aag acg agc gca aga aaa 144 Gly Gly Cys Ser Leu Ile Ile Leu Pro Lys Thr Ser Ala Arg Lys 35 40 45 tac ggg atc ttc caa tat ccc tat ttg att att tta ttg ttg gcg agg 192 Tyr Gly Ile Phe Gln Tyr Pro Tyr Leu Ile Ile Leu Leu Leu Ala Arg 50 55 60 agg gta atg agg aag gac gaa cac ctc acc tcc agg ggt tcg cta att 240 Arg Val Met Arg Lys Asp Glu His Leu Thr Ser Arg Gly Ser Leu Ile 65 70 75 ttg tga aga agc aga ctt tta ata aag tga agt ggt att tgg gtg ccc 288 Leu Arg Ser Arg Leu Leu Ile Lys Ser Gly Ile Trp Val Pro 80 85 90 gct gcc aca tcg aga aag cga aag gaa cag atc agc aga ata aag aat 336 Ala Ala Thr Ser Arg Lys Arg Lys Glu Gln Ile Ser Arg Ile Lys Asn 95 100 105 act gca gta aag aag gca act tac tga tgg agt gtg gag ctc cta gat 384 Thr Ala Val Lys Lys Ala Thr Tyr Trp Ser Val Glu Leu Leu Asp 110 115 120 ctc agg gac aac gga gtg acc tgt cta ctg ctg tga gta cct tgt tgg 432 Leu Arg Asp Asn Gly Val Thr Cys Leu Leu Leu Val Pro Cys Trp 125 130 135 aga gcg gga gtc tgg tga ccg ttg cag agc agc acc ctg taa cgt ttg 480 Arg Ala Gly Val Trp Pro Leu Gln Ser Ser Thr Leu Arg Leu 140 145 150 tca gaa att tcc gcg ggc tgg ctg aac ttt tga aag tga gcg gga aaa 528 Ser Glu Ile Ser Ala Gly Trp Leu Asn Phe Lys Ala Gly Lys 155 160 165 tgc aga agc gtg att gga aga cta atg tac acg tca ttg tgg ggc cac 576 Cys Arg Ser Val Ile Gly Arg Leu Met Tyr Thr Ser Leu Trp Gly His 170 175 180 ctg ggt gtg gta aaa gca aat ggg ctg cta att ttg cag acc cgg aaa 624 Leu Gly Val Val Lys Ala Asn Gly Leu Leu Ile Leu Gln Thr Arg Lys 185 190 195 cca cat act gga aac cac cta gaa aca agt ggt ggg atg gtt acc atg 672 Pro His Thr Gly Asn His Leu Glu Thr Ser Gly Gly Met Val Thr Met 200 205 210 215 gtg aag aag tgg ttg tta ttg atg act ttt atg gct ggc tgc cct ggg 720 Val Lys Lys Trp Leu Leu Leu Met Thr Phe Met Ala Gly Cys Pro Gly 220 225 230 atg atc tac tga gac tgt gtg atc gat atc cat tga ctg tag aga cta 768 Met Ile Tyr Asp Cys Val Ile Asp Ile His Leu Arg Leu 235 240 aag gtg gaa ctg tac ctt ttt tgg ccc gca gta ttc tga tta cca gca 816 Lys Val Glu Leu Tyr Leu Phe Trp Pro Ala Val Phe Leu Pro Ala 245 250 255 atc aga ccc cgt tgg aat ggt act cct caa ctg ctg tcc cag ctg tag 864 Ile Arg Pro Arg Trp Asn Gly Thr Pro Gln Leu Leu Ser Gln Leu 260 265 270 aag ctc ttt atc gga gga tta ctt cct tgg tat ttt gga aga atg cta 912 Lys Leu Phe Ile Gly Gly Leu Leu Pro Trp Tyr Phe Gly Arg Met Leu 275 280 285 290 cag aac aat cca cgg agg aag ggg gcc agt tcg tca ccc ttt ccc ccc 960 Gln Asn Asn Pro Arg Arg Lys Gly Ala Ser Ser Ser Pro Phe Pro Pro 295 300 305 cat gcc ctg aat ttc cat atg aaa taa att act gag tct ttt tta tca 1008 His Ala Leu Asn Phe His Met Lys Ile Thr Glu Ser Phe Leu Ser 310 315 320 ctt cgt aat ggt ttt tat tat tca tta agg gtt aag tgg ggg gtc ttt 1056 Leu Arg Asn Gly Phe Tyr Tyr Ser Leu Arg Val Lys Trp Gly Val Phe 325 330 335 aaa att aaa ttc tct gaa ttg tac ata cat ggt tac acg gat att gta 1104 Lys Ile Lys Phe Ser Glu Leu Tyr Ile His Gly Tyr Thr Asp Ile Val 340 345 350 ttc ctg gtc gta tat act gtt ttc gaa cgc agt gcc gag gcc tac gtg 1152 Phe Leu Val Val Tyr Thr Val Phe Glu Arg Ser Ala Glu Ala Tyr Val 355 360 365 gtc tac att tcc agc agt ttg tag tct cag cca cag ctg gtt tct ttt 1200 Val Tyr Ile Ser Ser Ser Leu Ser Gln Pro Gln Leu Val Ser Phe 370 375 380 gtt gtt tgg ttg gaa gta atc aat agt gaa atc tag gac agg ttt ggg 1248 Val Val Trp Leu Glu Val Ile Asn Ser Glu Ile Asp Arg Phe Gly 385 390 395 ggt aaa gta ccg gga gtg gta gga gaa ggg ctg ggt tat ggt atg gcg 1296 Gly Lys Val Pro Gly Val Val Gly Glu Gly Leu Gly Tyr Gly Met Ala 400 405 410 415 gga gga gta gtt tac ata ggg gtc ata ggt gag ggc tgt ggc ctt tgt 1344 Gly Gly Val Val Tyr Ile Gly Val Ile Gly Glu Gly Cys Gly Leu Cys 420 425 430 tac aaa gtt atc atc taa aat aac agc act gga gcc cac tcc cct gtc 1392 Tyr Lys Val Ile Ile Asn Asn Ser Thr Gly Ala His Ser Pro Val 435 440 445 acc ctg ggt gat cgg gga gca ggg cca gaa ttc aac ctt aac ctt tct 1440 Thr Leu Gly Asp Arg Gly Ala Gly Pro Glu Phe Asn Leu Asn Leu Ser 450 455 460 tat tct gta gta ttc aaa ggg cac aga gcg ggg gtt tga ccc ccc tcc 1488 Tyr Ser Val Val Phe Lys Gly His Arg Ala Gly Val Pro Pro Ser 465 470 475 tgg ggg aag aaa gtc att aat att gaa tct cat cat gtc cac cgc cca 1536 Trp Gly Lys Lys Val Ile Asn Ile Glu Ser His His Val His Arg Pro 480 485 490 gga ggg cgt tct gac tgt ggt tcg ctt gac agt ata tcc gaa ggt gcg 1584 Gly Gly Arg Ser Asp Cys Gly Ser Leu Asp Ser Ile Ser Glu Gly Ala 495 500 505 gga gag gcg ggt gtt gaa gat gcc att ttt cct tct cca gcg gta acg 1632 Gly Glu Ala Gly Val Glu Asp Ala Ile Phe Pro Ser Pro Ala Val Thr 510 515 520 525 gtg gcg ggg gtg gac gag cca ggg gcg gcg gcg gag gat ctg gcc aag 1680 Val Ala Gly Val Asp Glu Pro Gly Ala Ala Ala Glu Asp Leu Ala Lys 530 535 540 atg gct gcg ggg gcg gtg tct tct tct tcg gta acg cct cct tgg ata 1728 Met Ala Ala Gly Ala Val Ser Ser Ser Ser Val Thr Pro Pro Trp Ile 545 550 555 cgt cat atc tga aaa cga aag aag tgc gct gta agt att 1767 Arg His Ile Lys Arg Lys Lys Cys Ala Val Ser Ile 560 565 16 569 PRT Type B PWD circovirus 16 Thr Ser Ala Leu Arg Gln Arg Gln His Leu Gly Ser Thr Ser Ala Ala 1 5 10 15 Thr Cys Pro Ala Arg Arg Met Glu Glu Ala Asp Pro Asn Pro Ile Lys 20 25 30 Gly Gly Cys Ser Leu Ile Ile Leu Pro Lys Thr Ser Ala Arg Lys Tyr 35 40 45 Gly Ile Phe Gln Tyr Pro Tyr Leu Ile Ile Leu Leu Leu Ala Arg Arg 50 55 60 Val Met Arg Lys Asp Glu His Leu Thr Ser Arg Gly Ser Leu Ile Leu 65 70 75 80 Arg Ser Arg Leu Leu Ile Lys Ser Gly Ile Trp Val Pro Ala Ala Thr 85 90 95 Ser Arg Lys Arg Lys Glu Gln Ile Ser Arg Ile Lys Asn Thr Ala Val 100 105 110 Lys Lys Ala Thr Tyr Trp Ser Val Glu Leu Leu Asp Leu Arg Asp Asn 115 120 125 Gly Val Thr Cys Leu Leu Leu Val Pro Cys Trp Arg Ala Gly Val Trp 130 135 140 Pro Leu Gln Ser Ser Thr Leu Arg Leu Ser Glu Ile Ser Ala Gly Trp 145 150 155 160 Leu Asn Phe Lys Ala Gly Lys Cys Arg Ser Val Ile Gly Arg Leu Met 165 170 175 Tyr Thr Ser Leu Trp Gly His Leu Gly Val Val Lys Ala Asn Gly Leu 180 185 190 Leu Ile Leu Gln Thr Arg Lys Pro His Thr Gly Asn His Leu Glu Thr 195 200 205 Ser Gly Gly Met Val Thr Met Val Lys Lys Trp Leu Leu Leu Met Thr 210 215 220 Phe Met Ala Gly Cys Pro Gly Met Ile Tyr Asp Cys Val Ile Asp Ile 225 230 235 240 His Leu Arg Leu Lys Val Glu Leu Tyr Leu Phe Trp Pro Ala Val Phe 245 250 255 Leu Pro Ala Ile Arg Pro Arg Trp Asn Gly Thr Pro Gln Leu Leu Ser 260 265 270 Gln Leu Lys Leu Phe Ile Gly Gly Leu Leu Pro Trp Tyr Phe Gly Arg 275 280 285 Met Leu Gln Asn Asn Pro Arg Arg Lys Gly Ala Ser Ser Ser Pro Phe 290 295 300 Pro Pro His Ala Leu Asn Phe His Met Lys Ile Thr Glu Ser Phe Leu 305 310 315 320 Ser Leu Arg Asn Gly Phe Tyr Tyr Ser Leu Arg Val Lys Trp Gly Val 325 330 335 Phe Lys Ile Lys Phe Ser Glu Leu Tyr Ile His Gly Tyr Thr Asp Ile 340 345 350 Val Phe Leu Val Val Tyr Thr Val Phe Glu Arg Ser Ala Glu Ala Tyr 355 360 365 Val Val Tyr Ile Ser Ser Ser Leu Ser Gln Pro Gln Leu Val Ser Phe 370 375 380 Val Val Trp Leu Glu Val Ile Asn Ser Glu Ile Asp Arg Phe Gly Gly 385 390 395 400 Lys Val Pro Gly Val Val Gly Glu Gly Leu Gly Tyr Gly Met Ala Gly 405 410 415 Gly Val Val Tyr Ile Gly Val Ile Gly Glu Gly Cys Gly Leu Cys Tyr 420 425 430 Lys Val Ile Ile Asn Asn Ser Thr Gly Ala His Ser Pro Val Thr Leu 435 440 445 Gly Asp Arg Gly Ala Gly Pro Glu Phe Asn Leu Asn Leu Ser Tyr Ser 450 455 460 Val Val Phe Lys Gly His Arg Ala Gly Val Pro Pro Ser Trp Gly Lys 465 470 475 480 Lys Val Ile Asn Ile Glu Ser His His Val His Arg Pro Gly Gly Arg 485 490 495 Ser Asp Cys Gly Ser Leu Asp Ser Ile Ser Glu Gly Ala Gly Glu Ala 500 505 510 Gly Val Glu Asp Ala Ile Phe Pro Ser Pro Ala Val Thr Val Ala Gly 515 520 525 Val Asp Glu Pro Gly Ala Ala Ala Glu Asp Leu Ala Lys Met Ala Ala 530 535 540 Gly Ala Val Ser Ser Ser Ser Val Thr Pro Pro Trp Ile Arg His Ile 545 550 555 560 Lys Arg Lys Lys Cys Ala Val Ser Ile 565 17 542 PRT Type B PWD circovirus 17 Pro Ala His Phe Gly Ser Gly Ser Thr Ser Ala Ala Pro Gln Gln Gln 1 5 10 15 His Ala Gln Gln Glu Glu Trp Lys Lys Arg Thr Pro Thr Pro Lys Val 20 25 30 Gly Val His Ser Glu Ser Phe Arg Arg Arg Ala Gln Glu Asn Thr Gly 35 40 45 Ser Ser Asn Ile Pro Ile Leu Phe Tyr Cys Trp Arg Gly Gly Gly Arg 50 55 60 Thr Asn Thr Ser Pro Pro Gly Val Arg Phe Cys Glu Glu Ala Asp Phe 65 70 75 80 Ser Glu Val Val Phe Gly Cys Pro Leu Pro His Arg Glu Ser Glu Arg 85 90 95 Asn Arg Ser Ala Glu Arg Ile Leu Gln Arg Arg Gln Leu Thr Asp Gly 100 105 110 Val Trp Ser Ser Ile Ser Gly Thr Thr Glu Pro Val Tyr Cys Cys Glu 115 120 125 Tyr Leu Val Gly Glu Arg Glu Ser Gly Asp Arg Cys Arg Ala Ala Pro 130 135 140 Cys Asn Val Cys Gln Lys Phe Pro Arg Ala Gly Thr Phe Glu Ser Glu 145 150 155 160 Arg Glu Asn Ala Glu Ala Cys Thr Arg His Cys Gly Ala Thr Trp Val 165 170 175 Trp Lys Gln Met Gly Cys Phe Cys Arg Pro Gly Asn His Ile Leu Glu 180 185 190 Thr Thr Lys Gln Val Val Gly Trp Leu Pro Trp Arg Ser Gly Cys Tyr 195 200 205 Leu Leu Trp Leu Ala Ala Leu Gly Ser Thr Glu Thr Val Ser Ile Ser 210 215 220 Ile Asp Cys Arg Asp Arg Trp Asn Cys Thr Phe Phe Gly Pro Gln Tyr 225 230 235 240 Ser Asp Tyr Gln Gln Ser Asp Pro Val Gly Met Val Leu Leu Asn Cys 245 250 255 Cys Pro Ser Cys Arg Ser Ser Leu Ser Glu Asp Tyr Phe Leu Gly Ile 260 265 270 Leu Glu Glu Cys Tyr Arg Thr Ile His Gly Gly Arg Gly Pro Val Arg 275 280 285 His Pro Phe Pro Pro Met Pro Asn Lys Leu Leu Ser Leu Phe Tyr His 290 295 300 Phe Val Met Val Phe Ile Ile His Gly Leu Ser Gly Gly Ser Leu Lys 305 310 315 320 Leu Asn Ser Leu Asn Cys Thr Tyr Met Val Thr Arg Ile Leu Tyr Ser 325 330 335 Trp Ser Tyr Ile Leu Phe Ser Asn Ala Val Pro Arg Pro Thr Trp Ser 340 345 350 Thr Phe Pro Ala Val Cys Ser Leu Ser His Ser Trp Phe Leu Leu Leu 355 360 365 Phe Gly Trp Lys Ser Ile Val Lys Ser Arg Thr Gly Leu Gly Val Lys 370 375 380 Tyr Arg Glu Trp Glu Lys Gly Trp Val Met Val Trp Arg Glu Glu Val 385 390 395 400 Arg Ala Val Ala Phe Val Thr Lys Leu Ser Ser Lys Ile Thr Ala Leu 405 410 415 Glu Pro Thr Pro Leu Ser Pro Trp Val Ile Gly Glu Gln Gly Gln Asn 420 425 430 Ser Thr Leu Thr Phe Leu Ile Leu Tyr Ser Lys Gly Thr Glu Arg Gly 435 440 445 Phe Asp Pro Pro Pro Gly Gly Arg Lys Ser Leu Ile Leu Asn Leu Ile 450 455 460 Met Ser Thr Ala Gln Glu Gly Val Leu Thr Val Val Arg Leu Thr Val 465 470 475 480 Tyr Pro Lys Val Arg Glu Arg Arg Val Leu Lys Met Pro Phe Phe Leu 485 490 495 Leu Gln Arg Arg Trp Arg Gly Trp Thr Ser Gln Gly Arg Arg Arg Arg 500 505 510 Ile Trp Pro Arg Trp Leu Arg Gly Arg Cys Leu Leu Leu Arg Arg Leu 515 520 525 Leu Gly Tyr Val Ile Ser Glu Asn Glu Arg Ser Ala Leu Val 530 535 540 18 566 PRT Type B PWD circovirus 18 Gln Arg Thr Ser Ala Ala Ala Ala Pro Arg Gln His Leu Ser Ser Asn 1 5 10 15 Met Pro Ser Lys Lys Asn Gly Arg Ser Gly Pro Gln Pro His Lys Arg 20 25 30 Trp Val Phe Thr Leu Asn Asn Pro Ser Glu Asp Glu Arg Lys Lys Ile 35 40 45 Arg Asp Leu Pro Ile Ser Leu Phe Asp Tyr Phe Ile Val Gly Glu Glu 50 55 60 Gly Asn Glu Glu Gly Arg Thr Pro His Leu Gln Gly Phe Ala Asn Phe 65 70 75 80 Val Lys Lys Gln Thr Phe Asn Lys Val Lys Trp Tyr Leu Gly Ala Arg 85 90 95 Cys His Ile Glu Lys Ala Lys Gly Thr Asp Gln Gln Asn Lys Glu Tyr 100 105 110 Cys Ser Lys Glu Gly Asn Leu Leu Met Glu Cys Gly Ala Pro Arg Ser 115 120 125 Gln Gly Gln Arg Ser Asp Leu Ser Thr Ala Val Ser Thr Leu Leu Glu 130 135 140 Ser Gly Ser Leu Val Thr Val Ala Glu Gln His Pro Val Thr Phe Val 145 150 155 160 Arg Asn Phe Arg Gly Leu Ala Glu Leu Leu Lys Val Ser Gly Lys Met 165 170 175 Gln Lys Arg Asp Trp Lys Thr Asn Val His Val Ile Val Gly Pro Pro 180 185 190 Gly Cys Gly Lys Ser Lys Trp Ala Ala Asn Phe Ala Asp Pro Glu Thr 195 200 205 Thr Tyr Trp Lys Pro Pro Arg Asn Lys Trp Trp Asp Gly Tyr His Gly 210 215 220 Glu Glu Val Val Val Ile Asp Asp Phe Tyr Gly Trp Leu Pro Trp Asp 225 230 235 240 Asp Leu Leu Arg Leu Cys Asp Arg Tyr Pro Leu Thr Val Glu Thr Lys 245 250 255 Gly Gly Thr Val Pro Phe Leu Ala Arg Ser Ile Leu Ile Thr Ser Asn 260 265 270 Gln Thr Pro Leu Glu Trp Tyr Ser Ser Thr Ala Val Pro Ala Val Glu 275 280 285 Ala Leu Tyr Arg Arg Ile Thr Ser Leu Val Phe Trp Lys Asn Ala Thr 290 295 300 Glu Gln Ser Thr Glu Glu Gly Gly Gln Phe Val Thr Leu Ser Pro Pro 305 310 315 320 Cys Pro Glu Phe Pro Tyr Glu Ile Asn Tyr Val Phe Phe Ile Thr Ser 325 330 335 Trp Phe Leu Leu Phe Ile Lys Gly Val Gly Gly Leu Ile Val His Thr 340 345 350 Trp Leu His Gly Tyr Cys Ile Pro Gly Arg Ile Tyr Cys Phe Arg Thr 355 360 365 Gln Cys Arg Gly Leu Arg Gly Leu His Phe Gln Gln Phe Val Val Ser 370 375 380 Ala Thr Ala Gly Phe Phe Cys Cys Leu Val Gly Ser Asn Gln Asn Leu 385 390 395 400 Gly Gln Val Trp Gly Ser Thr Gly Ser Gly Arg Arg Arg Ala Gly Leu 405 410 415 Trp Tyr Gly Gly Arg Ser Ser Leu His Arg Gly His Arg Gly Leu Trp 420 425 430 Pro Leu Leu Gln Ser Tyr His Leu Lys Gln His Trp Ser Pro Leu Pro 435 440 445 Cys His Pro Gly Ser Gly Ser Arg Ala Arg Ile Gln Pro Pro Phe Leu 450 455 460 Phe Cys Ser Ile Gln Arg Ala Gln Ser Gly Gly Leu Thr Pro Leu Leu 465 470 475 480 Gly Glu Glu Ser His Ile Ser Ser Cys Pro Pro Pro Arg Arg Ala Phe 485 490 495 Leu Trp Phe Ala Gln Tyr Ile Arg Arg Cys Gly Arg Gly Gly Cys Arg 500 505 510 Cys His Phe Ser Phe Ser Ser Gly Asn Gly Gly Gly Gly Gly Arg Ala 515 520 525 Arg Gly Gly Gly Gly Gly Ser Gly Gln Asp Gly Cys Gly Gly Gly Val 530 535 540 Phe Phe Phe Gly Asn Ala Ser Leu Asp Thr Ser Tyr Leu Lys Thr Lys 545 550 555 560 Glu Val Arg Cys Lys Tyr 565 19 1767 DNA Type B PWD circovirus 19 aatacttaca gcgcacttct ttcgttttca gatatgacgt atccaaggag gcgttaccga 60 agaagaagac accgcccccg cagccatctt ggccagatcc tccgccgccg cccctggctc 120 gtccaccccc gccaccgtta ccgctggaga aggaaaaatg gcatcttcaa cacccgcctc 180 tcccgcacct tcggatatac tgtcaagcga accacagtca gaacgccctc ctgggcggtg 240 gacatgatga gattcaatat taatgacttt cttcccccag gaggggggtc aaacccccgc 300 tctgtgccct ttgaatacta cagaataaga aaggttaagg ttgaattctg gccctgctcc 360 ccgatcaccc agggtgacag gggagtgggc tccagtgctg ttattttaga tgataacttt 420 gtaacaaagg ccacagccct cacctatgac ccctatgtaa actactcctc ccgccatacc 480 ataacccagc ccttctccta ccactcccgg tactttaccc ccaaacctgt cctagatttc 540 actattgatt acttccaacc aaacaacaaa agaaaccagc tgtggctgag actacaaact 600 gctggaaatg tagaccacgt aggcctcggc actgcgttcg aaaacagtat atacgaccag 660 gaatacaata tccgtgtaac catgtatgta caattcagag aatttaattt taaagacccc 720 ccacttaacc cttaatgaat aataaaaacc attacgaagt gataaaaaag actcagtaat 780 ttatttcata tggaaattca gggcatgggg gggaaagggt gacgaactgg cccccttcct 840 ccgtggattg ttctgtagca ttcttccaaa ataccaagga agtaatcctc cgataaagag 900 cttctacagc tgggacagca gttgaggagt accattccaa cggggtctga ttgctggtaa 960 tcagaatact gcgggccaaa aaaggtacag ttccaccttt agtctctaca gtcaatggat 1020 atcgatcaca cagtctcagt agatcatccc agggcagcca gccataaaag tcatcaataa 1080 caaccacttc ttcaccatgg taaccatccc accacttgtt tctaggtggt ttccagtatg 1140 tggtttccgg gtctgcaaaa ttagcagccc atttgctttt accacaccca ggtggcccca 1200 caatgacgtg tacattagtc ttccaatcac gcttctgcat tttcccgctc actttcaaaa 1260 gttcagccag cccgcggaaa tttctgacaa acgttacagg gtgctgctct gcaacggtca 1320 ccagactccc gctctccaac aaggtactca cagcagtaga caggtcactc cgttgtccct 1380 gagatctagg agctccacac tccatcagta agttgccttc tttactgcag tattctttat 1440 tctgctgatc tgttcctttc gctttctcga tgtggcagcg ggcacccaaa taccacttca 1500 ctttattaaa agtctgcttc ttcacaaaat tagcgaaccc ctggaggtga ggtgttcgtc 1560 cttcctcatt accctcctcg ccaacaataa aataatcaaa tagggatatt ggaagatccc 1620 gtattttctt gcgctcgtct tcggaaggat tattcagagt gaacacccac cttttatggg 1680 gttggggtcc gcttcttcca ttcttcttgc tgggcatgtt gctgctgagg tgctgccgag 1740 gtgctgccgc tgccgaagtg cgctggt 1767 20 567 PRT Type B PWD circovirus 20 Gly Ala Cys Lys Pro Leu Pro Leu Val Glu Ala Ala Gly Cys Cys Cys 1 5 10 15 Ala Trp Cys Ser Ser His Phe Phe Arg Val Gly Val Gly Tyr Phe Thr 20 25 30 Pro Thr Glu Ser Tyr Asp Lys Arg Leu Arg Ala Cys Ser Phe Val Pro 35 40 45 Asp Glu Leu Ile Gly Ile Gln Asn Asn Gln Gln Arg Pro Pro Tyr His 50 55 60 Pro Leu Val Phe Val Glu Gly Gly Pro Thr Arg Asn Gln Ser Ser Ala 65 70 75 80 Ser Lys Tyr Leu Ser Thr Thr Asn Pro His Gly Ser Gly Cys Arg Ser 85 90 95 Leu Ser Leu Phe Leu Asp Ala Ser Tyr Leu Ile Ser Cys Tyr Leu Leu 100 105 110 Cys Ser Val Ser Pro Thr His Leu Glu Ile Glu Pro Val Val Ser His 115 120 125 Gly Thr Gln Gln Ser Tyr Arg Thr Pro Ser Arg Ser Asp Pro Ser Arg 130 135 140 Gln Leu Ala Ala Gly Gln Leu Thr Gln Phe Asn Gly Arg Ala Pro Gln 145 150 155 160 Val Lys Ser Leu Ser Arg Ser Phe Ala Ser Ala His Asn Ser Ser His 165 170 175 Val Arg Gln Pro Ala Val Gln Thr His Tyr Phe Cys Ile Pro Gln Asn 180 185 190 Gln Leu Gly Pro Phe Trp Met Ser Ser Val Val Phe Cys Thr Thr Pro 195 200 205 His Asn Gly His His Leu Leu Pro Gln Gln His Ser Lys His Ser Ala 210 215 220 Ala Arg Pro His Asp Val Ser Val Thr His Asp Ile Asp Met Ser Gln 225 230 235 240 Leu Ser Leu His Phe Gln Val Lys Lys Pro Gly Cys Tyr Glu Ser Trp 245 250 255 Cys Asp Ser Gly Thr Pro Ile Thr Ser Arg Leu Gln Gln Gly Leu Gln 260 265 270 Leu Leu Glu Lys Asp Ser Ser Lys Arg Pro Ile Lys Ser Ser His Leu 275 280 285 Val Ile Trp Pro Pro Leu Pro Gly Thr Arg Gly Lys Gly Gly Met Gly 290 295 300 Gln Ile Glu Met His Phe Leu Asn Ser Leu Arg Lys Lys Thr Ile Thr 305 310 315 320 Lys Ile Ile Pro Asn Leu Pro Pro Asp Lys Phe Asn Phe Glu Arg Phe 325 330 335 Gln Val Tyr Met Thr Val Arg Ile Asn Tyr Glu Gln Asp Tyr Ile Ser 340 345 350 Asn Glu Phe Ala Thr Gly Leu Gly Val His Asp Val Asn Gly Ala Thr 355 360 365 Gln Leu Arg Leu Trp Leu Gln Asn Arg Lys Asn Asn Pro Gln Phe Tyr 370 375 380 Asp Ile Thr Phe Asp Leu Val Pro Lys Pro Thr Phe Tyr Arg Ser His 385 390 395 400 Tyr Ser Phe Pro Gln Thr Ile Thr His Arg Ser Ser Tyr Asn Val Tyr 405 410 415 Pro Asp Tyr Thr Leu Ala Thr Ala Lys Thr Val Pro Asn Asp Asp Leu 420 425 430 Ile Val Ala Ser Ser Gly Val Gly Arg Asp Gly Gln Thr Ile Pro Ser 435 440 445 Cys Pro Trp Phe Glu Val Lys Val Lys Arg Ile Arg Tyr Tyr Glu Phe 450 455 460 Pro Val Ser Arg Pro Asn Ser Gly Gly Gly Pro Pro Leu Phe Asp Asn 465 470 475 480 Ile Asn Phe Arg Met Met Asp Val Ala Trp Ser Pro Thr Arg Val Thr 485 490 495 Thr Arg Lys Val Thr Tyr Gly Phe Thr Arg Ser Leu Arg Thr Asn Phe 500 505 510 Ile Gly Asn Lys Arg Arg Trp Arg Tyr Arg His Arg Pro His Val Leu 515 520 525 Trp Pro Arg Arg Arg Leu Ile Gln Gly Leu His Ser Arg Pro Arg His 530 535 540 Arg Arg Arg Arg Tyr Arg Arg Arg Pro Tyr Thr Met Asp Ser Phe Ser 545 550 555 560 Leu Leu Ala Ser Tyr Thr Asn 565 21 566 PRT Type B PWD circovirus 21 Trp Arg Val Glu Ala Ala Ala Ala Gly Arg Cys Cys Arg Leu Leu Leu 1 5 10 15 Met Gly Leu Leu Phe Phe Pro Leu Leu Pro Gly Trp Gly Trp Leu Leu 20 25 30 His Thr Asn Val Arg Phe Leu Gly Glu Ser Ser Ser Arg Leu Phe Ile 35 40 45 Arg Ser Arg Gly Ile Asp Arg Asn Ser Lys Ile Thr Pro Ser Ser Pro 50 55 60 Leu Ser Ser Pro Arg Val Gly Arg Trp Pro Asn Ala Leu Lys Thr Phe 65 70 75 80 Phe Cys Val Lys Leu Leu Thr Phe His Tyr Lys Pro Ala Arg Gln Trp 85 90 95 Met Ser Phe Ala Phe Pro Val Ser Cys Phe Leu Ser Tyr Gln Leu Leu 100 105 110 Ser Pro Leu Lys Ser Ile Ser His Pro Ala Gly Leu Asp Pro Cys Arg 115 120 125 Leu Ser Arg Asp Val Ala Thr Leu Val Lys Asn Ser Leu Pro Leu Arg 130 135 140 Thr Val Thr Ala Ser Cys Cys Gly Thr Val Asn Thr Leu Phe Lys Arg 145 150 155 160 Pro Ser Ala Ser Ser Lys Phe Thr Leu Pro Phe Ile Cys Phe Arg Ser 165 170 175 Gln Phe Val Leu Thr Cys Thr Met Thr Pro Gly Gly Pro His Pro Leu 180 185 190 Leu Leu His Ala Ala Leu Lys Ala Ser Gly Ser Val Val Tyr Gln Phe 195 200 205 Gly Gly Leu Phe Leu His His Ser Pro Trp Pro Ser Ser Thr Thr Thr 210 215 220 Ile Ser Ser Lys Pro Gln Ser Gly Gln Ser Ser Arg Ser Leu Ser His 225 230 235 240 Ser Arg Tyr Gly Asn Val Thr Ser Val Leu Pro Pro Val Thr Gly Lys 245 250 255 Lys Ala Arg Leu Ile Arg Ile Val Leu Leu Val Gly Asn Ser His Tyr 260 265 270 Glu Glu Val Ala Thr Gly Ala Thr Ser Ala Arg Arg Leu Ile Val Glu 275 280 285 Lys Thr Asn Gln Phe Phe Ala Val Ser Cys Asp Val Ser Ser Pro Pro 290 295 300 Trp Asn Thr Val Arg Glu Gly Gly His Gly Ser Asn Gly Tyr Ser Ile 305 310 315 320 Phe Gln Thr Lys Lys Ile Val Glu Tyr His Asn Lys Asn Asn Met Leu 325 330 335 Pro Thr Pro Pro Arg Phe Ile Arg Gln Ile Thr Cys Val His Asn Cys 340 345 350 Pro Tyr Gln Ile Gly Pro Arg Ile Tyr Gln Lys Arg Val Cys His Arg 355 360 365 Pro Arg Arg Pro Arg Cys Lys Trp Cys Asn Thr Thr Glu Ala Val Ala 370 375 380 Pro Lys Lys Gln Gln Lys Thr Pro Leu Leu Tyr His Phe Arg Pro Cys 385 390 395 400 Thr Gln Pro Tyr Leu Val Pro Leu Pro Leu Leu Leu Ala Pro Asn His 405 410 415 Tyr Pro Pro Leu Leu Leu Lys Cys Leu Pro Leu His Pro Ser His Gly 420 425 430 Lys Asn Cys Leu Arg Phe Tyr Cys Cys Gln Leu Gly Ser Gly Gln Gly 435 440 445 Pro His Asp Pro Leu Leu Ala Leu Ile Gly Gly Lys Lys Asn Gln Leu 450 455 460 Ile Leu Ala Cys Leu Pro Pro Lys Val Gly Arg Arg Pro Ser Ser Leu 465 470 475 480 Tyr Gln Ile Glu Asp His Gly Gly Gly Leu Leu Ala Asn Gln Ser His 485 490 495 Asn Ala Gln Cys Tyr Ile Arg Leu His Pro Leu Pro Pro His Gln Leu 500 505 510 His Trp Lys Glu Lys Glu Leu Pro Leu Pro Pro Pro Pro Pro Arg Ala 515 520 525 Leu Pro Pro Pro Pro Pro Asp Pro Trp Ser Pro Gln Pro Pro Pro Thr 530 535 540 Lys Lys Lys Pro Leu Ala Glu Lys Ser Val Asp Tyr Arg Phe Val Phe 545 550 555 560 Ser Thr Arg Gln Leu Tyr 565 22 569 PRT Type B PWD circovirus 22 Leu Ala Ser Arg Cys Arg Cys Cys Arg Pro Leu Val Glu Ala Ala Val 1 5 10 15 His Gly Ala Leu Leu Ile Ser Ser Ala Ser Gly Leu Gly Met Phe Pro 20 25 30 Pro His Glu Ser Gln Ile Ile Arg Gly Phe Val Leu Ala Leu Phe Tyr 35 40 45 Pro Ile Lys Trp Tyr Gly Lys Ile Ile Lys Asn Asn Ala Leu Leu Thr 50 55 60 Ile Leu Phe Ser Ser Cys Arg Val Glu Leu Pro Glu Ser Ile Lys His 65 70 75 80 Leu Leu Leu Ser Lys Ile Phe His Leu Pro Ile Gln Thr Gly Ala Ala 85 90 95 Val Asp Leu Phe Arg Phe Ser Cys Ile Leu Leu Ile Phe Phe Val Ala 100 105 110 Thr Phe Phe Ala Val Gln His Leu Thr Ser Ser Arg Ser Arg Leu Ser 115 120 125 Leu Pro Thr Val Gln Arg Ser Ser His Thr Gly Gln Gln Leu Ala Pro 130 135 140 Thr Gln His Gly Asn Cys Leu Leu Val Arg Tyr Arg Lys Asp Ser Ile 145 150 155 160 Glu Ala Pro Gln Ser Phe Lys Gln Phe His Ala Pro Phe His Leu Leu 165 170 175 Thr Ile Pro Leu Ser Ile Tyr Val Asp Asn His Pro Trp Arg Pro Thr 180 185 190 Thr Phe Ala Phe Pro Ser Ser Ile Lys Cys Val Arg Phe Gly Cys Val 195 200 205 Pro Phe Trp Arg Ser Val Leu Pro Pro Ile Thr Val Met Thr Phe Phe 210 215 220 His Asn Asn Asn Ile Val Lys Ile Ala Pro Gln Gly Pro Ile Ile Gln 225 230 235 240 Ser Gln Thr Ser Ser Ile Trp Gln Ser Tyr Leu Ser Phe Thr Ser Ser 245 250 255 Tyr Arg Lys Gln Gly Ala Thr Asn Gln Asn Gly Ala Ile Leu Gly Arg 260 265 270 Gln Phe Pro Val Gly Ser Ser Asp Trp Ser Tyr Phe Ser Lys Ile Pro 275 280 285 Pro Asn Ser Gly Gln Tyr Lys Pro Leu Ile Ser Cys Phe Leu Gly Arg 290 295 300 Leu Phe Pro Ala Leu Glu Asp Gly Lys Gly Gly Trp Ala Arg Phe Lys 305 310 315 320 Trp Ile Phe Trp Ile Val Ser Asp Lys Lys Asp Ser Arg Leu Pro Lys 325 330 335 Glu Asn Leu Thr Leu His Pro Thr Lys Leu Ile Leu Asn Glu Ser Asn 340 345 350 Tyr Met Cys Pro Val Ser Ile Thr Asn Arg Thr Thr Tyr Val Thr Lys 355 360 365 Ser Arg Leu Ala Ser Ala Thr Thr Met Glu Leu Leu Lys Tyr Asp Gly 370 375 380 Cys Ser Thr Glu Lys Thr Thr Gln Asn Ser Thr Ile Leu Leu Ser Ile 385 390 395 400 Ser Leu Asn Pro Pro Leu Thr Gly Pro Thr Thr Pro Ser Pro Ser Pro 405 410 415 Pro Ile Ala Pro Pro Thr Thr Met Pro Thr Met Pro Ser Pro Gln Pro 420 425 430 Arg Gln Leu Thr Ile Met Phe Leu Leu Val Pro Ala Trp Glu Gly Thr 435 440 445 Val Arg Pro Ser Arg Pro Ala Pro Gly Ser Asn Leu Arg Leu Arg Glu 450 455 460 Glu Thr Thr Asn Leu Pro Cys Leu Ala Pro Thr Gln Gly Gly Glu Gln 465 470 475 480 Pro Phe Phe Thr Met Leu Ile Ser Asp Thr Trp Arg Gly Pro Pro Arg 485 490 495 Glu Ser Gln Pro Glu Ser Ser Leu Ile Asp Ser Pro Ala Pro Ser Ala 500 505 510 Pro Thr Ser Ser Ala Met Lys Gly Glu Gly Ala Thr Val Thr Ala Pro 515 520 525 Thr Ser Ser Gly Pro Ala Ala Ala Ser Ser Arg Ala Leu Ile Ala Ala 530 535 540 Pro Ala Thr Asp Glu Glu Glu Thr Val Gly Gly Gln Ile Arg Ile Gln 545 550 555 560 Phe Arg Phe Phe His Ala Thr Leu Ile 565 23 945 DNA Type B PWD circovirus CDS (1)..(942) 23 atg ccc agc aag aag aat gga aga agc gga ccc caa ccc cat aaa agg 48 Met Pro Ser Lys Lys Asn Gly Arg Ser Gly Pro Gln Pro His Lys Arg 1 5 10 15 tgg gtg ttc act ctg aat aat cct tcc gaa gac gag cgc aag aaa ata 96 Trp Val Phe Thr Leu Asn Asn Pro Ser Glu Asp Glu Arg Lys Lys Ile 20 25 30 cgg gat ctt cca ata tcc cta ttt gat tat ttt att gtt ggc gag gag 144 Arg Asp Leu Pro Ile Ser Leu Phe Asp Tyr Phe Ile Val Gly Glu Glu 35 40 45 ggt aat gag gaa gga cga aca cct cac ctc cag ggg ttc gct aat ttt 192 Gly Asn Glu Glu Gly Arg Thr Pro His Leu Gln Gly Phe Ala Asn Phe 50 55 60 gtg aag aag cag act ttt aat aaa gtg aag tgg tat ttg ggt gcc cgc 240 Val Lys Lys Gln Thr Phe Asn Lys Val Lys Trp Tyr Leu Gly Ala Arg 65 70 75 80 tgc cac atc gag aaa gcg aaa gga aca gat cag cag aat aaa gaa tac 288 Cys His Ile Glu Lys Ala Lys Gly Thr Asp Gln Gln Asn Lys Glu Tyr 85 90 95 tgc agt aaa gaa ggc aac tta ctg atg gag tgt gga gct cct aga tct 336 Cys Ser Lys Glu Gly Asn Leu Leu Met Glu Cys Gly Ala Pro Arg Ser 100 105 110 cag gga caa cgg agt gac ctg tct act gct gtg agt acc ttg ttg gag 384 Gln Gly Gln Arg Ser Asp Leu Ser Thr Ala Val Ser Thr Leu Leu Glu 115 120 125 agc ggg agt ctg gtg acc gtt gca gag cag cac cct gta acg ttt gtc 432 Ser Gly Ser Leu Val Thr Val Ala Glu Gln His Pro Val Thr Phe Val 130 135 140 aga aat ttc cgc ggg ctg gct gaa ctt ttg aaa gtg agc ggg aaa atg 480 Arg Asn Phe Arg Gly Leu Ala Glu Leu Leu Lys Val Ser Gly Lys Met 145 150 155 160 cag aag cgt gat tgg aag act aat gta cac gtc att gtg ggg cca cct 528 Gln Lys Arg Asp Trp Lys Thr Asn Val His Val Ile Val Gly Pro Pro 165 170 175 ggg tgt ggt aaa agc aaa tgg gct gct aat ttt gca gac ccg gaa acc 576 Gly Cys Gly Lys Ser Lys Trp Ala Ala Asn Phe Ala Asp Pro Glu Thr 180 185 190 aca tac tgg aaa cca cct aga aac aag tgg tgg gat ggt tac cat ggt 624 Thr Tyr Trp Lys Pro Pro Arg Asn Lys Trp Trp Asp Gly Tyr His Gly 195 200 205 gaa gaa gtg gtt gtt att gat gac ttt tat ggc tgg ctg ccc tgg gat 672 Glu Glu Val Val Val Ile Asp Asp Phe Tyr Gly Trp Leu Pro Trp Asp 210 215 220 gat cta ctg aga ctg tgt gat cga tat cca ttg act gta gag act aaa 720 Asp Leu Leu Arg Leu Cys Asp Arg Tyr Pro Leu Thr Val Glu Thr Lys 225 230 235 240 ggt gga act gta cct ttt ttg gcc cgc agt att ctg att acc agc aat 768 Gly Gly Thr Val Pro Phe Leu Ala Arg Ser Ile Leu Ile Thr Ser Asn 245 250 255 cag acc ccg ttg gaa tgg tac tcc tca act gct gtc cca gct gta gaa 816 Gln Thr Pro Leu Glu Trp Tyr Ser Ser Thr Ala Val Pro Ala Val Glu 260 265 270 gct ctt tat cgg agg att act tcc ttg gta ttt tgg aag aat gct aca 864 Ala Leu Tyr Arg Arg Ile Thr Ser Leu Val Phe Trp Lys Asn Ala Thr 275 280 285 gaa caa tcc acg gag gaa ggg ggc cag ttc gtc acc ctt tcc ccc cca 912 Glu Gln Ser Thr Glu Glu Gly Gly Gln Phe Val Thr Leu Ser Pro Pro 290 295 300 tgc cct gaa ttt cca tat gaa ata aat tac tga 945 Cys Pro Glu Phe Pro Tyr Glu Ile Asn Tyr 305 310 24 314 PRT Type B PWD circovirus 24 Met Pro Ser Lys Lys Asn Gly Arg Ser Gly Pro Gln Pro His Lys Arg 1 5 10 15 Trp Val Phe Thr Leu Asn Asn Pro Ser Glu Asp Glu Arg Lys Lys Ile 20 25 30 Arg Asp Leu Pro Ile Ser Leu Phe Asp Tyr Phe Ile Val Gly Glu Glu 35 40 45 Gly Asn Glu Glu Gly Arg Thr Pro His Leu Gln Gly Phe Ala Asn Phe 50 55 60 Val Lys Lys Gln Thr Phe Asn Lys Val Lys Trp Tyr Leu Gly Ala Arg 65 70 75 80 Cys His Ile Glu Lys Ala Lys Gly Thr Asp Gln Gln Asn Lys Glu Tyr 85 90 95 Cys Ser Lys Glu Gly Asn Leu Leu Met Glu Cys Gly Ala Pro Arg Ser 100 105 110 Gln Gly Gln Arg Ser Asp Leu Ser Thr Ala Val Ser Thr Leu Leu Glu 115 120 125 Ser Gly Ser Leu Val Thr Val Ala Glu Gln His Pro Val Thr Phe Val 130 135 140 Arg Asn Phe Arg Gly Leu Ala Glu Leu Leu Lys Val Ser Gly Lys Met 145 150 155 160 Gln Lys Arg Asp Trp Lys Thr Asn Val His Val Ile Val Gly Pro Pro 165 170 175 Gly Cys Gly Lys Ser Lys Trp Ala Ala Asn Phe Ala Asp Pro Glu Thr 180 185 190 Thr Tyr Trp Lys Pro Pro Arg Asn Lys Trp Trp Asp Gly Tyr His Gly 195 200 205 Glu Glu Val Val Val Ile Asp Asp Phe Tyr Gly Trp Leu Pro Trp Asp 210 215 220 Asp Leu Leu Arg Leu Cys Asp Arg Tyr Pro Leu Thr Val Glu Thr Lys 225 230 235 240 Gly Gly Thr Val Pro Phe Leu Ala Arg Ser Ile Leu Ile Thr Ser Asn 245 250 255 Gln Thr Pro Leu Glu Trp Tyr Ser Ser Thr Ala Val Pro Ala Val Glu 260 265 270 Ala Leu Tyr Arg Arg Ile Thr Ser Leu Val Phe Trp Lys Asn Ala Thr 275 280 285 Glu Gln Ser Thr Glu Glu Gly Gly Gln Phe Val Thr Leu Ser Pro Pro 290 295 300 Cys Pro Glu Phe Pro Tyr Glu Ile Asn Tyr 305 310 25 702 DNA Type B PWD circovirus CDS (1)..(699) 25 atg acg tat cca agg agg cgt tac cga aga aga aga cac cgc ccc cgc 48 Met Thr Tyr Pro Arg Arg Arg Tyr Arg Arg Arg Arg His Arg Pro Arg 1 5 10 15 agc cat ctt ggc cag atc ctc cgc cgc cgc ccc tgg ctc gtc cac ccc 96 Ser His Leu Gly Gln Ile Leu Arg Arg Arg Pro Trp Leu Val His Pro 20 25 30 cgc cac cgt tac cgc tgg aga agg aaa aat ggc atc ttc aac acc cgc 144 Arg His Arg Tyr Arg Trp Arg Arg Lys Asn Gly Ile Phe Asn Thr Arg 35 40 45 ctc tcc cgc acc ttc gga tat act gtc aag cga acc aca gtc aga acg 192 Leu Ser Arg Thr Phe Gly Tyr Thr Val Lys Arg Thr Thr Val Arg Thr 50 55 60 ccc tcc tgg gcg gtg gac atg atg aga ttc aat att aat gac ttt ctt 240 Pro Ser Trp Ala Val Asp Met Met Arg Phe Asn Ile Asn Asp Phe Leu 65 70 75 80 ccc cca gga ggg ggg tca aac ccc cgc tct gtg ccc ttt gaa tac tac 288 Pro Pro Gly Gly Gly Ser Asn Pro Arg Ser Val Pro Phe Glu Tyr Tyr 85 90 95 aga ata aga aag gtt aag gtt gaa ttc tgg ccc tgc tcc ccg atc acc 336 Arg Ile Arg Lys Val Lys Val Glu Phe Trp Pro Cys Ser Pro Ile Thr 100 105 110 cag ggt gac agg gga gtg ggc tcc agt gct gtt att tta gat gat aac 384 Gln Gly Asp Arg Gly Val Gly Ser Ser Ala Val Ile Leu Asp Asp Asn 115 120 125 ttt gta aca aag gcc aca gcc ctc acc tat gac ccc tat gta aac tac 432 Phe Val Thr Lys Ala Thr Ala Leu Thr Tyr Asp Pro Tyr Val Asn Tyr 130 135 140 tcc tcc cgc cat acc ata acc cag ccc ttc tcc tac cac tcc cgg tac 480 Ser Ser Arg His Thr Ile Thr Gln Pro Phe Ser Tyr His Ser Arg Tyr 145 150 155 160 ttt acc ccc aaa cct gtc cta gat ttc act att gat tac ttc caa cca 528 Phe Thr Pro Lys Pro Val Leu Asp Phe Thr Ile Asp Tyr Phe Gln Pro 165 170 175 aac aac aaa aga aac cag ctg tgg ctg aga cta caa act gct gga aat 576 Asn Asn Lys Arg Asn Gln Leu Trp Leu Arg Leu Gln Thr Ala Gly Asn 180 185 190 gta gac cac gta ggc ctc ggc act gcg ttc gaa aac agt ata tac gac 624 Val Asp His Val Gly Leu Gly Thr Ala Phe Glu Asn Ser Ile Tyr Asp 195 200 205 cag gaa tac aat atc cgt gta acc atg tat gta caa ttc aga gaa ttt 672 Gln Glu Tyr Asn Ile Arg Val Thr Met Tyr Val Gln Phe Arg Glu Phe 210 215 220 aat ttt aaa gac ccc cca ctt aac cct taa 702 Asn Phe Lys Asp Pro Pro Leu Asn Pro 225 230 26 233 PRT Type B PWD circovirus 26 Met Thr Tyr Pro Arg Arg Arg Tyr Arg Arg Arg Arg His Arg Pro Arg 1 5 10 15 Ser His Leu Gly Gln Ile Leu Arg Arg Arg Pro Trp Leu Val His Pro 20 25 30 Arg His Arg Tyr Arg Trp Arg Arg Lys Asn Gly Ile Phe Asn Thr Arg 35 40 45 Leu Ser Arg Thr Phe Gly Tyr Thr Val Lys Arg Thr Thr Val Arg Thr 50 55 60 Pro Ser Trp Ala Val Asp Met Met Arg Phe Asn Ile Asn Asp Phe Leu 65 70 75 80 Pro Pro Gly Gly Gly Ser Asn Pro Arg Ser Val Pro Phe Glu Tyr Tyr 85 90 95 Arg Ile Arg Lys Val Lys Val Glu Phe Trp Pro Cys Ser Pro Ile Thr 100 105 110 Gln Gly Asp Arg Gly Val Gly Ser Ser Ala Val Ile Leu Asp Asp Asn 115 120 125 Phe Val Thr Lys Ala Thr Ala Leu Thr Tyr Asp Pro Tyr Val Asn Tyr 130 135 140 Ser Ser Arg His Thr Ile Thr Gln Pro Phe Ser Tyr His Ser Arg Tyr 145 150 155 160 Phe Thr Pro Lys Pro Val Leu Asp Phe Thr Ile Asp Tyr Phe Gln Pro 165 170 175 Asn Asn Lys Arg Asn Gln Leu Trp Leu Arg Leu Gln Thr Ala Gly Asn 180 185 190 Val Asp His Val Gly Leu Gly Thr Ala Phe Glu Asn Ser Ile Tyr Asp 195 200 205 Gln Glu Tyr Asn Ile Arg Val Thr Met Tyr Val Gln Phe Arg Glu Phe 210 215 220 Asn Phe Lys Asp Pro Pro Leu Asn Pro 225 230 27 315 DNA Type B PWD circovirus CDS (1)..(312) 27 atg gta acc atc cca cca ctt gtt tct agg tgg ttt cca gta tgt ggt 48 Met Val Thr Ile Pro Pro Leu Val Ser Arg Trp Phe Pro Val Cys Gly 1 5 10 15 ttc cgg gtc tgc aaa att agc agc cca ttt gct ttt acc aca ccc agg 96 Phe Arg Val Cys Lys Ile Ser Ser Pro Phe Ala Phe Thr Thr Pro Arg 20 25 30 tgg ccc cac aat gac gtg tac att agt ctt cca atc acg ctt ctg cat 144 Trp Pro His Asn Asp Val Tyr Ile Ser Leu Pro Ile Thr Leu Leu His 35 40 45 ttt ccc gct cac ttt caa aag ttc agc cag ccc gcg gaa att tct gac 192 Phe Pro Ala His Phe Gln Lys Phe Ser Gln Pro Ala Glu Ile Ser Asp 50 55 60 aaa cgt tac agg gtg ctg ctc tgc aac ggt cac cag act ccc gct ctc 240 Lys Arg Tyr Arg Val Leu Leu Cys Asn Gly His Gln Thr Pro Ala Leu 65 70 75 80 caa caa ggt act cac agc agt aga cag gtc act ccg ttg tcc ctg aga 288 Gln Gln Gly Thr His Ser Ser Arg Gln Val Thr Pro Leu Ser Leu Arg 85 90 95 tct agg agc tcc aca ctc cat cag taa 315 Ser Arg Ser Ser Thr Leu His Gln 100 28 104 PRT Type B PWD circovirus 28 Met Val Thr Ile Pro Pro Leu Val Ser Arg Trp Phe Pro Val Cys Gly 1 5 10 15 Phe Arg Val Cys Lys Ile Ser Ser Pro Phe Ala Phe Thr Thr Pro Arg 20 25 30 Trp Pro His Asn Asp Val Tyr Ile Ser Leu Pro Ile Thr Leu Leu His 35 40 45 Phe Pro Ala His Phe Gln Lys Phe Ser Gln Pro Ala Glu Ile Ser Asp 50 55 60 Lys Arg Tyr Arg Val Leu Leu Cys Asn Gly His Gln Thr Pro Ala Leu 65 70 75 80 Gln Gln Gly Thr His Ser Ser Arg Gln Val Thr Pro Leu Ser Leu Arg 85 90 95 Ser Arg Ser Ser Thr Leu His Gln 100 29 15 PRT Type B PWD circovirus 29 Val Asp Met Met Arg Phe Asn Ile Asn Asp Phe Leu Pro Pro Gly 1 5 10 15 30 15 PRT Type B PWD circovirus 30 Gln Gly Asp Arg Gly Val Gly Ser Ser Ala Val Ile Leu Asp Asp 1 5 10 15 31 15 PRT Type B PWD circovirus 31 Gly Val Gly Ser Ser Ala Val Ile Leu Asp Asp Asn Phe Val Thr 1 5 10 15 32 15 PRT Type B PWD circovirus 32 Val Asp His Val Gly Leu Gly Thr Ala Phe Glu Asn Ser Ile Tyr 1 5 10 15 33 8 DNA Type A PWD circovirus 33 tgtggcga 8 34 8 DNA Type A PWD circovirus 34 agtttcct 8 35 20 DNA Type A PWD circovirus 35 tcatttagag ggtctttcag 20 36 8 DNA Type A PWD circovirus 36 gtcaacct 8 37 8 DNA Type A PWD circovirus 37 gtggttgc 8 38 8 DNA Type A PWD circovirus 38 agcccagg 8 39 8 DNA Type A PWD circovirus 39 ttggctgg 8 40 12 DNA Type A PWD circovirus 40 tctagctctg gt 12 41 12 DNA Type A PWD circovirus 41 atctcagctc gt 12 42 12 DNA Type A PWD circovirus 42 tgtcctcctc tt 12 43 8 DNA Type A PWD circovirus 43 tctctaga 8 44 8 DNA Type A PWD circovirus 44 tgtaccaa 8 45 8 DNA Type A PWD circovirus 45 tccgtctt 8 46 20 DNA Primer 46 gtgtgctcga cattggtgtg 20 47 20 DNA Primer 47 tggaatgtta acgagctgag 20 48 20 DNA Primer 48 ctcgcagcca tcttggaatg 20 49 20 DNA Primer 49 cgcgcgtaat acgactcact 20 50 26 DNA Primer 50 cctgtctact gctgtgagta ccttgt 26 51 26 DNA Primer 51 gcagtagaca ggtcactccg ttgtcc 26 52 20 DNA Primer 52 tggaatgtta actacctcaa 20 53 23 DNA Primer 53 ggcggcgcca tctgtaacgg ttt 23 54 23 DNA Primer 54 gatggcgccg aaagacgggt atc 23 55 15 PRT Type B PWD circovirus 55 Asn Val Asn Glu Leu Arg Phe Asn Ile Gly Gln Phe Leu Pro Pro 1 5 10 15 56 14 PRT Type A PWD circovirus 56 Thr Ser Asn Gln Arg Gly Val Gly Ser Thr Val Val Ile Leu 1 5 10 57 15 PRT Type A PWD circovirus 57 Arg Gly Val Gly Ser Thr Val Val Ile Leu Asp Ala Asn Phe Val 1 5 10 15 58 15 PRT Type B PWD circovirus 58 Phe Thr Ile Asp Tyr Phe Gln Pro Asn Asn Lys Arg Asn Gln Leu 1 5 10 15 59 15 PRT Type A PWD circovirus 59 Asp Gln Thr Ile Asp Trp Phe Gln Pro Asn Asn Lys Arg Asn Gln 1 5 10 15 60 15 PRT Type A PWD circovirus 60 Asn Val Glu His Thr Gly Leu Gly Tyr Ala Leu Gln Asn Ala Thr 1 5 10 15 61 15 PRT Type B PWD circovirus 61 His Arg Pro Arg Ser His Leu Gly Gln Ile Leu Arg Arg Arg Pro 1 5 10 15 62 15 PRT Type B PWD circovirus 62 Ser His Leu Gly Gln Ile Leu Arg Arg Arg Pro Trp Leu Val His 1 5 10 15 63 15 PRT Type B PWD circovirus 63 Gln Ile Leu Arg Arg Arg Pro Trp Leu Val His Pro Arg His Arg 1 5 10 15 64 15 PRT Type B PWD circovirus 64 Arg Arg Pro Trp Leu Val His Pro Arg His Arg Tyr Arg Trp Arg 1 5 10 15 65 15 PRT Type B PWD circovirus 65 Leu Val His Pro Arg His Arg Tyr Arg Trp Arg Arg Lys Asn Gly 1 5 10 15 66 15 PRT Type B PWD circovirus 66 Arg His Arg Tyr Arg Trp Arg Arg Lys Asn Gly Ile Phe Asn Thr 1 5 10 15 67 15 PRT Type B PWD circovirus 67 Arg Trp Arg Arg Lys Asn Gly Ile Phe Asn Thr Arg Leu Ser Arg 1 5 10 15 68 15 PRT Type B PWD circovirus 68 Lys Asn Gly Ile Phe Asn Thr Arg Leu Ser Arg Thr Phe Gly Tyr 1 5 10 15 69 15 PRT Type B PWD circovirus 69 Phe Asn Thr Arg Leu Ser Arg Thr Phe Gly Tyr Thr Val Lys Arg 1 5 10 15 70 15 PRT Type B PWD circovirus 70 Leu Ser Arg Thr Phe Gly Tyr Thr Val Lys Arg Thr Thr Val Arg 1 5 10 15 71 15 PRT Type B PWD circovirus 71 Phe Gly Tyr Thr Val Lys Arg Thr Thr Val Arg Thr Pro Ser Trp 1 5 10 15 72 15 PRT Type B PWD circovirus 72 Val Lys Arg Thr Thr Val Arg Thr Pro Ser Trp Ala Val Asp Met 1 5 10 15 73 15 PRT Type B PWD circovirus 73 Thr Val Arg Thr Pro Ser Trp Ala Val Asp Met Met Arg Phe Asn 1 5 10 15 74 15 PRT Type B PWD circovirus 74 Pro Ser Trp Ala Val Asp Met Met Arg Phe Asn Ile Asn Asp Phe 1 5 10 15 75 15 PRT Type B PWD circovirus 75 Arg Phe Asn Ile Asn Asp Phe Leu Pro Pro Gly Gly Gly Ser Asn 1 5 10 15 76 15 PRT Type B PWD circovirus 76 Asn Asp Phe Leu Pro Pro Gly Gly Gly Ser Asn Pro Arg Ser Val 1 5 10 15 77 15 PRT Type B PWD circovirus 77 Pro Pro Gly Gly Gly Ser Asn Pro Arg Ser Val Pro Phe Glu Tyr 1 5 10 15 78 15 PRT Type B PWD circovirus 78 Gly Ser Asn Pro Arg Ser Val Pro Phe Glu Tyr Tyr Arg Ile Arg 1 5 10 15 79 15 PRT Type B PWD circovirus 79 Arg Ser Val Pro Phe Glu Tyr Tyr Arg Ile Arg Lys Val Lys Val 1 5 10 15 80 15 PRT Type B PWD circovirus 80 Phe Glu Tyr Tyr Arg Ile Arg Lys Val Lys Val Glu Phe Trp Pro 1 5 10 15 81 15 PRT Type B PWD circovirus 81 Arg Ile Arg Lys Val Lys Val Glu Phe Trp Pro Cys Ser Pro Ile 1 5 10 15 82 15 PRT Type B PWD circovirus 82 Val Lys Val Glu Phe Trp Pro Cys Ser Pro Ile Thr Gln Gly Asp 1 5 10 15 83 15 PRT Type B PWD circovirus 83 Phe Trp Pro Cys Ser Pro Ile Thr Gln Gly Asp Arg Gly Val Gly 1 5 10 15 84 15 PRT Type A PWD circovirus 84 Thr Arg Pro Arg Ser His Leu Gly Asn Ile Leu Arg Arg Arg Pro 1 5 10 15 85 15 PRT Type A PWD circovirus 85 Ser His Leu Gly Asn Ile Leu Arg Arg Arg Pro Tyr Leu Val His 1 5 10 15 86 15 PRT Type A PWD circovirus 86 Asn Ile Leu Arg Arg Arg Pro Tyr Leu Val His Pro Ala Phe Arg 1 5 10 15 87 15 PRT Type A PWD circovirus 87 Arg Arg Pro Tyr Leu Val His Pro Ala Phe Arg Asn Arg Tyr Arg 1 5 10 15 88 15 PRT Type A PWD circovirus 88 Leu Val His Pro Ala Phe Arg Asn Arg Tyr Arg Trp Arg Arg Lys 1 5 10 15 89 15 PRT Type A PWD circovirus 89 Ala Phe Arg Asn Arg Tyr Arg Trp Arg Arg Lys Thr Gly Ile Phe 1 5 10 15 90 15 PRT Type A PWD circovirus 90 Arg Tyr Arg Trp Arg Arg Lys Thr Gly Ile Phe Asn Ser Arg Leu 1 5 10 15 91 15 PRT Type A PWD circovirus 91 Arg Arg Lys Thr Gly Ile Phe Asn Ser Arg Leu Ser Arg Glu Phe 1 5 10 15 92 15 PRT Type A PWD circovirus 92 Gly Ile Phe Asn Ser Arg Leu Ser Arg Glu Phe Val Leu Thr Ile 1 5 10 15 93 15 PRT Type A PWD circovirus 93 Ser Arg Leu Ser Arg Glu Phe Val Leu Thr Ile Arg Gly Gly His 1 5 10 15 94 15 PRT Type A PWD circovirus 94 Arg Glu Phe Val Leu Thr Ile Arg Gly Gly His Ser Gln Pro Ser 1 5 10 15 95 15 PRT Type A PWD circovirus 95 Leu Thr Ile Arg Gly Gly His Ser Gln Pro Ser Trp Asn Val Asn 1 5 10 15 96 15 PRT Type A PWD circovirus 96 Gly Gly His Ser Gln Pro Ser Trp Asn Val Asn Glu Leu Arg Phe 1 5 10 15 97 15 PRT Type A PWD circovirus 97 Gln Pro Ser Trp Asn Val Asn Glu Leu Arg Phe Asn Ile Gly Gln 1 5 10 15 98 15 PRT Type A PWD circovirus 98 Asn Val Asn Glu Leu Arg Phe Asn Ile Gly Gln Phe Leu Pro Pro 1 5 10 15 99 15 PRT Type A PWD circovirus 99 Leu Arg Phe Asn Ile Gly Gln Phe Leu Pro Pro Ser Gly Gly Thr 1 5 10 15 100 15 PRT Type A PWD circovirus 100 Ile Gly Gln Phe Leu Pro Pro Ser Gly Gly Thr Asn Pro Leu Pro 1 5 10 15 101 15 PRT Type A PWD circovirus 101 Leu Pro Pro Ser Gly Gly Thr Asn Pro Leu Pro Leu Pro Phe Gln 1 5 10 15 102 15 PRT Type A PWD circovirus 102 Gly Gly Thr Asn Pro Leu Pro Leu Pro Phe Gln Tyr Tyr Arg Ile 1 5 10 15 103 15 PRT Type A PWD circovirus 103 Pro Leu Pro Leu Pro Phe Gln Tyr Tyr Arg Ile Arg Lys Ala Lys 1 5 10 15 104 15 PRT Type A PWD circovirus 104 Pro Phe Gln Tyr Tyr Arg Ile Arg Lys Ala Lys Tyr Glu Phe Tyr 1 5 10 15 105 15 PRT Type A PWD circovirus 105 Tyr Arg Ile Arg Lys Ala Lys Tyr Glu Phe Tyr Pro Arg Asp Pro 1 5 10 15 106 15 PRT Type A PWD circovirus 106 Lys Ala Lys Tyr Glu Phe Tyr Pro Arg Asp Pro Ile Thr Ser Asn 1 5 10 15 107 15 PRT Type A PWD circovirus 107 Glu Phe Tyr Pro Arg Asp Pro Ile Thr Ser Asn Gln Arg Gly Val 1 5 10 15 108 15 PRT Type A PWD circovirus 108 Arg Asp Pro Ile Thr Ser Asn Gln Arg Gly Val Gly Ser Thr Val 1 5 10 15 109 15 PRT Type A PWD circovirus 109 Thr Ser Asn Gln Arg Gly Val Gly Ser Thr Val Val Ile Leu Asp 1 5 10 15 110 15 PRT Type B PWD circovirus 110 Gly Val Gly Ser Ser Ala Val Ile Leu Asp Asp Asn Phe Val Thr 1 5 10 15 111 15 PRT Type B PWD circovirus 111 Ser Ala Val Ile Leu Asp Asp Asn Phe Val Thr Lys Ala Thr Ala 1 5 10 15 112 15 PRT Type B PWD circovirus 112 Leu Asp Asp Asn Phe Val Thr Lys Ala Thr Ala Leu Thr Tyr Asp 1 5 10 15 113 15 PRT Type B PWD circovirus 113 Phe Val Thr Lys Ala Thr Ala Leu Thr Tyr Asp Pro Tyr Val Asn 1 5 10 15 114 15 PRT Type B PWD circovirus 114 Ala Thr Ala Leu Thr Tyr Asp Pro Tyr Val Asn Tyr Ser Ser Arg 1 5 10 15 115 15 PRT Type B PWD circovirus 115 Thr Tyr Asp Pro Tyr Val Asn Tyr Ser Ser Arg His Thr Ile Thr 1 5 10 15 116 15 PRT Type B PWD circovirus 116 Tyr Val Asn Tyr Ser Ser Arg His Thr Ile Thr Gln Pro Phe Ser 1 5 10 15 117 15 PRT Type B PWD circovirus 117 Ser Ser Arg His Thr Ile Thr Gln Pro Phe Ser Tyr His Ser Arg 1 5 10 15 118 15 PRT Type B PWD circovirus 118 Thr Ile Thr Gln Pro Phe Ser Tyr His Ser Arg Tyr Phe Thr Pro 1 5 10 15 119 15 PRT Type B PWD circovirus 119 Pro Phe Ser Tyr His Ser Arg Tyr Phe Thr Pro Lys Pro Val Leu 1 5 10 15 120 15 PRT Type B PWD circovirus 120 His Ser Arg Tyr Phe Thr Pro Lys Pro Val Leu Asp Phe Thr Ile 1 5 10 15 121 15 PRT Type B PWD circovirus 121 Phe Thr Pro Lys Pro Val Leu Asp Phe Thr Ile Asp Tyr Phe Gln 1 5 10 15 122 15 PRT Type B PWD circovirus 122 Pro Val Leu Asp Phe Thr Ile Asp Tyr Phe Gln Pro Asn Asn Lys 1 5 10 15 123 15 PRT Type B PWD circovirus 123 Phe Thr Ile Asp Tyr Phe Gln Pro Asn Asn Lys Arg Asn Gln Leu 1 5 10 15 124 15 PRT Type B PWD circovirus 124 Tyr Phe Gln Pro Asn Asn Lys Arg Asn Gln Leu Trp Leu Arg Leu 1 5 10 15 125 15 PRT Type B PWD circovirus 125 Asn Asn Lys Arg Asn Gln Leu Trp Leu Arg Leu Gln Thr Ala Gly 1 5 10 15 126 15 PRT Type B PWD circovirus 126 Asn Gln Leu Trp Leu Arg Leu Gln Thr Ala Gly Asn Val Asp His 1 5 10 15 127 15 PRT Type B PWD circovirus 127 Leu Arg Leu Gln Thr Ala Gly Asn Val Asp His Val Gly Leu Gly 1 5 10 15 128 15 PRT Type B PWD circovirus 128 Thr Ala Gly Asn Val Asp His Val Gly Leu Gly Thr Ala Phe Glu 1 5 10 15 129 15 PRT Type B PWD circovirus 129 Gly Leu Gly Thr Ala Phe Glu Asn Ser Ile Tyr Asp Gln Glu Tyr 1 5 10 15 130 15 PRT Type B PWD circovirus 130 Ala Phe Glu Asn Ser Ile Tyr Asp Gln Glu Tyr Asn Ile Arg Val 1 5 10 15 131 15 PRT Type B PWD circovirus 131 Ser Ile Tyr Asp Gln Glu Tyr Asn Ile Arg Val Thr Met Tyr Val 1 5 10 15 132 15 PRT Type B PWD circovirus 132 Gln Glu Tyr Asn Ile Arg Val Thr Met Tyr Val Gln Phe Arg Glu 1 5 10 15 133 15 PRT Type B PWD circovirus 133 Ile Arg Val Thr Met Tyr Val Gln Phe Arg Glu Phe Asn Phe Lys 1 5 10 15 134 15 PRT Type B PWD circovirus 134 Met Tyr Val Gln Phe Arg Glu Phe Asn Phe Lys Asp Pro Pro Leu 1 5 10 15 135 15 PRT Type B PWD circovirus 135 Val Gln Phe Arg Glu Phe Asn Phe Lys Asp Pro Pro Leu Asn Pro 1 5 10 15 136 15 PRT Type A PWD circovirus 136 Arg Gly Val Gly Ser Thr Val Val Ile Leu Asp Ala Asn Phe Val 1 5 10 15 137 15 PRT Type A PWD circovirus 137 Ser Thr Val Val Ile Leu Asp Ala Asn Phe Val Thr Pro Ser Thr 1 5 10 15 138 15 PRT Type A PWD circovirus 138 Ile Leu Asp Ala Asn Phe Val Thr Pro Ser Thr Asn Leu Ala Tyr 1 5 10 15 139 15 PRT Type A PWD circovirus 139 Asn Phe Val Thr Pro Ser Thr Asn Leu Ala Tyr Asp Pro Tyr Ile 1 5 10 15 140 15 PRT Type A PWD circovirus 140 Pro Ser Thr Asn Leu Ala Tyr Asp Pro Tyr Ile Asn Tyr Ser Ser 1 5 10 15 141 15 PRT Type A PWD circovirus 141 Leu Ala Tyr Asp Pro Tyr Ile Asn Tyr Ser Ser Arg His Thr Ile 1 5 10 15 142 15 PRT Type A PWD circovirus 142 Pro Tyr Ile Asn Tyr Ser Ser Arg His Thr Ile Arg Gln Pro Phe 1 5 10 15 143 15 PRT Type A PWD circovirus 143 Tyr Ser Ser Arg His Thr Ile Arg Gln Pro Phe Thr Tyr His Ser 1 5 10 15 144 15 PRT Type A PWD circovirus 144 His Thr Ile Arg Gln Pro Phe Thr Tyr His Ser Arg Tyr Phe Thr 1 5 10 15 145 15 PRT Type A PWD circovirus 145 Gln Pro Phe Thr Tyr His Ser Arg Tyr Phe Thr Pro Lys Pro Glu 1 5 10 15 146 15 PRT Type A PWD circovirus 146 Tyr His Ser Arg Tyr Phe Thr Pro Lys Pro Glu Leu Asp Gln Thr 1 5 10 15 147 15 PRT Type A PWD circovirus 147 Tyr Phe Thr Pro Lys Pro Glu Leu Asp Gln Thr Ile Asp Trp Phe 1 5 10 15 148 15 PRT Type A PWD circovirus 148 Lys Pro Glu Leu Asp Gln Thr Ile Asp Trp Phe Gln Pro Asn Asn 1 5 10 15 149 15 PRT Type A PWD circovirus 149 Asp Gln Thr Ile Asp Trp Phe Gln Pro Asn Asn Lys Arg Asn Gln 1 5 10 15 150 15 PRT Type A PWD circovirus 150 Asp Trp Phe Gln Pro Asn Asn Lys Arg Asn Gln Leu Trp Leu His 1 5 10 15 151 15 PRT Type A PWD circovirus 151 Pro Asn Asn Lys Arg Asn Gln Leu Trp Leu His Leu Asn Thr His 1 5 10 15 152 15 PRT Type A PWD circovirus 152 Arg Asn Gln Leu Trp Leu His Leu Asn Thr His Thr Asn Val Glu 1 5 10 15 153 15 PRT Type A PWD circovirus 153 Trp Leu His Leu Asn Thr His Thr Asn Val Glu His Thr Gly Leu 1 5 10 15 154 15 PRT Type A PWD circovirus 154 Asn Thr His Thr Asn Val Glu His Thr Gly Leu Gly Tyr Ala Leu 1 5 10 15 155 15 PRT Type A PWD circovirus 155 Asn Val Glu His Thr Gly Leu Gly Tyr Ala Leu Gln Asn Ala Thr 1 5 10 15 156 15 PRT Type A PWD circovirus 156 Thr Gly Leu Gly Tyr Ala Leu Gln Asn Ala Thr Thr Ala Gln Asn 1 5 10 15 157 15 PRT Type A PWD circovirus 157 Tyr Ala Leu Gln Asn Ala Thr Thr Ala Gln Asn Tyr Val Val Arg 1 5 10 15 158 15 PRT Type A PWD circovirus 158 Asn Ala Thr Thr Ala Gln Asn Tyr Val Val Arg Leu Thr Ile Tyr 1 5 10 15 159 15 PRT Type A PWD circovirus 159 Ala Gln Asn Tyr Val Val Arg Leu Thr Ile Tyr Val Gln Phe Arg 1 5 10 15 160 15 PRT Type A PWD circovirus 160 Val Val Arg Leu Thr Ile Tyr Val Gln Phe Arg Glu Phe Ile Leu 1 5 10 15 161 15 PRT Type A PWD circovirus 161 Thr Ile Tyr Val Gln Phe Arg Glu Phe Ile Leu Lys Asp Pro Leu 1 5 10 15 162 15 PRT Type A PWD circovirus 162 Tyr Val Gln Phe Arg Glu Phe Ile Leu Lys Asp Pro Leu Asn Glu 1 5 10 15 163 1759 DNA Type A PWD circovirus 163 accagcgcac ttcggcagcg gcagcacctc ggcagcgtca gtgaaaatgc caagcaagaa 60 aagcggcccg caaccccata agaggtgggt gttcaccctt aataatcctt ccgaggagga 120 gaaaaacaaa atacgggagc ttccaatctc cctttttgat tattttgttt gcggagagga 180 aggtttggaa gagggtagaa ctcctcacct ccaggggttt gcgaattttg ctaagaagca 240 gacttttaac aaggtgaagt ggtattttgg tgcccgctgc cacatcgaga aagcgaaagg 300 aaccgaccag cagaataaag aatactgcag taaagaaggc cacatactta tcgagtgtgg 360 agctccgcgg aaccagggga agcgcagcga cctgtctact gctgtgagta cccttttgga 420 gacggggtct ttggtgactg tagccgagca gttccctgta acgtatgtga gaaatttccg 480 cgggctggct gaacttttga aagtgagcgg gaagatgcag aagcgtgatt ggaagacagc 540 tgtacacgtc atagtgggcc cgcccggttg tgggaagagc cagtgggccc gtaattttgc 600 tgagcctagg gacacctact ggaagcctag tagaaataag tggtgggatg gatatcatgg 660 agaagaagtt gttgttttgg atgattttta tggctggtta ccttgggatg atctactgag 720 actgtgtgac cggtatccat tgactgtaga gactaaaggg ggtactgttc cttttttggc 780 ccgcagtatt ttgattacca gcaatcaggc cccccaggaa tggtactcct caactgctgt 840 cccagctgta gaagctctct atcggaggat tactactttg caattttgga agactgctgg 900 agaacaatcc acggaggtac ccgaaggccg atttgaagca gtggacccac cctgtgccct 960 tttcccatat aaaataaatt actgagtctt ttttgttatc acatcgtaat ggtttttatt 1020 tttatttatt tagagggtct tttaggataa attctctgaa ttgtacataa atagtcagcc 1080 ttaccacata attttgggct gtggttgcat tttggagcgc atagcccagg cctgtgtgct 1140 cgacattggt gtgggtattt aaatggagcc acagctggtt tcttttatta tttgggtgga 1200 accaatcaat tgtttggtcc agctcaggtt tgggggtgaa gtacctggag tggtaggtaa 1260 agggctgcct tatggtgtgg cgggaggagt agttaatata ggggtcatag gccaagttgg 1320 tggagggggt tacaaagttg gcatccaaga taacaacagt ggacccaaca cctctttgat 1380 tagaggtgat ggggtctctg gggtaaaatt catatttagc ctttctaata cggtagtatt 1440 ggaaaggtag gggtaggggg ttggtgccgc ctgagggggg gaggaactgg ccgatgttga 1500 atttcagcta gttaacattc caagatggct gcgagtatcc tccttttatg gtgagtacaa 1560 attctgtaga aaggcgggaa ttgaagatac ccgtctttcg gcgccatctg taacggtttc 1620 tgaaggcggg gtgtgccaaa tatggtcttc tccggaggat gtttccaaga tggctgcggg 1680 ggcgggtcct tcttctgcgg taacgcctcc ttggccacgt catcctataa aagtgaaaga 1740 agtgcgctgc tgtagtatt 1759 164 1759 DNA Type A PWD circovirus 164 accagcgcac ttcggcagcg gcagcacctc ggcagcgtca gtgaaaatgc caagcaagaa 60 aagcggcccg caaccccata agaggtgggt gttcaccctt aataatcctt ccgaggagga 120 gaaaaacaaa atacgggagc ttccaatctc cctttttgat tattttgttt gcggagagga 180 aggtttggaa gagggtagaa ctcctcacct ccaggggttt gctaattttg ctaagaagca 240 gacttttaac aaggtgaagt ggtattttgg tgcccgctgc cacatcgaga aagcgaaagg 300 aaccgaccag cagaataaag aatactgcag taaagaaggc cacatactta tcgagtgtgg 360 agctccgcgg aaccagggga agcgcagcga cctgtctact gctgtgagta cccttttgga 420 gacggggtct ttggtgactg tagccgagca gttccctgta acgtatgtga gaaatttccg 480 cgggctggct gaacttttga aagtgagcgg gaagatgcag aagcgtgatt ggaagacagc 540 tgtacacgtc atagtgggcc cgcccggttg tgggaagagc cagtgggccc gtaattttgc 600 tgagcctagc gacacctact ggaagcctag tagaaataag tggtgggatg gatatcatgg 660 agaagaagtt gttgttttgg atgattttta tggctggtta ccttgggatg atctactgag 720 actgtgtgac cggtatccat tgactgtaga gactaaaggc ggtactgttc cttttttggc 780 tcgcagtatt ttgattacca gcaatcaggc cccccaggaa tggtactcct caactgctgt 840 cccagctgta gaagctctct atcggaggat tactactttg caattttgga agactgctgg 900 agaacaatca acggaggtac ccgaaggccg atttgaagca gtggacccac cctgtgccct 960 tttcccatat aaaataaatt actgagtctt ttttgttatc acatcgtaat ggtttttatt 1020 tttatttatt tagagggtct tttaggataa attctctgaa ttgtacataa atagtcagcc 1080 ttaccacata attttgggct gtggttgcat tttggagcgc atagcccagg cctgtgtgct 1140 cgacattggt gtgggtattt aaatggagcc acagctggtt tcttttatta tttgggtgga 1200 accattcaat tgtttggtcc agctcaggtt tgggggtgaa gtacctggag tggtaggtaa 1260 agggctgcct tatggtgtgg cgggaggagt agttaatata ggggtcatag gccaagttgg 1320 tggagggggt tacaaagttg gcatccaaga taacaacagt ggacccaaca cctctttcat 1380 tagaggtgat ggggtctctg gggtaaaatt catatttagc ctttctaata cggtagtatt 1440 ggaaaggtag gggtaggggg ttggtgccgc ctgagggggg gaggaactgg ccgatgttga 1500 atctgaggtg gttaacatgc caagatggct gcgagtatcc tccttttatg gtgattacaa 1560 attctttaga aaggcggcaa ttgaagatac ccgtctttcg gcgccatctg taacggtttc 1620 tgaaggcggg gtgtgccaaa tatggtcttc tccggaggat gtttccaaga tggctgcggg 1680 ggcgggtcct tcttctgcgg taacgcctcc ttggccacgt catcctataa aagtgaaaga 1740 agtgcgctgc tgtagtatt 1759 165 312 PRT Type A PWD circovirus 165 Met Pro Ser Lys Lys Ser Gly Pro Gln Pro His Lys Arg Trp Val Phe 1 5 10 15 Thr Leu Asn Asn Pro Ser Gly Gly Gly Lys Asn Lys Ile Arg Gly Leu 20 25 30 Pro Ile Ser Leu Phe Asp Tyr Phe Val Cys Gly Gly Gly Gly Leu Gly 35 40 45 Gly Gly Arg Thr Pro His Leu Gln Gly Phe Ala Asn Phe Ala Lys Lys 50 55 60 Gln Thr Phe Asn Lys Val Lys Trp Tyr Phe Gly Ala Arg Cys His Ile 65 70 75 80 Gly Lys Ala Lys Gly Thr Asp Gln Gln Asn Lys Gly Tyr Cys Ser Lys 85 90 95 Gly Gly His Ile Leu Ile Gly Cys Gly Ala Pro Arg Asn Gln Gly Lys 100 105 110 Arg Ser Asp Leu Ser Thr Ala Val Ser Thr Leu Leu Gly Thr Gly Ser 115 120 125 Leu Val Thr Val Ala Gly Gln Phe Pro Val Thr Tyr Val Arg Asn Phe 130 135 140 Arg Gly Leu Ala Gly Leu Leu Lys Val Ser Gly Lys Met Gln Gln Arg 145 150 155 160 Asp Trp Lys Thr Ala Val His Val Ile Val Gly Pro Pro Gly Cys Gly 165 170 175 Lys Ser Gln Trp Ala Arg Asn Phe Ala Gly Pro Arg Asp Thr Tyr Trp 180 185 190 Lys Pro Ser Arg Asn Lys Trp Trp Asp Gly Tyr His Gly Gly Gly Val 195 200 205 Val Val Leu Asp Asp Phe Tyr Gly Trp Leu Pro Trp Asp Asp Leu Leu 210 215 220 Arg Leu Cys Asp Arg Tyr Pro Leu Thr Val Gly Thr Lys Gly Gly Thr 225 230 235 240 Val Pro Phe Leu Ala Arg Ser Ile Leu Ile Thr Ser Asn Gln Ala Pro 245 250 255 Gln Gly Trp Tyr Ser Ser Thr Ala Val Pro Ala Val Gly Ala Leu Tyr 260 265 270 Arg Arg Ile Thr Thr Leu Gln Phe Trp Lys Thr Ala Gly Gly Gln Ser 275 280 285 Thr Gly Val Pro Gly Gly Arg Phe Gly Ala Val Asp Pro Pro Cys Ala 290 295 300 Leu Phe Pro Tyr Lys Ile Asn Tyr 305 310 166 312 PRT Type A PWD circovirus 166 Met Pro Ser Lys Lys Ser Gly Pro Gln Pro His Lys Arg Trp Val Phe 1 5 10 15 Thr Leu Asn Asn Pro Ser Gly Gly Gly Lys Asn Lys Ile Arg Gly Leu 20 25 30 Pro Ile Ser Leu Phe Asp Tyr Phe Val Cys Gly Gly Gly Gly Leu Gly 35 40 45 Gly Gly Arg Thr Ala His Leu Gln Gly Phe Ala Asn Phe Ala Lys Lys 50 55 60 Gln Thr Phe Asn Lys Val Lys Trp Tyr Phe Gly Ala Arg Cys His Ile 65 70 75 80 Gly Lys Ala Lys Gly Thr Asp Gln Gln Asn Lys Gly Tyr Cys Ser Lys 85 90 95 Gly Gly His Ile Leu Ile Gly Cys Gly Ala Pro Arg Asn Gln Gly Lys 100 105 110 Arg Ser Asp Leu Ser Thr Ala Val Ser Thr Leu Leu Gly Thr Gly Ser 115 120 125 Leu Val Thr Val Ala Gly Gln Phe Pro Val Thr Tyr Val Arg Asn Phe 130 135 140 Arg Gly Leu Ala Gly Leu Leu Lys Val Ser Gly Lys Met Gln Gln Arg 145 150 155 160 Asp Trp Lys Thr Ala Val His Val Ile Val Gly Pro Pro Gly Cys Gly 165 170 175 Lys Ser Gln Trp Ala Arg Asn Phe Ala Gly Pro Ser Asp Thr Tyr Trp 180 185 190 Lys Pro Ser Arg Asn Lys Trp Trp Asp Gly Tyr His Gly Gly Gly Val 195 200 205 Val Val Leu Asp Asp Phe Tyr Gly Trp Leu Pro Trp Asp Asp Leu Leu 210 215 220 Arg Leu Cys Asp Arg Tyr Pro Leu Thr Val Gly Thr Lys Gly Gly Thr 225 230 235 240 Val Pro Phe Leu Ala Arg Ser Ile Leu Ile Thr Ser Asn Gln Ala Pro 245 250 255 Gln Gly Trp Tyr Ser Ser Thr Ala Val Pro Ala Val Gly Ala Leu Tyr 260 265 270 Arg Arg Ile Thr Thr Leu Gln Phe Trp Lys Thr Ala Gly Gly Gln Ser 275 280 285 Thr Gly Val Pro Gly Gly Arg Phe Gly Ala Val Asp Pro Pro Cys Ala 290 295 300 Leu Phe Pro Tyr Lys Ile Asn Tyr 305 310 167 233 PRT Type A PWD circovirus 167 Met Thr Trp Pro Arg Arg Arg Tyr Arg Arg Arg Arg Thr Arg Pro Arg 1 5 10 15 Ser His Leu Gly Asn Ile Leu Arg Arg Arg Pro Tyr Leu Ala His Pro 20 25 30 Ala Phe Arg Asn Arg Tyr Arg Trp Arg Arg Lys Thr Gly Ile Phe Asn 35 40 45 Ser Arg Leu Ser Thr Glu Phe Val Leu Thr Ile Arg Gly Gly His Ser 50 55 60 Gln Pro Ser Trp Asn Val Asn Tyr Leu Lys Phe Asn Ile Gly Gln Phe 65 70 75 80 Leu Pro Pro Ser Gly Gly Thr Asn Pro Leu Pro Leu Pro Phe Gln Tyr 85 90 95 Tyr Arg Ile Arg Lys Ala Lys Tyr Glu Phe Tyr Pro Arg Asp Pro Ile 100 105 110 Thr Ser Asn Gln Arg Gly Val Gly Ser Thr Val Val Ile Leu Asp Ala 115 120 125 Asn Phe Val Thr Pro Ser Thr Asn Leu Ala Tyr Asp Pro Tyr Ile Asn 130 135 140 Tyr Ser Ser Arg His Thr Ile Arg Gln Pro Phe Thr Tyr His Ser Arg 145 150 155 160 Tyr Phe Thr Pro Lys Pro Glu Leu Asp Gln Thr Ile Asp Trp Phe His 165 170 175 Pro Asn Asn Lys Arg Asn Gln Leu Trp Leu His Leu Asn Thr His Thr 180 185 190 Asn Val Glu His Thr Gly Leu Gly Tyr Ala Leu Gln Asn Ala Ala Thr 195 200 205 Ala Gln Asn Tyr Val Val Arg Leu Thr Ile Tyr Val Gln Phe Arg Glu 210 215 220 Phe Ile Leu Lys Asp Pro Leu Asn Lys 225 230 168 233 PRT Type A PWD circovirus 168 Met Thr Trp Pro Arg Arg Arg Tyr Arg Arg Arg Arg Thr Arg Pro Arg 1 5 10 15 Ser His Leu Gly Asn Ile Leu Arg Arg Arg Pro Tyr Leu Val His Pro 20 25 30 Ala Phe Arg Asn Arg Tyr Arg Trp Arg Arg Lys Thr Gly Ile Phe Asn 35 40 45 Cys Arg Leu Ser Lys Glu Phe Val Ile Thr Ile Arg Gly Gly His Ser 50 55 60 Gln Pro Ser Trp Ile Val Asn Ile Leu Arg Phe Asn Ile Gly Gln Phe 65 70 75 80 Leu Pro Pro Ser Gly Gly Thr Asn Pro Leu Pro Leu Pro Phe Gln Tyr 85 90 95 Tyr Arg Ile Arg Lys Ala Lys Tyr Glu Phe Tyr Pro Arg Asp Pro Ile 100 105 110 Thr Ser Asn Glu Arg Gly Val Gly Ser Thr Val Val Ile Leu Asp Ala 115 120 125 Asn Phe Val Thr Pro Ser Thr Asn Leu Ala Tyr Asp Pro Tyr Ile Asn 130 135 140 Tyr Ser Ser Arg His Thr Ile Arg Gln Pro Phe Thr Tyr His Ser Arg 145 150 155 160 Tyr Phe Thr Pro Lys Pro Glu Leu Asp Gln Thr Ile Glu Trp Phe His 165 170 175 Pro Asn Asn Lys Arg Asn Gln Leu Trp Leu His Leu Asn Thr His Thr 180 185 190 Asn Val Glu His Thr Gly Leu Gly Tyr Ala Leu Gln Asn Ala Ala Thr 195 200 205 Ala Gln Asn Tyr Val Val Arg Leu Thr Ile Tyr Val Gln Phe Arg Glu 210 215 220 Phe Ile Leu Lys Asp Pro Leu Asn Lys 225 230 169 206 PRT Type A PWD circovirus 169 Met Ile Ser Ile Pro Pro Leu Ile Ser Thr Arg Leu Pro Val Gly Val 1 5 10 15 Pro Arg Leu Ser Lys Ile Thr Gly Pro Leu Ala Leu Pro Thr Thr Gly 20 25 30 Arg Ala His Tyr Asp Val Tyr Ser Cys Leu Pro Ile Thr Leu Leu His 35 40 45 Leu Pro Ala His Phe Gln Lys Phe Ser Gln Pro Ala Glu Ile Ser His 50 55 60 Ile Arg Tyr Arg Glu Leu Leu Gly Tyr Ser His Gln Arg Pro Arg Leu 65 70 75 80 Gln Lys Gly Thr His Ser Ser Arg Gln Val Ala Ala Leu Pro Leu Val 85 90 95 Pro Arg Ser Ser Thr Leu Asp Lys Tyr Val Ala Phe Phe Thr Ala Val 100 105 110 Phe Phe Ile Leu Leu Val Gly Ser Phe Arg Phe Leu Asp Val Ala Ala 115 120 125 Gly Thr Lys Ile Pro Leu His Leu Val Lys Ser Leu Leu Leu Ser Lys 130 135 140 Ile Arg Lys Pro Leu Glu Val Arg Ser Ser Thr Leu Phe Gln Thr Phe 145 150 155 160 Leu Ser Ala Asn Lys Ile Ile Lys Lys Gly Asp Trp Lys Leu Pro Tyr 165 170 175 Phe Val Phe Leu Leu Leu Gly Arg Ile Ile Lys Gly Glu His Pro Pro 180 185 190 Leu Met Gly Leu Arg Ala Ala Phe Leu Ala Trp His Phe His 195 200 205 170 206 PRT Type A PWD circovirus 170 Met Ile Ser Ile Pro Pro Leu Ile Ser Thr Arg Leu Pro Val Gly Val 1 5 10 15 Ala Arg Leu Ser Lys Ile Thr Gly Pro Leu Ala Leu Pro Thr Thr Gly 20 25 30 Arg Ala His Tyr Asp Val Tyr Ser Cys Leu Pro Ile Thr Leu Leu His 35 40 45 Leu Pro Ala His Phe Gln Lys Phe Ser Gln Pro Ala Glu Ile Ser His 50 55 60 Ile Arg Tyr Arg Glu Leu Leu Gly Tyr Ser His Gln Arg Pro Arg Leu 65 70 75 80 Gln Lys Gly Thr His Ser Ser Arg Gln Val Ala Ala Leu Pro Leu Val 85 90 95 Pro Arg Ser Ser Thr Leu Asp Lys Tyr Val Ala Phe Phe Thr Ala Val 100 105 110 Phe Phe Ile Leu Leu Val Gly Ser Phe Arg Phe Leu Asp Val Ala Ala 115 120 125 Gly Thr Lys Ile Pro Leu His Leu Val Lys Ser Leu Leu Leu Ser Lys 130 135 140 Ile Ser Lys Pro Leu Glu Val Ser Ser Ser Thr Leu Phe Gln Thr Phe 145 150 155 160 Leu Ser Ala Asn Lys Ile Ile Lys Lys Gly Asp Trp Lys Leu Pro Tyr 165 170 175 Phe Val Phe Leu Leu Leu Gly Arg Ile Ile Lys Gly Glu His Pro Pro 180 185 190 Leu Met Gly Leu Arg Ala Ala Phe Leu Ala Trp His Phe His 195 200 205 

We claim:
 1. A vaccine comprising a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof, and an acceptable pharmaceutical or veterinary vehicle.
 2. A vaccine according to claim 1, wherein the nucleotide sequence is selected from SEQ ID No. 15 or SEQ ID No.
 19. 3. A vaccine according to claim 1, wherein the homologue has at least 80% sequence identity to SEQ ID No. 15 or SEQ ID No.
 19. 4. A vaccine according to claim 1, wherein the nucleotide sequence is selected from SEQ ID No. 23 or SEQ ID No. 25, or a homologue or fragment thereof.
 5. A vaccine according to claim 4, wherein the homologue has at least 80% sequence identity to SEQ ID No. 23 or SEQ ID No.
 25. 6. A vaccine according to claim 4, wherein the nucleotide sequence is SEQ ID No.
 25. 7. A vaccine comprising a polypeptide encoded by a nucleotide sequence of the genome of PCVB, or a homologue or fragment thereof, and an acceptable pharmaceutical or veterinary vehicle.
 8. A vaccine according to claim 7, wherein the homologue has at least 80% sequence identity to SEQ ID No. 15 or SEQ ID No.
 19. 9. A vaccine according to claim 7, wherein the nucleotide sequence is selected from SEQ ID No. 23 or SEQ ID No. 25, or a homologue or fragment thereof.
 10. A vaccine according to claim 9, wherein the homologue has at least 80% sequence identity to SEQ ID No. 23 or SEQ ID No.
 25. 11. A vaccine according to claim 9, wherein the nucleotide sequence is SEQ ID No.
 25. 12. A vaccine according to claim 7, wherein the polypeptide has the amino acid sequence of SEQ ID No. 24 or SEQ ID No.
 26. 13. A vaccine according to claim 12, wherein the polypeptide has the amino acid sequence of SEQ ID No.
 26. 14. A vaccine according to claim 7, wherein the homologue has at least 80% sequence identity to SEQ ID No. 24 or SEQ ID No.
 26. 15. A vaccine according to claim 14, wherein the homologue has at least 80% sequence identity to SEQ ID No.
 26. 16. A vaccine according to claim 7, wherein the polypeptide has the amino acid sequence of SEQ ID No. 29, SEQ ID No. 30, SEQ ID No. 31, or SEQ ID No.
 32. 17. A vaccine comprising a vector and an acceptable pharmaceutical or veterinary vehicle, the vector comprising a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof.
 18. A vaccine according to claim 17, further comprising a gene coding for an expression product capable of inhibiting or retarding the establishment or development of a genetic or acquired disease.
 19. A vaccine comprising a cell and an acceptable pharmaceutical or veterinary vehicle, wherein the cell is transformed with a nucleotide sequence of the genome of Porcine circovirus type B, or a homologue or fragment thereof.
 20. A vaccine according to claim 1, further comprising an adjuvant.
 21. A vaccine comprising a pharmaceutically acceptable vehicle and a single polypetide, wherein the single polypeptide consists of SEQ ID No.
 26. 22. A method of immunizing a mammal against piglet weight loss disease comprising administering to a mammal an effective amount of the vaccine of any one of claims 1-21. 